Compounds

ABSTRACT

The present specification provides a compound of formula (I): 
                         
or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an RORγ and/or RORγt mediated disease state.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.15/997,310, filed on Jun. 4, 2018, which is a continuation of U.S.application Ser. No. 15/378,360, filed on Dec. 14, 2016, which claimsthe benefit under 35 U.S.C. § 119(e) of U.S. Provisional PatentApplication No. 62/267,391, filed on Dec. 15, 2015. All of the abovelisted applications are incorporated by reference herein in its entiretyfor all purposes.

REFERENCE TO THE SEQUENCE LISTING

This application incorporates by reference a Sequence Listing submittedwith this application as text file entitled 200357-US-CNT-2_SL, createdon Nov. 25, 2019, and having a size of 10.5 KB.

This specification relates to arylamide compounds having pharmaceuticalactivity, to processes for preparing such compounds, to pharmaceuticalcompositions comprising such compounds and to the use of such compoundsas active therapeutic agents.

Retinoic acid receptor-related orphan receptors (RORs) are a family oftranscription factors which belong to the nuclear receptor superfamily.The family is comprised of three genes, RORA, RORB, and RORC, all ofwhich express more than one isoform of the protein (Jetten, A M;Kurebayashi, S; Ueda, E. (2006) Prog. Nucleic Acid Res. Mol. Biol.69:205-47). RORC (also known as RORγ or NR1F3) is translated into twomajor protein isoforms which share most of the amino acid sequence,including the ligand binding domain, but differ 21 amino acids in lengthin the N-terminal end. The two isoforms are differentially expressed.The longer form (RORγ) is found in many tissues such as liver, kidney,muscle and some cells of hematopoetic origin whereas the shorter form(RORγt) is expressed in the thymus and cells of the immune system (He, YW; Deftos, M L; Ojala, E W; Bevan, M J (1998) Immunity 9(6):797-806).RORγt has been shown to be required for differentiation and function ofTh17 cells and coordinates the expression of IL17 in many immune cells(Ivanov, II; McKenzie, BS; Zhou, L; Littman, D R et al. (2006) Cell126:1121-1133). Th17 cells are a subset of T helper cells that produceIL17, IL22, and other cytokines. They attain their Th17 phenotypethrough local exposure to a combination of cytokines such as TGFβ, IL1βand IL2β. The mediators and transcription factors that are required fortheir differentiation, polarization and effector function are referredto as the Th17 axis, and the Th17 axis includes other cell types whichproduce the same cytokines (and corresponding receptors), such as innatelymphoid cells (ILCs) and γδ T cells.

The Th17 axis of biological processes has been implicated in thepathology of many human diseases with an immune component or autoimmunepathology, such as psoriasis, ankylosing spondylitis, psoriaticarthritis, asthma, chronic obstructive pulmonary disease, ulcerativecholitis, Crohn's disease, multiple sclerosis, inflammatory boweldisease, rheumatoid arthritis, graft versus host disease, systemic lupuserythematosis, lupus nephtritis, insulin dependent diabetes type I, andalso in cancer (Wilke C M, Bishop K, Fox D, Zou W (2011) Trends Immunol.32(12):603-11; Bartlett, H S; Million, R P (2015) Nat. Rev. DrugDiscovery 14:11-12). Many of these diseases share genetic associationsto genes contained in the Th17 axis (Gaffen S L, Jain R, Garg A V, Cua DJ (2014) Nat. Rev. Immunol. 14(9):585-600).

RORγt is central to the Th17 axis since it is required for the functionof Th17 cells and governs cytokine production and related biologicalprocesses in many other cell types. Due to the central role of RORγt itis desirable to regulate RORγt activity as a means of treatment ofdiseases where the Th17 axis is perturbed. Accordingly there is a needfor new therapeutic agents which modulate RORγt.

Briefly, this specification describes, in part, a compound of formula(I):

wherein:

R¹ is H or (CO)R⁴;

R² is C₁₋₆ alkyl, cyclopropyl, CH₂-cyclopropyl, or NR⁵R⁶, wherein saidC₁₋₆ alkyl is optionally substituted with OH or C₁₋₆ alkoxy and saidCH₂-cyclopropyl is optionally substituted with halo, OH, CN or C₁₋₆alkoxy;

R³ is H, C₁₋₆ alkyl, C₁₋₆ alkoxy, halo or CN.

R⁴ is:

-   -   H;    -   C₁₋₆ alkyl optionally substituted with (R⁷)_(a);    -   C₃₋₇ cycloalkyl optionally substituted with halo, C₁₋₆ alkyl,        OH, CN, C₁₋₆ alkoxy, or C₁₋₃ alkyl-OR⁸;    -   heterocycloalkyl optionally substituted with C₁₋₆ alkyl or OH;    -   C₁₋₆ alkoxy; or    -   NHR¹³;

a is 1, 2 or 3;

R⁶ is H, C₁₋₆ alkyl or C₃₋₇ cycloalkyl;

R⁷ is independently selected from the group consisting of halo, OH, CN,C₁₋₆ alkoxy, NR⁹R¹⁰, C₃₋₇ cycloalkyl, heterocycloalkyl and aryl, whereinsaid C₃₋₇ cycloalkyl, heterocycloalkyl or aryl groups are furtheroptionally substituted with 1, 2 or 3 groups independently selected fromthe group consisting of C₁₋₆ alkyl, CN, OH, C₁₋₆ alkoxy and NR¹¹R¹²;

R¹³ is H, C₁₋₆ alkyl or C₃₋₇ cycloalkyl;

R⁵, R⁸, R⁹, R¹⁰, R¹¹ and R¹² are each independently H or C₁₋₆ alkyl;

or a pharmaceutically acceptable salt thereof.

This specification also describes, in part, pharmaceutical compositionswhich comprise a compound of the formula (I), or a pharmaceuticallyacceptable salt thereof, and at least one pharmaceutically acceptableexcipient.

This specification also describes, in part, a compound of formula (I),or a pharmaceutically acceptable salt thereof, for use in therapy.

This specification also describes, in part, a compound of formula (I),or a pharmaceutically acceptable salt thereof, for the treatment orprevention of an RORγ and/or RORγt mediated disease state.

This specification also describes, in part, the use of a compound offormula (I), or a pharmaceutically acceptable salt thereof, in themanufacture of a medicament for the treatment or prevention of an RORγand/or RORγt mediated disease state.

This specification also describes, in part, a method of treating or ofpreventing an RORγ and/or RORγt mediated disease state in a mammalsuffering from, or at risk of, said disease, which comprisesadministering to a mammal in need of such treatment a therapeuticallyeffective amount of a compound of formula (I), or a pharmaceuticallyacceptable salt thereof.

Further aspects of the specification will be apparent to one skilled inthe art from reading this specification.

The compounds of the specification may exist in salt-form or in non-saltform (ie. as a free base), and the present specification covers bothsalt forms and non-salt forms. Compounds described in this specificationmay form acid addition salts or base addition salts. In general, an acidaddition salt can be prepared using various inorganic or organic acids.Such salts can typically be formed by, for example, mixing the compoundwith an acid (e.g. a stoichiometric amount of an acid) using variousmethods known in the art. This mixing may occur in water, an organicsolvent (e.g. ether, ethyl acetate, ethanol, methanol, isopropanol, oracetonitrile), or an aqueous/organic mixture. In another aspect of thespecification acid addition salts are, for example, trifluoroacetate,formate, acetate or hydrochloric. In general, a base addition salt canbe prepared using various inorganic or organic bases, for example analkali or alkaline earth metal salt such as a sodium, calcium ormagnesium salt, or other metal salts, such as potassium or zinc, or anammonium salt, or a salt with an organic base such as methylamine,dimethylamine, trimethylamine, piperidine or morpholine. The skilledperson will be aware of the general principles and techniques ofpreparing pharmaceutical salts, such as those described in, for example,Berge et al., J. Pharm. Sci., 66, 1-19 (1977).

Compounds and salts described in this specification include one or morechiral (i.e. asymmetric) centres. To the extent a structure or chemicalname in this specification does not indicate the chirality, thestructure or name is intended to encompass any single stereoisomer (i.e.any single chiral isomer) corresponding to that structure or name, aswell as any mixture of stereoisomers (e.g. a racemate). In someembodiments, a single stereoisomer is obtained by isolating it from amixture of isomers (e.g. a racemate) using, for example, chiralchromatographic separation. In other embodiments, a single stereoisomeris obtained through direct synthesis from, for example, a chiralstarting material.

A particular enantiomer of a compound described herein may be moreactive than other enantiomers of the same compound.

According to one embodiment there is provided a compound of formula (I),or a pharmaceutically acceptable salt thereof, which is a singleenantiomer being in an enantiomeric excess (% ee) of ≥95, ≥98% or ≥99%.Conveniently, the single enantiomer is present in an enantiomeric excess(% ee) of ≥99%.

According to another embodiment there is provided a pharmaceuticalcomposition, which comprises a compound of formula (I), which is asingle enantiomer being in an enantiomeric excess (% ee) of ≥95, ≥98% or≥99% or a pharmaceutically acceptable salt thereof, in association withone or more pharmaceutically acceptable excipients. Conveniently, thesingle enantiomer is present in an enantiomeric excess (% ee) of ≥99%.

When in solid crystalline form a compound of formula (I) can be in theform of a co-crystal with another chemical entity and the specificationencompasses all such co-crystals.

The compounds of the specification may exist as a solvate (such as ahydrate) as well as unsolvated forms, and the present specificationcovers all such solvates.

Compounds and salts described in this specification may exist in varioustautomeric forms and the specification encompasses all such tautomericforms. “Tautomers” are structural isomers that exist in equilibriumresulting from the migration of a hydrogen atom.

Compounds and salts described in this specification may beisotopically-labeled (or “radio-labeled”). In that instance, one or moreatoms are replaced by an atom having an atomic mass or mass numberdifferent from the atomic mass or mass number typically found in nature.The specification encompasses isotopically-labelled forms of compoundsdisclosed herein. Examples of isotopes that may be incorporated include²H (also written as “D” for deuterium), ³H (also written as “T” fortritium), ¹¹C, ¹³C, ¹⁴C, ¹³N, ¹⁵N, ¹⁵O, ¹⁷O, ¹⁸O and ³⁶Cl. The isotopethat is used will depend on the specific application of thatradio-labeled derivative. For example, for in vitro receptor labelingand competition assays, H or ¹⁴C are often useful. For radio-imagingapplications, ¹¹C is often useful. In some embodiments, the radionuclideis ³H. In some embodiments, the radionuclide is ¹⁴C. In someembodiments, the radionuclide is ¹¹C.

Unless otherwise stated, halo is selected from chloro (Cl), fluoro (F),bromo (Br) and iodo (I), such as fluoro.

Cycloalkyl is a non-aromatic carbocyclic ring. The carbocyclic ring maybe saturated or unsaturated, and may be bridged or unbridged. C₃₋₇cycloalkyl is any such carbocyclic ring containing 3 to 7 carbon atoms.An example of C₃₋₇ cycloalkyl is an unsaturated non-aromatic carbocyclicring containing 3 to 7 carbon atoms. Examples of suitable cycloalkylgroups are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl andcycloheptyl, such as cyclopropyl and cyclobutyl.

Heterocycloalkyl is a 3 to 9 membered non-aromatic, mono- or bi-cyclicring comprising one or two heteroatoms independently selected fromnitrogen, oxygen or sulphur; or an N-oxide thereof, or an S-oxide orS-dioxide thereof. The ring may be saturated or unsaturated, and may bebridged or unbridged. An example of heterocycloalkyl is an unsaturated 4to 6 membered non-aromatic, mono-cyclic ring comprising one heteroatomindependently selected from nitrogen or oxygen; or an N-oxide thereof.Examples of suitable heterocycloalkyl groups include oxiranyl,aziridinyl, azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl,tetrahydropyranyl, piperidinyl, morpholinyl, thiomorpholinyl, andpiperazinyl, such as azetidinyl, oxetanyl, pyrrolidinyl ortetrahydrofuranyl, for example oxetanyl or tetrahydrofuranyl. For theavoidance of doubt, substituents on the heterocycloalkyl ring may belinked via either a carbon atom or a heteroatom.

Aryl is an aromatic ring containing 6 or 10 carbon atoms. Examples ofsuitable aryl groups include phenyl and naphthyl, such as phenyl.

Unless otherwise stated alkyl, alkoxy and haloalkyl groups containingthe requisite number of carbon atoms can be branched or unbranched.Examples of suitable C₁₋₆ alkyl groups include methyl (Me), ethyl (Et),n-propyl, i-propyl, n-butyl, sec-butyl, i-butyl, t-butyl, n-pentyl,i-pentyl, neo-pentyl, n-hexyl and i-hexyl, such as methyl, ethyl,n-propyl, i-propyl, and i-butyl. Examples of suitable C₁₋₆ alkoxy groupsinclude methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, sec-butoxy,t-butoxy, n-pentoxy, i-pentoxy, n-hexoxy, i-hexoxy, methoxyethyl,methoxypropyl, ethoxyethyl and methoxybutyl, such as methoxy, ethoxy,i-propoxy and t-butoxy. Examples of suitable C₁₋₃ alkyl-OH groupsinclude —CH₂OH and —CH₂CH₂OH, such as —CH₂OH.

For the avoidance of doubt, where multiple substituents areindependently selected from a given group, the selected substituents maycomprise the same substituents or different substituents from within thegiven group. By way of example only, where R⁴ is C₁₋₆ alkyl optionallysubstituted with (R⁷)_(a), and where a is 2, the two R⁷ substituentscould be the same, for instance both fluoro, or could be different, forinstance one fluoro and one OH.

In one embodiment R¹ is H.

In another embodiment R¹ is (CO)R⁴.

In one embodiment R² is C₁₋₆ alkyl (optionally substituted with OH orC₁₋₆ alkoxy), cyclopropyl, unsubstituted CH₂-cyclopropyl, or NR⁵R⁶.

In one embodiment R² is C₁₋₆ alkyl (optionally substituted with OH orC₁₋₆ alkoxy), or CH₂-cyclopropyl (optionally substituted with halo, OH,CN or C₁₋₆ alkoxy).

In one embodiment R² is C₁₋₆ alkyl (optionally substituted with OH orC₁₋₆ alkoxy), or CH₂-cyclopropyl (optionally substituted with OH, CN orC₁₋₆ alkoxy).

In another embodiment R² is unsubstituted C₁₋₆ alkyl or unsubstitutedCH₂-cyclopropyl.

In another embodiment R² is C₁₋₆ alkyl optionally substituted with OH orC₁₋₆ alkoxy.

In another embodiment R² is C₁₋₆ alkyl substituted with OH, such as—CH₂CH₂OH, —CH₂CH₂CH₂OH or —CH₂CH(OH)CH₃, for example —CH₂CH₂OH.

In another embodiment R² is C₁₋₆ alkyl substituted with C₁₋₆ alkoxy,such as —CH₂CH₂OCH₃, or —CH₂CH₂CH₂OCH₃, for example —CH₂CH₂OCH₃.

In another embodiment R² is unsubstituted C₁₋₆ alkyl, such as methyl,ethyl or i-propyl.

In another embodiment R² is unsubstituted methyl or unsubstituted ethyl.In a further embodiment R² is unsubstituted methyl.

In another embodiment R² is cyclopropyl or CH₂-cyclopropyl (optionallysubstituted with OH, CN or C₁₋₆ alkoxy).

In another embodiment R² is CH₂-cyclopropyl (optionally substituted withhalo, OH, CN or C₁₋₆ alkoxy).

In another embodiment R² is CH₂-cyclopropyl substituted with halo, suchas fluoro.

In another embodiment R² is CH₂-cyclopropyl (optionally substituted withOH, CN or C₁₋₆ alkoxy).

In another embodiment R² is unsubstituted CH₂-cyclopropyl.

In another embodiment R² is NR⁵R⁶.

In one embodiment R³ is H, C₁₋₆ alkyl or halo.

In another embodiment R³ is H, methyl or fluoro.

In another embodiment R³ is H.

In another embodiment R³ is C₁₋₆ alkyl such as methyl, ethyl ori-propyl, for example methyl.

In another embodiment R³ is halo, for example fluoro.

In one embodiment R⁴ is:

-   -   H;    -   C₁₋₆ alkyl optionally substituted with (R⁷)_(a);    -   C₃₋₇ cycloalkyl optionally substituted with C₁₋₆ alkyl, OH, CN,        C₁₋₆ alkoxy, or C₁₋₃ alkyl-OR⁸;    -   heterocycloalkyl optionally substituted with C₁₋₆ alkyl or OH;        or    -   C₁₋₆ alkoxy;

In one embodiment R⁴ is H.

In one embodiment R⁴ is C₁₋₆ alkyl optionally substituted with (R⁷)_(a).

In another embodiment R⁴ is unsubstituted C₁₋₆ alkyl. In a furtherembodiment, R⁴ is unsubstituted methyl. In a further embodiment, R⁴ isunsubstituted ethyl.

In another embodiment a is 1 or 2. In another embodiment a is 2 or 3. Inanother embodiment a is 1. In another embodiment a is 2. In anotherembodiment a is 3.

In another embodiment R⁴ is C₃₋₇ cycloalkyl (such as cyclopropyl orcyclobutyl) optionally substituted with C₁₋₆ alkyl, OH, CN, C₁₋₆ alkoxyor C₁₋₃ alkyl-OR⁸. In another embodiment, R⁴ is unsubstituted C₃₋₇cycloalkyl.

In another embodiment R⁴ is C₃₋₇ cycloalkyl (such as cyclopropyl)optionally substituted with halo.

In another embodiment R⁴ is cyclopropyl optionally substituted with OH,CN, C₁₋₆ alkoxy (such as methoxy or ethoxy) or C₁₋₃ alkyl-OR⁸ (such as—CH₂OH).

In another embodiment R⁴ is cyclobutanyl optionally substituted with OH,CN, C₁₋₆ alkoxy (such as methoxy or ethoxy) or C₁₋₃ alkyl-OR⁸ (such as—CH₂OH), for example OH.

In another embodiment R⁴ is heterocycloalkyl optionally substituted withC₁₋₆ alkyl or OH. In another embodiment, R⁴ is unsubstitutedheterocycloalkyl.

In a further embodiment R⁴ is tetrahydrofuranyl optionally substitutedwith C₁₋₆ alkyl or OH.

In a further embodiment R⁴ is oxetanyl optionally substituted with C₁₋₆alkyl or OH.

In another embodiment R⁴ is C₁₋₆ alkoxy, such as methoxy, ethoxy,i-propoxy or t-butoxy, for example methoxy.

In one embodiment R⁴ is NHR¹³.

In one embodiment R⁶ is C₁₋₆ alkyl, such as methyl.

In another embodiment R⁶ is C₃₋₇ cycloalkyl, such as cyclopropyl.

In one embodiment R⁷ is independently selected from the group consistingof halo (such as fluoro), OH, CN, C₁₋₆ alkoxy (such as methoxy), NR⁹R¹⁰,C₃₋₇ cycloalkyl (such as cyclopropyl or cyclobutyl), heterocycloalkyl(such as oxetanyl) and aryl (such as phenyl), wherein said C₃₋₇cycloalkyl, heterocycloalkyl or aryl groups are further optionallysubstituted with 1, 2 or 3 groups independently selected from the groupconsisting of CN, OH, C₁₋₆ alkoxy (such as methoxy) and NR¹¹R¹².

In another embodiment R⁷ is independently selected from the groupconsisting of fluoro, OH, CN, methoxy, NH₂, cyclopropyl, cyclobutyl,oxetanyl and phenyl, wherein said cyclopropyl, cyclobutyl, oxetanyl orphenyl groups are further optionally substituted with 1, 2 or 3 groupsindependently selected from the group consisting of CN, OH, methoxy andNR¹¹R¹².

In another embodiment R⁷ is independently selected from the groupconsisting of halo (such as fluoro) and C₃₋₇ cycloalkyl (such ascyclopropyl).

In another embodiment R⁷ is halo, such as fluoro.

In another embodiment R⁷ is OH.

In another embodiment R⁷ is CN.

In another embodiment R⁷ is C₁₋₆ alkoxy, such as methoxy or ethoxy.

In another embodiment R⁷ is NR⁹R¹⁰, such as —NH₂ or —N(CH₃)₂.

In another embodiment R⁷ is C₃₋₇ cycloalkyl (such as cyclopropyl orcyclobutyl) optionally substituted with 1, 2 or 3 groups (such as 1 or 2groups, for example 1 group) independently selected from the groupconsisting of CN, OH, C₁₋₆ alkoxy (such as methoxy) and NR¹¹R¹² (such as—N(CH₃)₂). In another embodiment, R⁷ is unsubstituted C₃₋₇ cycloalkyl.

In another embodiment R⁷ is heterocycloalkyl (such as oxetanyl)optionally substituted with 1, 2 or 3 groups (such as 1 or 2 groups, forexample 1 group) independently selected from the group consisting of CN,OH, C₁₋₆ alkoxy (such as methoxy) and NR^(11R12). In another embodiment,R⁷ is unsubstituted heterocycloalkyl.

In another embodiment R⁷ is phenyl optionally substituted with 1, 2 or 3groups (such as 1 or 2 groups, for example 1 group) independentlyselected from the group consisting of CN, OH, halo, C₁₋₆ alkoxy (such asmethoxy) or NR¹¹R¹². In another embodiment, R⁷ is unsubstituted phenyl.

In one embodiment R⁹ and R¹⁰ are independently H or methyl.

In one embodiment R¹¹ and R¹² are independently H or methyl.

In a further embodiment, there is provided a compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R², R³ and R⁴ areas defined in the compound of formula (I):

In a further embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R² is C₁₋₆ alkyloptionally substituted with OH or C₁₋₆ alkoxy, such as methyl, ethyl,—CH₂CH₂OH, or —CH₂CH₂OCH₃.

In a further embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R² is cyclopropylor CH₂-cyclopropyl (optionally substituted with halo, OH, CN or C₁₋₆alkoxy), such as CH₂-cyclopropyl (optionally substituted with OH, CN orC₁₋₆ alkoxy).

In a further embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R² is NR⁵R⁶, suchas —NHR⁶ where R⁶ is methyl or cyclopropyl.

In a further embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R² isunsubstituted C₁₋₆ alkyl or unsubstituted CH₂-cyclopropyl.

In a further embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R² isunsubstituted C₁₋₆ alkyl.

In a further embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R² isunsubstituted methyl or unsubstituted ethyl.

In a further embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R² isunsubstituted methyl.

In a further embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R² isunsubstituted ethyl.

In a further embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R² iscyclopropyl.

In a further embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R² isCH₂-cyclopropyl optionally substituted with halo, OH, CN or C₁₋₆ alkoxy.

In a further embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R² isCH₂-cyclopropyl optionally substituted with OH, CN or C₁₋₆ alkoxy.

In a further embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R² isunsubstituted CH₂-cyclopropyl.

In a further embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R² is—CH₂CH₂OCH₃.

In a further embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R² is —CH₂CH₂OH.

In a further embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R² is—CH₂CH(OH)CH₃.

In a further embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R² is —NHCH₃.

In a further embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R² is—NH-cyclopropyl.

In a further embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R³ is H.

In a further embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R³ is C₁₋₆ alkyl,such as methyl.

In a further embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R³ is fluoro.

In a further embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R⁴ is H.

In a further embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R⁴ is C₁₋₆ alkyloptionally substituted with (R⁷)_(a). In a further embodiment a is 1 or2, such as 1. In another embodiment, R⁴ is unsubstituted C₁₋₆ alkyl. Inanother embodiment, R⁴ is unsubstituted methyl. In another embodiment,R⁴ is unsubstituted ethyl.

In a further embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R⁴ is C₃₋₇cycloalkyl (such as cyclopropyl or cyclobutyl) optionally substitutedwith C₁₋₆ alkyl, OH, CN, C₁₋₆ alkoxy (such as methoxy or ethoxy) or C₁₋₃alkyl-OR⁸ (such as —CH₂OH). In another embodiment, R⁴ is unsubstitutedC₃₋₇ cycloalkyl.

In a further embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R⁴ isheterocycloalkyl (such as oxetanyl or tetrahydrofuranyl) optionallysubstituted with C₁₋₆ alkyl or OH. In another embodiment, R⁴ isunsubstituted heterocycloalkyl.

In a further embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R⁴ is C₁₋₆ alkoxy(such as methoxy, ethoxy, i-propoxy or t-butoxy).

In a further embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R⁴ is NHR¹³ (suchas —NH₂, —NHCH₃, —NHCH₂CH₃ or —NH-cyclopropyl).

In one embodiment, there is provided the compound of formula (II), or apharmaceutically acceptable salt thereof, wherein R² is C₁₋₆ alkyl(optionally substituted with OH or C₁₋₆ alkoxy) or CH₂-cyclopropyl(optionally substituted with halo, OH, CN or C₁₋₆ alkoxy); R³ is H; andR⁴ is C₁₋₆ alkyl (optionally substituted with (R⁷)_(a)), C₃₋₇ cycloalkyl(optionally substituted with halo, C₁₋₆ alkyl, OH, CN, C₁₋₆ alkoxy orC₁₋₃ alkyl-OR⁸), heterocycloalkyl (optionally substituted with C₁₋₆alkyl or OH) or C₁₋₆ alkoxy.

In one embodiment, there is provided the compound of formula (II), or apharmaceutically acceptable salt thereof, wherein R² is C₁₋₆ alkyl(optionally substituted with OH or C₁₋₆ alkoxy) or CH₂-cyclopropyl(optionally substituted with halo, OH, CN or C₁₋₆ alkoxy); R³ is H; andR⁴ is C₁₋₆ alkyl (optionally substituted with (R⁷)_(a)) or C₃₋₇cycloalkyl (optionally substituted with halo, C₁₋₆ alkyl, OH, CN, C₁₋₆alkoxy or C₁₋₃ alkyl-ORs).

In one embodiment, there is provided the compound of formula (II), or apharmaceutically acceptable salt thereof, wherein R² is C₁₋₆ alkyl(optionally substituted with OH or C₁₋₆ alkoxy) or CH₂-cyclopropyl(optionally substituted with halo, OH, CN or C₁₋₆ alkoxy); R³ is H; andR⁴ is C₁₋₆ alkyl optionally substituted with (R⁷)_(a).

In one embodiment, there is provided the compound of formula (II), or apharmaceutically acceptable salt thereof, wherein R² is unsubstitutedC₁₋₆ alkyl or unsubstituted CH₂-cyclopropyl; R³ is H; and R⁴ is C₁₋₆alkyl optionally substituted with (R⁷)_(a).

In one embodiment, there is provided the compound of formula (II), or apharmaceutically acceptable salt thereof, wherein R² is unsubstitutedC₁₋₆ alkyl; R³ is H; and R⁴ is C₁₋₆ alkyl optionally substituted with(R⁷)_(a).

In one embodiment, there is provided the compound of formula (II), or apharmaceutically acceptable salt thereof, wherein R² is unsubstitutedCH₂-cyclopropyl; R³ is H; and R⁴ is C₁₋₆ alkyl optionally substitutedwith (R⁷)_(a).

In another embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R² isunsubstituted methyl or unsubstituted ethyl; R³ is H; and R⁴ is C₁₋₆alkyl optionally substituted with (R⁷)_(a).

In another embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R² isunsubstituted methyl; R³ is H; and R⁴ is C₁₋₆ alkyl optionallysubstituted with (R⁷)_(a).

In another embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R² isunsubstituted ethyl; R³ is H; and R⁴ is C₁₋₆ alkyl optionallysubstituted with (R⁷)_(a).

In another embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R² isunsubstituted CH₂-cyclopropyl; R³ is H; and R⁴ is C₁₋₆ alkyl optionallysubstituted with (R⁷)_(a).

In one embodiment, there is provided the compound of formula (II), or apharmaceutically acceptable salt thereof, wherein R² is unsubstitutedC₁₋₆ alkyl or unsubstituted CH₂-cyclopropyl; R³ is H; and R⁴ isunsubstituted C₁₋₆ alkyl.

In another embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R² isunsubstituted C₁₋₆ alkyl; R³ is H; and R⁴ is unsubstituted C₁₋₆ alkyl.

In another embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R² isunsubstituted CH₂-cyclopropyl; R³ is H; and R⁴ is unsubstituted C₁₋₆alkyl.

In another embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R² isunsubstituted methyl; R³ is H; and R⁴ is unsubstituted methyl.

In another embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R² isunsubstituted ethyl; R³ is H; and R⁴ is unsubstituted methyl.

In another embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R² isunsubstituted CH₂-cyclopropyl; R³ is H; and R⁴ is unsubstituted methyl.

In another embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R² isunsubstituted methyl; R³ is H; and R⁴ is unsubstituted ethyl.

In another embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R² isunsubstituted ethyl; R³ is H; and R⁴ is unsubstituted ethyl.

In another embodiment, there is provided the compound of formula (II),or a pharmaceutically acceptable salt thereof, wherein R² isunsubstituted CH₂-cyclopropyl; R³ is H; and R⁴ is unsubstituted ethyl.

In another embodiment, there is provided the compound of formula (I) orformula (II) which exhibits R-stereochemistry at the carbon atom markedwith an asterisk as shown below:

or a pharmaceutically acceptable salt thereof.

Where any embodiment within this specification includes a group which issaid to be “optionally substituted”, then unless otherwise stated thesaid group may be unsubstituted or may be substituted with 1, 2 or 3substituents (such as 1 or 2 substituents, for example 1 substituent)independently selected from the list of substituents provided. For theavoidance of doubt a further embodiment will include that embodimentwherein the said group is unsubstituted.

Where any embodiment within this specification includes a sub-selectionof a smaller group (using the words “such as” or “for example”), thenfor the avoidance of doubt each sub-selected group represents anadditional embodiment.

An example of a compound of the specification is:

-   5-(Ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   5-(Ethylsulfonyl)-2-formyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-[(1-Cyanocyclopropyl)acetyl]-5-(ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-Acetyl-5-(ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-[Cyclopropyl(difluoro)acetyl]-5-(ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-[(1-Cyanocyclopropyl)carbonyl]-5-(ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   5-(Ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   5-(Ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(1-hydroxycyclopropyl)acetyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   5-(Ethylsulfonyl)-2-(3-fluoropropanoyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-(Cyclobutylacetyl)-5-(ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   5-(Ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(oxetan-2-ylcarbonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-(3-Cyanopropanoyl)-5-(ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   5-(Ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(1-methoxycyclopropyl)acetyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   5-(Ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(tetrahydrofuran-3-ylcarbonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   5-(Ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(tetrahydrofuran-2-ylcarbonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-{[1-(Dimethylamino)cyclopropyl]acetyl}-5-(ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   5-[(Cyclopropylmethyl)sulfonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-Acetyl-5-[(cyclopropylmethyl)sulfonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   5-[(cyclopropylmethyl)sulfonyl]-2-formyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   5-[(Cyclopropylmethyl)sulfonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(methoxyacetyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   Ethyl    5-[(cyclopropylmethyl)sulfonyl]-1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-1,3-dihydro-2H-isoindole-2-carboxylate;-   5-[(Cyclopropylmethyl)sulfonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(1-methoxycyclopropyl)acetyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   5-[(Cyclopropylmethyl)sulfonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(1-hydroxycyclopropyl)acetyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   5-[(Cyclopropylmethyl)sulfonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   5-[(Cyclopropylmethyl)sulfonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(tetrahydrofuran-2-ylcarbonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-[(1-Cyanocyclopropyl)carbonyl]-5-[(cyclopropylmethyl)sulfonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   5-[(Cyclopropylmethyl)sulfonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(tetrahydrofuran-3-ylcarbonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-[Amino(cyclopropyl)acetyl]-5-[(cyclopropylmethyl)sulfonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   5-[(Cyclopropylmethyl)sulfonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(1-methoxycyclopropyl)carbonyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   Methyl    5-[(cyclopropylmethyl)sulfonyl]-1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-1,3-dihydro-2H-isoindole-2-carboxylate;-   2-[Cyclopropyl(difluoro)acetyl]-5-[(cyclopropylmethyl)sulfonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfamoyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-Acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfamoyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-Formyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfamoyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(2R)-2-hydroxybutanoyl]-5-(methylsulfamoyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   Methyl    1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-5-(methylsulfamoyl)-1,3-dihydro-2H-isoindole-2-carboxylate;-   Ethyl    1-{[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-5-(methylsulfamoyl)-1,3-dihydro-2H-isoindole-2-carboxylate;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(1-methoxycyclopropyl)carbonyl]-5-(methylsulfamoyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(2S)-2-hydroxybutanoyl]-5-(methylsulfamoyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(methoxyacetyl)-5-(methylsulfamoyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfamoyl)-2-(oxetan-2-ylcarbonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfamoyl)-2-[(2R)-tetrahydrofuran-2-ylcarbonyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfamoyl)-2-[(2S)-tetrahydrofuran-2-ylcarbonyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-Acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2-(phenylacetyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   Methyl    1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-5-(methylsulfonyl)-1,3-dihydro-2H-isoindole-2-carboxylate;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(1-methoxycyclopropyl)carbonyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-[(1-Cyanocyclopropyl)carbonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-Formyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2-(oxetan-2-ylcarbonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-(3-Fluoro-2-methylpropanoyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(2R)-2-hydroxybutanoyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(3-methylbutanoyl)-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-(Cyclopropylacetyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(1-hydroxycyclopropyl)acetyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-[(3S)-3-Fluorobutanoyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(methoxyacetyl)-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-(3-Fluoropropanoyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-[(1-Ethoxycyclopropyl)carbonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(1-methoxycyclopropyl)acetyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-[(3R)-3-Fluorobutanoyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(2-methoxy-2-methylpropanoyl)-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   Propan-2-yl    1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-5-(methylsulfonyl)-1,3-dihydro-2H-isoindole-2-carboxylate;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(3-hydroxy-3-methylbutanoyl)-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(2R)-2-hydroxy-3-methylbutanoyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(2S)-2-hydroxy-3-methylbutanoyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(2S)-2-hydroxybutanoyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(3-hydroxy-2-methylpropanoyl)-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2-(oxetan-3-ylacetyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-[(1-Cyanocyclopropyl)acetyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(1-hydroxycyclopropyl)carbonyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-(3-Cyanopropanoyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(trans-3-hydroxycyclobutyl)carbonyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(cis-3-hydroxycyclobutyl)carbonyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(3R)-3-hydroxybutanoyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(3S)-3-hydroxybutanoyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-Acetyl-N-[3-fluoro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-[(1-cyanocyclopropyl)carbonyl]-N-[2-fluoro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-Acetyl-N-[2-fluoro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[2-Fluoro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-[(1-Cyanocyclopropyl)carbonyl]-N-[3-fluoro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[3-Fluoro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(1-methoxycyclopropyl)carbonyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-Acetyl-5-(cyclopropylsulfamoyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   5-(Cyclopropylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-Acetyl-5-(cyclopropylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   Methyl    5-(cyclopropylsulfonyl)-1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-1,3-dihydro-2H-isoindole-2-carboxylate;-   5-(cyclopropylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(1-methoxycyclopropyl)carbonyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   5-(cyclopropylsulfonyl)-2-formyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-[(2-methoxyethyl)sulfonyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-Formyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-[(2-methoxyethyl)sulfonyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-Acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-[(2-methoxyethyl)sulfonyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(1-methoxycyclopropyl)carbonyl]-5-[(2-methoxyethyl)sulfonyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-[(2-hydroxyethyl)sulfonyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-Acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-[(2-hydroxyethyl)sulfonyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-[(2-hydroxyethyl)sulfonyl]2-[(1-methoxycyclopropyl)carbonyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   (1R)-2-Acetyl-5-(ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-5    yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   (1S)-2-Acetyl-5-(ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   (1R)-2-Acetyl-5-[(cyclopropylmethyl)sulfonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide;    10-   (1S)-2-Acetyl-5-[(cyclopropylmethyl)sulfonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   (1R)—N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(2R)-2-hydroxybutanoyl]-5-(methylsulfamoyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   (1S)—N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(2R)-2-15    hydroxybutanoyl]-5-(methylsulfamoyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   (1R)—N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(2S)-2-hydroxybutanoyl]-5-(methylsulfamoyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   (1S)—N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(2S)-2-hydroxybutanoyl]-5-(methylsulfamoyl)-2,3-dihydro-1H-isoindole-1-carboxamide;    20-   (1R)-2-Acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   (1S)-2-Acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   (1R)—N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(1-25    methoxycyclopropyl)carbonyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   (1S)—N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(1-methoxycyclopropyl)carbonyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   (1R)—N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(2R)-2-hydroxybutanoyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   (1S)—N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(2R)-2-hydroxybutanoyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   (1R)—N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(2S)-2-5    hydroxybutanoyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   (1S)—N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(2S)-2-hydroxybutanoyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;    or a pharmaceutically acceptable salt thereof.

A further example of a compound of the specification is:

-   2-(Cyanoacetyl)-5-(ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   5-(Ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-{[1-(hydroxymethyl)cyclopropyl]carbonyl}-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(2-methoxybutanoyl)-5-(methylsulfamoyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(hydroxyacetyl)-5-(methylsulfamoyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[2-Fluoro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(1-methoxycyclopropyl)carbonyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[2-Fluoro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-   2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(3-methyloxetan-3-yl)carbonyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2-(oxetan-3-ylcarbonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(2-methyloxetan-2-yl)carbonyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-[(1-Fluorocyclopropyl)carbonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(2-methoxybutanoyl)-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(1-methoxycyclobutyl)carbonyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(2R)-2-methoxypropanoyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-Acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)(1-²H)-2,3-dihydro-1H-isoindole-1-carboxamide;-   (1R)—N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(2-methyloxetan-2-yl)carbonyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   5-(Cyclopropylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(hydroxyacetyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   5-(Cyclopropylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(methoxyacetyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-[(1-Cyanocyclopropyl)carbonyl]-5-(cyclopropylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   5-(Cyclopropylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(2S)-tetrahydrofuran-2-ylcarbonyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   5-(Cyclopropylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(2R)-tetrahydrofuran-2-ylcarbonyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   Methyl    1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-5-[(2-methoxyethyl)sulfonyl]-1,3-dihydro-2H-isoindole-2-carboxylate;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(hydroxyacetyl)-5-[(2-methoxyethyl)sulfonyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(methoxyacetyl)-5-[(2-methoxyethyl)sulfonyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   5-{[(1-Cyanocyclopropyl)methyl]sulfonyl}-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-Acetyl-5-{[(1-cyanocyclopropyl)methyl]sulfonyl}-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   Methyl    5-{[(1-cyanocyclopropyl)methyl]sulfonyl}-1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-1,3-dihydro-2H-isoindole-2-carboxylate;-   N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-[(2-methylpropyl)sulfonyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-Acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-[(2-methylpropyl)sulfonyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-{[(1-hydroxycyclopropyl)methyl]sulfonyl}-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-Acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-{[(1-hydroxycyclopropyl)methyl]sulfonyl}-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-Formyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-{[(1-hydroxycyclopropyl)methyl]sulfonyl}-2,3-dihydro-1H-isoindole-1-carboxamide;-   N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(hydroxyacetyl)-5-{[(1-hydroxycyclopropyl)methyl]sulfonyl}-2,3-dihydro-1H-isoindole-1-carboxamide;-   2-Acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-[(2-hydroxypropyl)sulfonyl]-2,3-dihydro-1H-isoindole-1-carboxamide;-   (1R)-2-[(1-Cyanocyclopropyl)carbonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   (1S)-2-[(1-Cyanocyclopropyl)carbonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   (1R)-2-Acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)(1-²H)-2,3-dihydro-1H-isoindole-1-carboxamide;-   (1S)-2-Acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)(1-²H)-2,3-dihydro-1H-isoindole-1-carboxamide;-   (1R)—N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(2R)-(2-methyloxetan-2-yl)carbonyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   (1R)—N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(2S)-(2-methyloxetan-2-yl)carbonyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;-   N²—Cyclopropyl-N¹-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfamoyl)-1,3-dihydro-2H-isoindole-1,2-dicarboxamide;-   N¹-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-N²-methyl-5-(methylsulfonyl)-1,3-dihydro-2H-isoindole-1,2-dicarboxamide;-   N²-Ethyl-N¹-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-1,3-dihydro-2H-isoindole-1,2-dicarboxamide;-   N¹-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-1,3-dihydro-2H-isoindole-1,2-dicarboxamide;-   N²—Cyclopropyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-1,3-dihydro-2H-isoindole-1,2-dicarboxamide;-   5-(Cyclopropylsulfonyl)-N¹-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-N²-methyl-1,3-dihydro-2H-isoindole-1,2-dicarboxamide;-   N¹-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-[(2-methoxyethyl)sulfonyl]-N²-methyl-1,3-dihydro-2H-isoindole-1,2-dicarboxamide;    or a pharmaceutically acceptable salt thereof.

A further feature is any of the embodiments described above with theproviso that any of the specific Examples are individually disclaimed.For example, a further feature is any of the embodiments described abovewith the proviso that any one or more of the compounds selected from theabove list of examples of compounds of the specification areindividually disclaimed.

In some embodiments, the compound is a compound of formula (I) excludingat least one compound recited in the Examples below. To illustrate, insome such embodiments, the compound is a compound of formula (I)excluding the compound disclosed in Example X, wherein X may be 1, 2, 3,etc. In other embodiments, the compound is a compound of formula (I)excluding the compounds disclosed in Examples Y, wherein Y may be anycombination of 1, 2, 3, etc.

The compounds of general Formula I described in the present inventioncan be readily prepared according to the following reaction schemes.Furthermore, a skilled organic chemist will appreciate that wherespecific reaction conditions are used, it is understood that othersuitable reaction conditions may be used to achieve the sametransformation and are thus included in the present invention. It willalso be clear to the skilled person that where synthetic schemes containfunctionality which may interfere with the desired reaction, suitableprotecting groups can be applied. For examples of protecting groups seeT. W. Greene and P. G. M. Wuts, “Protective Groups in OrganicSynthesis”, Third Edition, John Wiley & Sons, New York, 1999.

Scheme 1 represents a general reaction scheme for preparing compounds ofFormula (I), where R² and R³ are defined as above, and where Z isdefined below. An intermediate (IV) is condensed under standard amidebond forming conditions with intermediate (III). Conditions for thistransformation include, but are not limited to the use of reagents suchas EDC and HOBt, HATU and T3P and are conducted in solvents such as DCM,ethyl actetate or DMF in the presence of bases such as triethylamine,DMAP, diisopropyl ethylamine (DIPEA) or 2,6-lutidine. The intermediates(IV) and (III) and the reagents described are either commerciallyavailable or can be prepared using methods known to those skilled in theart.

Z is either R¹ which is defined as above, but excluding R¹═H, leadingdirectly to compounds of Formula (I), or it is a commonly used amineprotecting group such as, but not limited to tert-butyl carbamate (Boc),9-Fluorenylmethyl carbamate (Fmoc) or benzyl carbamate (Cbz), which isremoved to give the amine (V), a special case of formula I where R¹═H,either as a the free base or a salt, depending on the deprotection andisolation conditions (Scheme 2).

As shown in Scheme 3, amine (V) can then be transformed to an amide, aurea or a carbamate using standard organic chemistry procedures to givecompounds of Formula (II). The reagents for these transformations suchas, but not limited to, carboxylic acids, acid chlorides or anhydrides(R⁴CO₂H, R⁴COCl, (R⁴CO)₂O), isocyanates (R¹³N═C═O) and chloroformates(R^(4′)OCOCl) are either commercially available or can be prepared usingmethods known to those skilled in the art. For the avoidance of doubt,R^(4′)O represents R⁴ as defined as above, wherein the final atom of thecorresponding R⁴ is oxygen.

Another possibility is to use the functionality present in the R⁴substituent of compounds of Formula (II) to transform it into othercompounds of Formula (II). For some of these reactions, it might beadvantageous to protect the hydroxy group with known protecting groups,such as, but not limited to, benzyl ethers. Scheme 4 shows an example ofthis approach.

Intermediates such as (IV) are either commercially available or may beprepared by the method shown in Scheme 5 from anilines. Other methodsfor the preparation of intermediates (IV) can be found for example in:Cheng, J. F. et al. Bioorganic & Medicinal Chemistry Letters 2006,16,3484 or Nishimura, N. et al., Journal of Medicinal Chemistry 2014, 57,3094.

Intermediates (III) can be prepared by one of the general methods shownin the following Schemes. Introduction of the sulphur residue onto bromolactam (VIII) can be conducted in several ways, by base-catalyzed ormetal catalyzed substitution of the bromine with R²SH, where R² is asdefined above, but not NR⁵R⁶. This leads to thioethers (IX), which afterprotection of the lactam NH with a suitable protecting group, such as,but not limited to Boc, gives compounds (X), which can be subsequentlyoxidized to sulphones (XI) (Scheme 6). The order of the protection andoxidation step may be changed.

Another approach to thioethers (IX) is shown in Scheme 7. A thioether isformed from the bromo lactam as shown in Scheme 6, but the substituenton the sulphur is a protecting group, for example, but not limited to,benzyl or a methyl-propanoate group. Removal of the protecting group andalkylation of the resulting thiol then leads to thioethers (IX).

For R²═NR⁵R⁶ the route in Scheme 8 can be used. Benzyl thioether (XIV)is oxidized to the sulphonylchloride, which reacts with amines HNR⁵R⁶ togive sulphonamides (XVI). These can then be protected on the lactamnitrogen with a suitable protecting group, such as, but not limited to,Boc.

Further elaboration of these intermediate lactams to the isoindolinecarboxylic acids (III) is shown in Scheme 9. Similar chemistry isdescribed in Moran-Ramallal et al. Org. Lett. 2012, 14, 1696-1699.Reduction of protected lactams (XI) or (XVII) is followed byintroduction of the cyano group, which is subsequently hydrolyzed to thecarboxylic acid. The resulting isoindoline (XX) is then protected at thenitrogen with a suitable protecting group such as, but not limited toFmoc or Boc. Alternatively, the group R⁴CO can be introduced at thisstage.

Scheme 10 shows a further possibility to access building blocks (III).Here, the R²-moiety is introduced after elaboration of the lactam to thecarboxylic acid by alkylation of the thiol with electrophiles R²X, whereX is a typical leaving group such as tosylate or halogen.

In Scheme 11, bromo lactam (VIII) is converted to intermediate (XXV),which is transformed to the advanced intermediate (XXVI). Subsequently,the bromine can be converted to a protected thiol derivative, as in(XXVII), or converted directly to precursor of the desired sulfone R²and eventually to compounds of formula (II).

Compounds of formula (I) contain a stereogenic center in the isoindolinemoiety. Compounds of formula (I) can be separated into the (R)- and(S)-stereoisomers using appropriate chromatographic methods, as showngenerically in Scheme 12 and described in the examples provided below.These stereoisomers can also be obtained by condensing intermediate (IV)under standard amide bond forming conditions with a chiral intermediate(III) as described in Scheme 1. Chiral intermediate III may be obtainedfrom the corresponding unprotected chiral amino-acid using routineprotection protocols known to those skilled in the art. The saidunprotected chiral amino-acids are commercially available (for examplefrom NetChem), or may be synthesised using procedures known to thoseskilled in the art. Where Z is a commonly used amine protecting group,such as those described for Scheme 2, then deprotection leads to thechiral amine (V), which can then react under conditions described forScheme 3 to give compounds of formula (R)-II.

Detailed processes to the compounds of the specification are furtherdescribed in the Examples below.

Compounds and salts described in this specification generally may beused in methods to treat various disorders in animals, particularlymammals. Mammals include, for example, humans.

The compounds of the specification, and pharmaceutically acceptablesalts thereof, have activity as pharmaceuticals, in particular asmodulators of RORγ and/or RORγt, and can be used in the treatment of anRORγ and/or RORγt mediated disease state. Disease states that may betreated with a compound of the specification, or a pharmaceuticallyacceptable salt thereof, include but are not limited to immune disorderssuch as psoriasis, ankylosing spondylitis, psoriatic arthritis,ulcerative cholitis, Crohn's disease, multiple sclerosis, inflammatorybowel disease, rheumatoid arthritis, graft versus host disease, systemiclupus erythematosis, lupus nephtritis and insulin dependent diabetestype I, and to respiratory disorders such as chronic obstructivepulmonary disease (COPD) and asthma, and to cancer.

The present specification further provides a compound of formula (I) to(II) as hereinbefore defined, or a pharmaceutically acceptable saltthereof, for use in therapy.

In another aspect, the specification provides the use of a compound offormula (I) to (II) as hereinbefore defined, or a pharmaceuticallyacceptable salt thereof, in the manufacture of a medicament for use intherapy.

In the context of the present specification, the term “therapy” alsoincludes “prophylaxis” unless there are specific indications to thecontrary. The terms “therapeutic” and “therapeutically” should beconstrued accordingly.

A further aspect provides a method of treating a disease state in amammal suffering from, or at risk of, said disease, which comprisesadministering to a mammal in need of such treatment a therapeuticallyeffective amount of a compound of formula (I) to (II) as hereinbeforedefined, or a pharmaceutically acceptable salt thereof.

The present specification also provides the use of a compound of formula(I) to (II) as hereinbefore defined, or a pharmaceutically acceptablesalt thereof, in the manufacture of a medicament for use in thetreatment of chronic obstructive pulmonary disease (COPD), asthma orpsoriasis.

The present specification further provides the use of a compound offormula (I) to (II) as hereinbefore defined, or a pharmaceuticallyacceptable salt thereof, in the manufacture of a medicament for use inthe treatment of psoriasis. In a further aspect, the use is in thetreatment of ankylosing spondylitis or psoriatic arthritis.

The present specification also provides the use of a compound of formula(I) to (II) as hereinbefore defined, or a pharmaceutically acceptablesalt thereof, for treating chronic obstructive pulmonary disease (COPD),asthma or psoriasis.

The present specification further provides the use of a compound offormula (I) to (II) as hereinbefore defined, or a pharmaceuticallyacceptable salt thereof, for treating psoriasis. In a further aspect,the use is in the treatment of ankylosing spondylitis or psoriaticarthritis.

The present specification further provides a method of treating chronicobstructive pulmonary disease (COPD), asthma or psoriasis in awarm-blooded animal, such as man, which comprises administering to amammal in need of such treatment a therapeutically effective amount of acompound of formula (I) to (II) as hereinbefore defined, or apharmaceutically acceptable salt thereof.

The present specification further provides a method of treatingpsoriasis in a warm-blooded animal, such as man, which comprisesadministering to a mammal in need of such treatment a therapeuticallyeffective amount of a compound of formula (I) to (II) as hereinbeforedefined, or a pharmaceutically acceptable salt thereof. In a furtheraspect is a method of treating ankylosing spondylitis or psoriaticarthritis.

When a compound or salt described in this specification is administeredto treat a disorder, a “therapeutically effective amount” is an amountsufficient to reduce or completely alleviate symptoms or otherdetrimental effects of the disorder; cure the disorder; reverse,completely stop, or slow the progress of the disorder; or reduce therisk of the disorder getting worse.

In some embodiments in which a combination therapy is used, the amountof the compound or salt described in this specification and the amountof the other pharmaceutically active agent(s) are, when combined,therapeutically effective to treat a targeted disorder in the animalpatient. In this context, the combined amounts are “therapeuticallyeffective amounts” if they are, when combined, sufficient to reduce orcompletely alleviate symptoms or other detrimental effects of thedisorder; cure the disorder; reverse, completely stop, or slow theprogress of the disorder; or reduce the risk of the disorder gettingworse. Typically, such amounts may be determined by one skilled in theart by, for example, starting with the dosage range described in thisspecification for the compound or salt and an approved or otherwisepublished dosage range(s) of the other pharmaceutically activecompound(s).

In order to use a compound of the specification, or a pharmaceuticallyacceptable salt thereof, for the therapeutic treatment of a mammal, suchas human, said ingredient is normally formulated in accordance withstandard pharmaceutical practice as a pharmaceutical composition.Therefore in another aspect the present specification provides apharmaceutical composition which comprises a compound of the formula(I), or a pharmaceutically acceptable salt thereof (active ingredient),and at least one pharmaceutically acceptable excipient.

The pharmaceutical composition is typically intended for use in thetherapeutic and/or prophylactic treatment of a warm-blooded animal, suchas man.

Therefore the present specification provides a pharmaceuticalcomposition that comprises a compound of the specification (or apharmaceutically acceptable salt thereof) and one or morepharmaceutically acceptable excipients.

By the term “pharmaceutically acceptable excipient” we mean a substancethat serves as a vehicle or medium for the compound of the specification(or a pharmaceutically acceptable salt thereof), i.e. so as to preparethe active ingredient in a form suitable for administration. Generallythe pharmaceutically acceptable excipients are pharmacologicallyinactive. Each excipient should be compatible with the other ingredientsin the composition and should be acceptable for administration to awarm-blooded animal, such as man.

The excipient(s) selected for inclusion in a particular composition willdepend on factors such as the mode of administration and the form of thecomposition provided. Suitable pharmaceutically acceptable excipientsare well known to persons skilled in the art and are described, forexample, in the Handbook of Pharmaceutical Excipients, Sixth edition,Pharmaceutical Press, edited by Rowe, Ray C; Sheskey, Paul J; Quinn,Marian. Pharmaceutically acceptable excipients may function as, forexample, adjuvants, diluents, carriers, stabilisers, flavorings,colourants, fillers, binders, disintegrants, lubricants, glidants,thickening agents and coating agents. As persons skilled in the art willappreciate, certain pharmaceutically acceptable excipients may servemore than one function and may serve alternative functions depending onhow much of the excipient is present in the composition and what otherexcipents are present in the composition.

A pharmaceutical composition of the specification may comprise one ormore further active ingredients, as appropriate, examples ofcombinations of a compound of the specification (or a pharmaceuticallyacceptable salt thereof) and one or more additional active ingredientsare described herein.

A process for the preparation of the pharmaceutical composition maycomprise the step of mixing a compound of the specification (or apharmaceutically acceptable salt thereof) with one or morepharmaceutically acceptable excipients. The process may further comprisethe step of mixing one or more further active ingredients with acompound of the specification (or a pharmaceutically acceptable saltthereof) and one or more pharmaceutically acceptable excipients. Theprocesses are conducted using techniques and methods known to personsskilled in the art.

The pharmaceutical composition of the specification may be administeredin a standard manner for the disease that it is desired to treat and/orprevent. For example, suitable modes of administration include oral,intravenous, rectal, parenteral, topical, ocular, nasal, buccal orpulmonary administration. For these purposes a compound of thespecification (or a pharmaceutically acceptable salt thereof) may beformulated by means known in the art into the form of, for example,tablets, capsules, syrups, powders, granules, aqueous or oily solutionsor suspensions, (lipid) emulsions, dispersible powders, suppositories,ointments, creams, drops, aerosols, dry powder formulations, and sterileinjectable aqueous or oily solutions or suspensions.

The magnitude of prophylactic or therapeutic dose of a compound of thespecification (or a pharmaceutically acceptable salt thereof) will varydepending upon a range of factors, including the activity of thespecific compound (or pharmaceutically acceptable salt thereof) that isused, the age, body weight, diet, general health and sex of the patient,time of administration, the route of administration, the rate ofexcretion, the use of any other active ingredients, and the severity ofthe disease undergoing treatment.

Depending on the mode of administration, the pharmaceutical compositionof the specification will comprise from 0.05 to 99% w/w (percent byweight), such as from 0.05 to 80% w/w, for example from 0.10 to 70% w/w,such as from 0.10 to 50% w/w, of a compound of the specification (or apharmaceutically acceptable salt thereof), all percentages by weightbeing based on the total composition.

The present specification provides a pharmaceutical compositioncomprising a compound of the specification (or a pharmaceuticallyacceptable salt thereof) and one or more pharmaceutically acceptableexcipients, which composition is formulated for oral administration.

A pharmaceutical composition of the specification that is suitable fororal administration may be provided in unit dosage form, for example inthe form of a tablet or capsule. Such a unit dosage form may containfrom 0.1 mg to 1 g, for example from 5 mg to 250 mg, of a compound ofthe specification (or a pharmaceutically acceptable salt thereof) asactive ingredient.

For oral administration a compound of the specification (or apharmaceutically acceptable salt thereof) may be admixed with one ormore excipients, such as a carrier and/or a binder and/or a lubricant.Suitable carriers include, for example, lactose, saccharose, sorbitol,mannitol, a starch (for example, potato starch, corn starch oramylopectin) and a cellulose derivative. Suitable binders include, forexample, gelatine or polyvinylpyrrolidone. Suitable lubricants include,for example, magnesium stearate, calcium stearate, polyethylene glycol,a wax, paraffin, and the like. The mixture may then be compressed intotablets using known techniques. If coated tablets are required, thecores, prepared as described above, may be coated with a suitablecoating agent, for example with a concentrated sugar solution which maycontain, for example, gum arabic, gelatine, talcum and/or titaniumdioxide. Alternatively, the tablet may be coated with a suitable polymerdissolved in a readily volatile organic solvent.

For the preparation of soft gelatine capsules, a compound of thespecification (or a pharmaceutically acceptable salt thereof) may beadmixed with one or more excipients, such as a diluent. Suitablediluents include, for example, a vegetable oil or polyethylene glycol.Hard gelatine capsules may contain granules of the compound (or salt)using the above-mentioned excipients for tablets. Also liquid orsemi-solid formulations of a compound of the specification (or apharmaceutically acceptable salt thereof) may be filled into hardgelatine capsules.

Liquid preparations for oral application may be in the form of syrups orsuspensions, for example, solutions containing a compound of thespecification (or a pharmaceutically acceptable salt thereof), thebalance being sugar and a mixture of ethanol, water, glycerol andpropylene glycol. Optionally such liquid preparations may containcolourants, flavours, saccharine and/or carboxymethylcellulose as athickening agent or other excipients known to those skilled in art.

The present specification further provides a pharmaceutical compositioncomprising a compound of the specification (or a pharmaceuticallyacceptable salt thereof) and one or more pharmaceutically acceptableexcipients, which composition is formulated for topical administration.Topical administration may, for example, be in the form of creams,lotions, ointments or transdermal patches. Creams and ointments maycomprise an aqueous or oily base to which suitable thickening or gellingagents are applied. Lotions may comprise an aqueous or oily base towhich one or more emulsifying agents, stabilising agents, dispersingagents, suspending agents or thickening agents are applied.

A pharmaceutical composition of a compound of the specification that issuitable for pulmonary administration may be provided for inhaledadministration. Administration may be by oral inhalation. In anotherembodiment administration may be by intra-nasal administration. Thepresent specification therefore provides a pharmaceutical compositioncomprising a compound of the specification (or a pharmaceuticallyacceptable salt thereof) and one or more pharmaceutically acceptableexcipients, which composition is formulated for inhaled administration(particularly for oral inhaled administration).

When administered by oral inhalation, a compound of the specification(or a pharmaceutically acceptable salt thereof) may be used effectivelyat a daily dose in the μg range, for example up to 500 μg, such as from0.1 to 50 μg, from 0.1 to 40 μg, from 0.1 to g, from 0.1 to 20 μg orfrom 0.1 to 10 μg, of a compound of the specification (or apharmaceutically acceptable salt thereof) as active ingredient.

A pharmaceutical composition of the specification may be administered byoral inhalation in any suitable form and using any suitable inhalerdevice. Suitable inhaler devices are known to persons skilled in the artand may be manual or breath actuated. The pharmaceutical composition maybe formulated as a dry powder, as a suspension (in a liquid or gas) oras a solution (in a liquid) for administration by oral inhalation bymeans of a suitable inhaler device.

Inhaler devices suitable for pulmonary administration include metereddose inhalers (MDIs), dry powder inhalers (DPIs), nebulisers and softmist inhalers. Multi-chamber devices may be used to allow for deliveryof a compound of the specification (or a pharmaceutically acceptablesalt thereof) and one or more further active ingredients (when present).

The specification further relates to a combination therapy wherein acompound of the specification, or a pharmaceutically acceptable saltthereof, and a second active ingredient are administered concurrently,sequentially or in admixture, for the treatment of one or more of theconditions listed above. Such a combination may be used in combinationwith one or more further active ingredients.

In one aspect there is provided a combination (for example, for use as amedicament for the treatment of one of the diseases or conditions listedherein, such as psoriasis, COPD or asthma, for example COPD or asthma)comprising a compound of the specification, or a pharmaceuticallyacceptable salt thereof, and at least one active ingredient selectedfrom:

a) a beta-adrenoceptor agonist;

b) a muscarinic receptor antagonist;

c) a joint muscarinic receptor antagonist and beta-adrenoceptor agonist;and

d) a glucocorticoid receptor agonist (steroidal or non-steroidal).

In another aspect there is provided a combination (for example, for useas a medicament for the treatment of one of the diseases or conditionslisted herein, such as psoriasis, COPD or asthma) comprising a compoundof the specification, or a pharmaceutically acceptable salt thereof, anda phosphodiesterase-4 (PDE4) inhibitor.

In a further aspect of the present specification there is provided apharmaceutical composition (for example, for use as a medicament for thetreatment of one of the diseases or conditions listed herein, such aspsoriasis, COPD or asthma) comprising a compound of the specification,or a pharmaceutically acceptable salt thereof, and at least one activeingredient selected from:

a) a beta-adrenoceptor agonist;

b) a muscarinic receptor antagonist;

c) a joint muscarinic receptor antagonist and beta-adrenoceptor agonist;and

d) a glucocorticoid receptor agonist (steroidal or non-steroidal).

In another aspect there is provided a pharmaceutical composition (forexample, for use as a medicament for the treatment of one of thediseases or conditions listed herein, such as psoriasis, COPD or asthma)comprising a compound of the specification, or a pharmaceuticallyacceptable salt thereof, and a phosphodiesterase-4 (PDE4) inhibitor.

The compounds described in this specification are further illustrated inthe following Examples. These Examples are given by way of illustrationonly and are non-limiting.

Chemical names are preferably IUPAC names which were generated using ACDLabs 2014, or ChemDraw Ultra version 11.0.

Abbreviations

-   -   ACN acetonitrile    -   Boc₂O di-tert-butyl dicarbonate    -   CDI 1,1′-carbonyldiimidazole    -   DCM dichloromethane    -   DAST diethylaminosulfur trifluoride    -   DBU 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine    -   DIBAL-H diisobutylaluminum hydride    -   DIPEA diisopropylethylamine    -   DMAP 4-N,N-dimethylamino pyridine    -   DMF dimethylformamide    -   DMSO dimethylsulfoxide    -   dppf 1,1′-bis(diphenylphosphino)ferrocene    -   EDC N¹-((ethylimino)methylene)-N³,N³-dimethylpropane-1,3-diamine        hydrochloride    -   ESI electrospray ionization    -   EtOH ethanol    -   EtOAc ethyl acetate    -   Fmoc-Cl 9-fluorenylmethyl chloroformate    -   h hour    -   HATU        1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium        3-oxid hexafluorophosphate    -   HOBt 1H-benzo[d][1,2,3]triazol-1-ol hydrate    -   HPLC high-performance liquid chromatography    -   IPA isopropyl alcohol    -   LC/MS liquid chromatography-mass spectroscopy    -   LHMDS lithium bis(trimethylsilyl)amide    -   mCPBA 3-chloroperoxybenzoic acid    -   MeOH methanol    -   MsCl methanesulfonyl chloride    -   MTBE methyl tert-butyl ether    -   NBS N-bromosuccinimide    -   NCS N-chlorosuccinimide    -   NsCl 4-nitrobenzenesulfonyl chloride    -   (PinB)₂ bis(pinacolato)diboron    -   PPTs pyridinium para-toluenesulphonate    -   rt room temperature    -   RP-HPLC reverse phase HPLC    -   SFC supercritical fluid chromatography    -   TEA triethylamine    -   T3P 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane        2,4,6-trioxide    -   TBAF tetra-n-butylammonium fluoride    -   TBDMSCl tert-Butyldimethylsilyl chloride    -   TBDMSOTf tert-butyldimethylsilyl trifluoromethanesulfonate    -   TBTU        2-(1H-benzo[d][1,2,3]triazol-1-yl)-1,1,3,3-tetramethylisouronium        tetrafluoroborate    -   TFA trifluoroacetic acid    -   TFAA trifluoroacetic anhydride    -   THF tetrahydrofuran    -   TMSCN trimethylsilyl cyanide    -   TsCl para-toluenesulphonyl chloride    -   TsOH para-toluenesulphonic acid        General Methods

NMR spectra were recorded on a Bruker Avance, Avance II or Avance IIIspectrometer at a proton frequency of 300, 400, 500 or 600 MHz. Thecentral peaks of chloroform-δ (H 7.26 ppm), CD₃OD (H 3.30 ppm) orDMSO-d₆ (H 2.49 ppm) were used as internal references.

Optical rotations were measured on a Perkin Elmer 341 polarimeter.

LC/MS experiments were performed using a Waters Acquity system combinedwith a Waters Xevo Q-ToF Mass or a Shimadzu 2010EV UPLC system in ESImode. LC was run in two set ups: 1) BEH C18 column (1.7 μm 2.1×50 mm) incombination with a gradient (2-95% B in 5 minutes) of aqueous 46 mMammonium carbonate/ammonia buffer at pH 10 (A) and MeCN (B) at a flowrate of 1.0 mL/min or in combination with a gradient (5-95% B in 2minutes) of water and TFA (0.05%) (A) and CH₃CN and TFA (0.05%) at aflow rate of 1.0 mL/min (B).

Optical purity, indicated as enantiomeric excess (% ee), was determinedeither on by HPLC using an Agilent 1100 series chromatograph, or on aNovasep Supersep 2. Preparative HPLC was performed with a WatersFractionLynx system with integrated MS detection and equipped with PrepC18 OBD 5 μm 19×150 mm columns from X-Bridge or Sunfire. AlternativelyGilson GX-281 with intregrated UV detection was used, equipped witheither Kromasil C8 10 μm, 20×250 ID or 50×250 ID mm. As eluent (acidic)gradients of water/MeCN/acetic acid (95/5/0.1) or water/0.05% TFA (A)and MeCN/0.05% TFA (B) or (basic) MeCN or MeOH (A) and 0.03% ammonia inwater or 0.03% NH₄HCO₃ (B) were applied.

Preparative SCF was performed with a Waters Prep100 SCF system withintegrated MS detection, equipped with Waters Viridis 2-EP or PhenomenexLuna Hilic, 30×250 mm, 5 m. As eluent gradients of CO₂ (100 g/min, 120bar, 40° C.) (A) and MeOH/NH3 (20 mM) or MeOH (5% formic acid) or MeOH(B) were applied.

Unless otherwise stated, starting materials were commercially availableor previously described in the literature. All solvents and commercialreagents were of laboratory grade and were used as received unlessotherwise stated.

Intermediate 1: 9H-Fluoren-9-yl1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-5-(ethylsulfonyl)-1,3-dihydro-2H-isoindole-2-carboxylate

Step 1: 5-(Ethylthio)isoindolin-1-one

5-Bromoisoindolin-1-one (10 g, 47.16 mmol) and sodium ethanethiolate(9.92 g, 117.90 mmol) were mixed together in DMF (100 mL) and thereaction heated to 100° C. for 20 min. The reaction was cooled to roomtemperature, poured into water (100 mL) and the product extracted withEtOAc (3×200 mL). The combined organic extracts were washed with brine(4×50 mL). LCMS indicated product in the aqueous washings consequentlythey were combined and extracted with EtOAc (4×50 mL). The organicextracts were combined, dried using a phase separator cartridge andconcentrated in vacuo. The solid obtained was dried under high vacuumovernight. 5-(Ethylthio)isoindolin-1-one (8.68 g, 95%) was obtained as ayellow solid. The material was used in the next step without furtherpurification.

LC/MS: m/z=194 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 1.27 (t, 3H), 3.06(q, 2H), 4.33 (s, 2H), 7.36 (dd, 1H), 7.47-7.48 (m, 1H), 7.57 (d, 1H),8.45 (s, 1H).

Step 2: tert-Bulyl 5-(ethylthio)-1-oxoisoindoline-2-carboxylate

5-(Ethylthio)isoindolin-1-one (8.68 g, 44.91 mmol) was suspended inacetonitrile (400 mL) and DMAP (7.68 g, 62.88 mmol) was added in oneportion. After 10 min Boc-anhydride (13.72 g, 62.88 mmol) was added andthe mixture was stirred at room temperature for 30 min. The reaction wasconcentrated in vacuo. The residue was dissolved in EtOAc and washedwith 0.1M aqueous HCl (4×100 mL). The organic extract was dried using aphase separator cartridge and concentrated in vacuo to afford tert-butyl5-(ethylthio)-1-oxoisoindoline-2-carboxylate (12.50 g, 95%) as an orangesolid. The material was used in the next step without furtherpurification.

¹H NMR (500 MHz, DMSO-d₆) δ 1.29 (t, 3H), 1.51 (s, 9H), 3.09 (q, 2H),4.74 (s, 2H), 7.39 (dd, 1H), 7.52-7.53 (m, 1H), 7.65 (d, 1H) 1H).

Step 3: tert-Butyl 5-(ethylsulfonyl)-1-oxoisoindoline-2-carboxylate

tert-Butyl 5-(ethylthio)-1-oxoisoindoline-2-carboxylate (13.18 g, 44.91mmol) was dissolved in DCM (500 mL) and to this mCPBA (≥77%) (24.16 g,107.78 mmol) was added portionwise (an increase of the temperature to ca35° C. was observed). The reaction was stirred at room temperature for30 min. The reaction was washed twice with 1M aq NaOH and the DCM phasewas dried using a phase separator cartridge and concentrated in vacuo.tert-Butyl 5-(ethylsulfonyl)-1-oxoisoindoline-2-carboxylate (14.00 g,96%) was obtained as a yellow solid. The material was used in the nextstep without purification. LC/MS: m/z=324 [M−H]⁻. ¹H NMR (500 MHz,DMSO-d₆) δ 1.12 (t, 3H), 1.53 (s, 9H), 3.38 (q, 2H), 4.89 (s, 2H),7.99-8.04 (m, 2H), 8.21 (s, 1H).

Step 4: tert-Butyl 5-(ethylsulfonyl)-1-hydroxyisoindoline-2-carboxylate

tert-Butyl 5-(ethylsulfonyl)-1-oxoisoindoline-2-carboxylate (12 g, 36.88mmol) was dissolved in DCM (300 mL) and the mixture was cooled in an icebath. DIBAL-H (63 mL, 63.00 mmol) 1M solution in THF was added and thereaction stirred at this temperature for 15 min. Saturated aqueousRochelle's salt (300 mL) was added and the mixture stirred for 20 min.DCM (300 mL) was added and the layers separated. The aqueous phase wasextracted with DCM. The combined organic extracts were dried using aphase separator cartridge and concentrated in vacuo. The material wasused crude in the next step. LC/MS: m/z=326 [M−H]⁻.

Step 5: tert-Butyl 5-(ethylsulfonyl)-1-methoxyisoindoline-2-carboxylate

tert-Butyl 5-(ethylsulfonyl)-1-hydroxyisoindoline-2-carboxylate (12.07g, 36.88 mmol) was dissolved in MeOH (210 mL) and to this PPTs (0.927 g,3.69 mmol) was added and the reaction stirred at room temperature. After20 min LCMS indicated that no starting material remained and a singleproduct formed however, the desired mass ion was not seen. The reactionwas quenched by addition of triethylamine (81 mL, 581.14 mmol) andconcentrated in vacuo to afford a dark purple oil. This was used withoutfurther purification in the next step.

Step 6: tert-Butyl 1-cyano-5-(ethylsulfonyl)isoindoline-2-carboxylate

tert-Butyl 5-(ethylsulfonyl)-1-methoxyisoindoline-2-carboxylate (12.59g, 36.88 mmol) was dissolved in DCM (300 mL) and the solution cooled to−78° C. TMS-CN (7.42 mL, 55.32 mmol) and then BF₃.OEt₂ (7.01 mL, 55.32mmol) was added. The reaction was stirred at −78° C. for 15 min. Sat. aqNaHCO₃ solution (300 mL) and DCM (300 mL) were added and the reactionallowed to warm to room temperature. The two layers were separated andthe aqueous extracted with DCM. The combined organic extracts were driedusing a phase separator cartridge and concentrated in vacuo. Thematerial was purified by flash chromatography eluting with 40% EtOAc inheptane. tert-Butyl 1-cyano-5-(ethylsulfonyl)isoindoline-2-carboxylate(7.58 g, 61.1%) was obtained as a pink solid. LC/MS: m/z=335 [M−H]⁻. ¹HNMR (500 MHz, DMSO-d₆, mixture of rotamers, 1:1) δ 1.11 (t, 3H), 1.49,1.51 (s, 9H), 3.29-3.36 (m, 2H), 4.75, 4.77 (s, 2H), 6.18, 6.20 (s, 1H),7.83, 7.85 (s, 1H), 7.93, 7.95 (s, 1H), 7.96, 7.99 (s, 1H).

Step 7: 5-(Ethylsulfonyl)isoindoline-1-carboxylic acid, hydrochloridesalt

6M aq HCl (50 ml, 300.00 mmol) was added to tert-butyl1-cyano-5-(ethylsulfonyl)isoindoline-2-carboxylate (5 g, 14.86 mmol) andthe mixture heated at 70° C. for 2 h. The reaction was cooled to roomtemperature and concentrated to dryness in vacuo. The dark solidobtained was used crude in the next step.

LC/MS: m/z=254 [M−H]⁻.

Step 8:2-((9H-Fluoren-9-yl)methoxy)carbonyl)-5-(ethylsulfonyl)isoindoline-1-carboxylicacid

To 5-(ethylsulfonyl)isoindoline-1-carboxylic acid, HCl (4.35 g, 14.9mmol) in dioxane (80 mL)/water (80 mL) was added potassium carbonate(10.30 g, 74.50 mmol) and 9-fluorenylmethyl chloroformate (3.47 g, 13.41mmol). The reaction was stirred at room temperature overnight. Thedioxane was removed in vacuo and the aqueous acidified with 1M aq HCland extracted with EtOAc until no product remained in the aqueous (asjudged by LCMS). The combined organic extracts were dried using a phaseseparator cartridge and concentrated in vacuo. This material was usedcrude in the next step.

Step 9: (9H-Fluoren-9-yl)methyl5-(ethylsulfonyl)-1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)isoindoline-2-carboxylate

T3P (50% solution in EtOAc) (22.17 mL, 37.25 mmol) was added to amixture of2-(((9H-fluoren-9-yl)methoxy)carbonyl)-5-(ethylsulfonyl)isoindoline-1-carboxylicacid (7.12 g, 14.9 mmol),2-(4-aminophenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol (2.317 g, 8.94 mmol)and triethylamine (4.15 mL, 29.80 mmol) in DCM (200 mL). This wasstirred at room temperature for 30 min. The reaction mixture waspartitioned between DCM and water. The layers were separated in a phaseseparator cartridge and the organic layer was concentrated in vacuo. Theresidue was purified by flash chromatography eluting with 20%-50% EtOAcin heptane. All product containing fractions were combined andconcentrated in vacuo. The residue was triturated with methanol and asolid was obtained. This was collected by filtration and washed withmethanol. The mother liquor was concentrated in vacuo and thetrituration process repeated. A second batch of product was obtainedwhich was less pure however, the two batches were combined (5.40 g,50.4%) and used in the next step.

LC/MS: m/z=719 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆, mixture of rotamers,1:1) δ 1.09-1.14 (m, 3H), 3.28-3.33 (m, 2H), 4.14-4.39 (m, 3H),4.87-5.05 (m, 2H), 5.72, 5.81 (s, 1H), 6.93-6.99 (m, 1H), 7.23-7.47 (m,3H), 7.56-7.95 (m, 10H), 8.01-8.05 (m, 1H), 8.64, 8.66 (s, 1H), 10.82,10.87 (s, 1H).

Intermediate 2: 9H-Fluoren-9-yl5-[(cyclopropylmethyl)sulfonyl]-1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-1,3-dihydro-2H-isoindole-2-carboxylate

Step 1: Methyl 3-((1-oxoisoindolin-5-yl)thio)propanoate

A solution of 5-bromoisoindolin-1-one (10 g, 47.16 mmol) in dioxane (450mL) was degassed before Xantphos (2.73 g, 4.72 mmol), DIPEA (9.88 mL,56.59 mmol), Pd₂(dba)₃ (2.159 g, 2.36 mmol) and methyl3-mercaptopropanoate (32.6 mL, 330.12 mmol) was added. The reaction washeated to 80° C. for 1 h. The reaction was concentrated in vacuo.Approximately half of the material was purified by flash chromatographyeluting with 0-5% methanol in EtOAc to afford 4.69 g of product. Onlyhalf the material was purified this way because the crude materialsolidified part way through loading onto the column. The solidifiedmaterial was triturated with methanol and 4.48 g of product wascollected by filtration as a colorless solid. The mother liquor wasconcentrated in vacuo and purified by flash chromatography eluting with0-5% methanol in EtOAc to afford 1. g product. This was combined withthe material from the first column to give 10.27 g (86%) of the titlecompound.

LC/MS: m/z=252 [M+H]⁺. ¹H NMR (500 MHz, DMSO) δ 2.69 (t, 2H), 3.26 (t,2H), 3.60 (s, 3H), 4.34 (s, 2H), 7.38 (d, 1H), 7.52 (s, 1H), 7.58 (d,1H), 8.48 (s, 1H).

Step 2: 5-((Cyclopropylmethyl)thio)isoindolin-1-one

To a suspension of methyl 3-((1-oxoisoindolin-5-yl)thio)propanoate (5.79g, 23.04 mmol) in THF (250 mL) was added potassium tert-butoxide (46.1mL, 46.08 mmol, 1M solution in THF). The reaction was stirred for 5 minat room temperature, followed by addition of (bromomethyl)cyclopropane(6.22 g, 46.08 mmol). The reaction was stirred for 30 min at roomtemperature. The reaction was poured into water and the productextracted into EtOAc. The combined organic extracts were washed withbrine, dried using a phase separator cartridge and concentrated invacuo. The solid obtained was slurried in EtOAc, collected by filtrationand then washed with diethyl ether to afford5-((cyclopropylmethyl)thio)isoindolin-1-one (2.35 g, 46%).

LC/MS: m/z=220 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆) δ 0.17-0.33 (m, 2H),0.44-0.62 (m, 2H), 0.94-1.11 (m, 1H), 3.01 (d, 2H), 4.33 (s, 2H), 7.38(d, 1H), 7.50 (s, 1H), 7.55 (d, 1H), 8.45 (s, 1H).

Step 3: tert-Butyl5-((cyclopropylmethyl)thio)-1-oxoisoindoline-2-carboxylate

5-((Cyclopropylmethyl)thio)isoindolin-1-one (4.13 g, 18.83 mmol) wassuspended in acetonitrile (150 mL) and DMAP (3.22 g, 26.37 mmol) wasadded in one portion. Boc-anhydride (5.75 g, 26.37 mmol) was then addedand the reaction stirred at room temperature for 20 min. Theacetonitrile was removed in vacuo. The residue was dissolved in EtOAcand washed with 0.5M aqueous HCl (3×200 mL). The organic extract wasdried using a phase separator cartridge and concentrated in vacuo.tert-Butyl 5-((cyclopropylmethyl)thio)-1-oxoisoindoline-2-carboxylatewas obtained as a brown oil that solidified on standing. The materialwas used in the next step without further purification ¹H NMR (500 MHz,DMSO-d₆) δ 0.23-0.34 (m, 2H), 0.5-0.6 (m, 2H), 1-1.13 (m, 1H), 1.51 (s,9H), 3.04 (d, 2H), 4.73 (s, 2H), 7.41 (d, 1H), 7.55 (s, 1H), 7.64 (d,1H).

Step 4: tert-Butyl5-((cyclopropylmethyl)sulfonyl)-1-oxoisoindoline-2-carboxylate

tert-Butyl 5-((cyclopropylmethyl)thio)-1-oxoisoindoline-2-carboxylate(6.01 g, 18.83 mmol) was dissolved in DCM (200 mL) and to this mCPBA(≥77%) (10.13 g, 45.19 mmol) was added (an exotherm of ca 36° C. wasobserved). The reaction was stirred at room temperature for 20 min. Thereaction mixture was washed twice with 1M aq NaOH. The DCM was driedusing a phase separator cartridge and concentrated in vacuo to affordtert-butyl5-((cyclopropylmethyl)sulfonyl)-1-oxoisoindoline-2-carboxylate (5.98 g,90%) as an off-white solid. The material was used in the next stepwithout further purification. LC/MS: m/z=350 [M−H]⁻. ¹H NMR (500 MHz,DMSO-d₆) δ 0.01-0.2 (m, 2H), 0.33-0.5 (m, 2H), 0.78-0.93 (m, 1H), 1.53(s, 9H), 3.35 (d, 2H), 4.89 (s, 2H), 7.97-8.05 (m, 2H), 8.21 (s, 1H).

Step 5: tert-Butyl5-((cyclopropylmethyl)sulfonyl)-1-hydroxyisoindoline-2-carboxylate

tert-Butyl5-((cyclopropylmethyl)sulfonyl)-1-oxoisoindoline-2-carboxylate (5.48 g,15.59 mmol) was dissolved in DCM (150 mL) and the mixture was cooled inan ice bath. DIBAL-H (26.5 mL, 26.51 mmol) 1M solution in THF was addedand the reaction stirred at this temperature for 15 min. 100 mlsaturated aq Rochelle's salt was added and the resultant mixture wasstirred for 20 min whilst warming to room temperature. DCM (150 mL) wasadded and the layers separated. The aqueous layer was extracted withDCM. The combined organic extracts were dried using a phase separatorcartridge and concentrated in vacuo. The product was obtained as a pinkgum/foam. The material was used as such in the next step.

LC/MS: m/z=352 [M−H]⁻.

Step 6: tert-Butyl5-((cyclopropylmethyl)sulfonyl)-1-methoxyisoindoline-2-carboxylate

tert-Butyl5-((cyclopropylmethyl)sulfonyl)-1-hydroxyisoindoline-2-carboxylate (5.51g, 15.59 mmol) was dissolved in MeOH (110 mL) and to this PPTs (0.392 g,1.56 mmol) was added and the reaction stirred at room temperature. After20 min LCMS indicated no starting material remained and a single producthad formed however, the desired mass ion was not seen. The reaction wasquenched by addition of triethylamine (34.8 mL, 249.44 mmol) andconcentrated in vacuo to afford a dark purple oil. This was used withoutfurther purification in the next step.

Step 7: tert-butyl1-cyano-5-((cyclopropylmethyl)sulfonyl)isoindoline-2-carboxylate

tert-Butyl5-((cyclopropylmethyl)sulfonyl)-1-methoxyisoindoline-2-carboxylate (5.73g, 15.59 mmol) was dissolved in DCM (110 mL). This was cooled to −78° C.before TMS-CN (3.14 mL, 23.39 mmol) and BF₃. OEt₂ (2.96 mL, 23.39 mmol)was added. The reaction was stirred at −78° C. for 15 min. Sat. aqNaHCO₃ and DCM was added and the reaction allowed to warm to roomtemperature. The two layers were separated and the aqueous extractedwith DCM. The combined organic extracts were dried using a phaseseparator cartridge and concentrated in vacuo. The residue was purifiedon silica eluting with 25-50% EtOAc in heptane. tert-Butyl1-cyano-5-((cyclopropylmethyl)sulfonyl)isoindoline-2-carboxylate (3.22g, 57%) was obtained as a pale pink foam.

LC/MS: m/z=361 [M−H]⁻. ¹H NMR (500 MHz, DMSO) δ 0.06-0.16 (m, 2H),0.33-0.53 (m, 2H), 0.7-0.95 (m, 1H), 1.49, 1.51 (s, 9H), 3.27-3.31 (m,2H), 4.75, 4.77 (s, 2H), 6.18, 6.20 (s, 1H), 7.82, 7.84 (s, 1H), 7.94,7.96 (s, 1H), 7.97, 7.99 (s, 1H).

Step 8: 5-((Cyclopropylmethyl)sulfonyl)isoindoline-1-carboxylic acid,hydrochloride salt

6M aq HCl (35 ml, 210.00 mmol) was added to tert-butyl1-cyano-5-((cyclopropylmethyl)sulfonyl)isoindoline-2-carboxylate (3.48g, 9.60 mmol) and the mixture heated at 70° C. for 2.5 h. The reactionwas cooled to room temperature and concentrated to dryness in vacuo. Thedark solid obtained was used crude in the next step. LC/MS: m/z=280[M−H]⁻.

Step 9:5-[(Cyclopropylmethyl)sulfonyl]-2-[(9H-fluoren-9-yloxy)carbonyl]-2,3-dihydro-1H-isoindole-1-carboxylicacid

To 5-((cyclopropylmethyl)sulfonyl)isoindoline-1-carboxylic acid, HCl(3.05 g, 9.6 mmol) in dioxane (70 mL)/water (70 mL) was added potassiumcarbonate (6.63 g, 48.00 mmol) and 9-fluorenylmethyl chloroformate(2.235 g, 8.64 mmol). The reaction was stirred at room temperatureovernight. The dioxane was removed in vacuo. The aqueous was thenacidified with 1M aq HCl and extracted with EtOAc. The organic extractswere combined, dried using a phase separator cartridge and concentratedin vacuo. The material was used as such in the next step.

LC/MS: m/z=504 [M+H]⁺.

Step 10: 9H-Fluoren-9-yl5-[(cyclopropylmethyl)sulfonyl]-1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-1,3-dihydro-2H-isoindole-2-carboxylate

T3P (50% solution in EtOAc, 10.29 mL, 17.28 mmol) was added to a mixture5-[(cyclopropylmethyl)sulfonyl]-2-[(9H-fluoren-9-yloxy)carbonyl]-2,3-dihydro-1H-isoindole-1-carboxylicacid (4.35 g, 8.64 mmol),2-(4-aminophenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol (1.791 g, 6.91 mmol)and triethylamine (2.408 mL, 17.28 mmol) in DCM (100 mL). This reactionwas stirred at room temperature for 30 min. The reaction mixture waswashed with water and the layers separated using a phase separatorcartridge. The DCM was removed in vacuo to afford a black tar. This wastriturated with methanol and the solid (1.8 g) obtained was collected byfiltration and washed with methanol. The mother liquor was concentratedin vacuo and purified on silica eluting with 25-50% EtOAc in heptane. Anadditional 1.4 g of material was obtained. The two batches were combinedand used directly in the next step.

LC/MS: m/z=754 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆, mixture of rotamers,1:1) δ 0.05-0.2 (m, 2H), 0.4-0.52 (m, 2H), 0.84 (m, 1H), 3.22-3.3 (m,2H), 4.13-4.4 (m, 3H), 4.83-5.04 (m, 2H), 5.72, 5.81 (s, 1H), 6.92-7 (m,1H), 7.22-7.48 (m, 3H), 7.56-7.83 (m, 8H), 7.87-7.95 (m, 2H), 8-8.05 (m,1H), 8.66 (br s, 1H), 10.82, 10.86 (s, 1H).

Intermediate 3: tert-Butyl1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-5-(methylsulfamoyl)-1,3-dihydro-2H-isoindole-2-carboxylate

Step 1: 5-(Benzylthio)isoindolin-1-one

Benzyl mercaptan (11.71 g, 94.32 mmol) was added to5-bromoisoindolin-1-one (10 g, 47.16 mmol) and sodium2-methyl-2-butoxide (5.19 g, 47.16 mmol) in DMF (100 mL) under nitrogen.The resulting mixture was stirred at 100° C. for 2 hours. The reactionmixture was quenched with water (300 mL) and extracted with EtOAc (3×300mL). The organic layer was dried over Na₂SO₄, filtered and evaporated todryness to afford 5-(benzylthio)isoindolin-1-one (7.00 g, 58.1%) as ayellow solid.

LC/MS: m/z=256 [M+H]⁺. ¹H NMR (300 MHz, DMSO-d₆) δ 4.33 (s, 2H), 4.35(s, 2H), 7.23-7.61 (m, 8H), 8.48 (s, 1H).

Step 2: 1-Oxoisoindoline-5-sulfonyl chloride

SOCl₂ (6.86 mL, 93.99 mmol) was added to 5-(benzylthio)isoindolin-1-one(6 g, 23.50 mmol), AcOH (6.73 mL, 117.49 mmol) and water (1.69 mL, 93.99mmol) in DCM (80 mL) cooled to 0° C. under nitrogen. The resultingmixture was stirred at room temperature for 2 hours. The reactionmixture was quenched with saturated NaHCO₃ (100 mL), extracted with DCM(3×125 mL), the organic layer was dried over Na₂SO₄, filtered andevaporated to afford 1-oxoisoindoline-5-sulfonyl chloride (5.00 g,crude) as a yellow solid. The product was used directly in the next stepwithout further purification.

LC/MS: m/z=232 [M+H]⁺.

Step 3: N-Methyl-1-oxoisoindoline-5-sulfonamide

Methanamine (4.02 g, 129.50 mmol) was added to1-oxoisoindoline-5-sulfonyl chloride (10 g, 43.17 mmol) in DCM (200 mL)under nitrogen. The resulting mixture was stirred at room temperaturefor 2 hours. The reaction mixture was quenched with water (100 mL),extracted with DCM (3×250 mL), the organic layer was dried over Na₂SO₄,filtered and evaporated to affordN-methyl-1-oxoisoindoline-5-sulfonamide (8.0 g, 82%) as an orange solid.The product was used in the next step directly without furtherpurification.

LC/MS: m/z=227 [M+H]+.

Step 4: tert-Butyl5-(N-(tert-butoxycarbonyl)-N-methylsulfamoyl)-1-oxoisoindoline-2-carboxylate

Di-tert-butyl dicarbonate (10.80 g, 49.50 mmol) was added toN-methyl-1-oxoisoindoline-5-sulfonamide (8 g, 35.36 mmol) and DMAP (6.05g, 49.50 mmol) in MeCN (200 mL) under nitrogen. The resulting mixturewas stirred at room temperature for 2 hours. The reaction mixture wasquenched with water (100 mL), extracted with EtOAc (3×150 mL), theorganic layer was dried over Na₂SO₄, filtered and evaporated to affordtert-butyl5-(N-(tert-butoxycarbonyl)-N-methylsulfamoyl)-1-oxoisoindoline-2-carboxylate(7.00 g, 46.4%) as a pale yellow oil.

LC/MS: m/z=490 [M+Na+MeCN]⁺. ¹H NMR (400 MHz, CDCl₃) δ 1.38 (s, 9H),1.65 (s, 9H), 3.42 (s, 3H), 4.87 (s, 2H), 8.01-8.09 (m, 3H).

Step 5:tert-Butyl5-(N-(tert-butoxycarbonyl)-N-methylsulfamoyl)-1-hydroxyisoindoline-2-carboxylate

Lithium triethylborohydride (3.97 g, 37.52 mmol) was added to tert-butyl5-(N-(tert-butoxycarbonyl)-N-methylsulfamoyl)-1-oxoisoindoline-2-carboxylate(8 g, 18.76 mmol) in DCM (200 mL) cooled to 0° C. under nitrogen. Theresulting mixture was stirred at 0° C. for 30 minutes. Another part oflithium triethylborohydride (1.987 g, 18.76 mmol) was added. Theresulting mixture was stirred at 0° C. for more 30 minutes. The reactionmixture was quenched with saturated Rochelle's salt (100 mL), extractedwith EtOAc (3×100 mL), the organic layer was dried over Na₂SO₄, filteredand evaporated to afford tert-butyl5-(N-(tert-butoxycarbonyl)-N-methylsulfamoyl)-1-hydroxyisoindoline-2-carboxylate(8.0 g) as a pale yellow oil.

LC/MS: m/z=411 [M-OH]⁺.

Step 6: tert-Butyl5-(N-(tert-butoxycarbonyl)-N-methylsulfamoyl)-1-methoxyisoindoline-2-carboxylate

PPTs (0.47 g, 1.87 mmol) was added to tert-butyl5-(N-(tert-butoxycarbonyl)-N-methylsulfamoyl)-1-hydroxyisoindoline-2-carboxylate(8 g, 18.67 mmol) in MeOH (150 mL) under nitrogen. The resulting mixturewas stirred at room temperature for 2 hours. The reaction was quenchedby addition of Et₃N (41.6 mL, 298.72 mmol) and concentrated in vacuo toafford tert-butyl5-(N-(tert-butoxycarbonyl)-N-methylsulfamoyl)-1-methoxyisoindoline-2-carboxylate(8.00 g) as a purple oil.

LC/MS: m/z=411 [M-MeO]⁺.

Step 7: tert-Butyl5-(N-(tert-butoxycarbonyl)-N-methylsulfamoyl)-1-cyanoisoindoline-2-carboxylate

tert-Butyl5-(N-(tert-butoxycarbonyl)-N-methylsulfamoyl)-1-methoxyisoindoline-2-carboxylate(1.20 g, 2.71 mmol) in DCM (20 mL) cooled to −78° C. over a period of 5minutes under nitrogen. Trimethylsilanecarbonitrile (0.40 g, 4.07 mmol)and BF₃.Et₂O (0.51 mL, 4.07 mmol) was added to. The resulting mixturewas stirred at −78° C. for 30 minutes. The reaction mixture was quenchedwith saturated NaHCO₃ (150 mL), extracted with DCM (3×150 mL), theorganic layer was dried over Na₂SO₄, filtered and evaporated to affordyellow oil. The crude product was purified by flash silicachromatography, elution gradient 20 to 40% EtOAc in petroleum ether.Pure fractions were evaporated to dryness to afford tert-butyl5-(N-(tert-butoxycarbonyl)-N-methylsulfamoyl)-1-cyanoisoindoline-2-carboxylate(0.80 g, 67.4%) as a yellow solid.

LC/MS: m/z=455 [M+H+NH₃]+. ¹H NMR (400 MHz, CDCl₃, mixture of rotamers,1.6*:1) δ 1.41 (s, 9H), 1.57, 1.61*(s, 9H), 3.39 (3H, s), 4.79, 4.83*(s,2H), 5.80*, 5.85 (s, 1H), 7.61-7.66*, 7.66-7.70 (m, 1H), 7.89-8.01 (m,2H).

Step 8:5-(N-Methylsulfamoyl)isoindoline-1-carboxylic acid

tert-Butyl5-(N-(tert-butoxycarbonyl)-N-methylsulfamoyl)-1-cyanoisoindoline-2-carboxylate(7 g, 16.00 mmol) was added to HCl (6 M) (140 mL, 840.00 mmol) undernitrogen. The resulting mixture was stirred at 70° C. for 2 hours. Thesolvent was removed under reduced pressure to afford5-(N-methylsulfamoyl)isoindoline-1-carboxylic acid (4.0 g) as a blacksolid.

LC/MS: m/z=257 [M+H]⁺.

Step 9:2-(tert-Butoxycarbonyl)-5-(N-methylsulfamoyl)isoindoline-1-carboxylicacid

Di-tert-butyl dicarbonate (5.13 g, 23.50 mmol) was added to5-(N-methylsulfamoyl)isoindoline-1-carboxamide (4 g, 15.67 mmol) andEt₃N (3.28 mL, 23.50 mmol) in DCM (50 mL) under nitrogen. The resultingmixture was stirred at room temperature for 2 hours. The reactionmixture was quenched with 0.1M HCl (100 mL), extracted with DCM (2×100mL), the organic layer was dried over Na₂SO₄, filtered and evaporated toafford dark solid. The crude product was purified by flash silicachromatography, elution gradient 5 to 10% MeOH in DCM. Pure fractionswere evaporated to dryness to afford2-(tert-butoxycarbonyl)-5-(N-methylsulfamoyl)isoindoline-1-carboxylicacid (3.0 g, 53.7%) as a black solid.

LC/MS: m/z=301 [M+H-tBu]⁺. ¹H NMR (300 MHz, DMSO-d₆, mixture ofrotamers, 1.5*:1) δ 1.41*, 1.46 (s, 9H), 2.42 (d, 3H), 4.67-4.78 (m,2H), 5.42 (s, 1H), 7.48-7.60 (m, 2H), 7.73-7.82 (m, 2H), 13.20 (brs,1H).

Step 10: tert-Butyl1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-5-(methylsulfamoyl)-1,3-dihydro-2H-isoindole-2-carboxylate

2-(4-Aminophenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol (2.84 g, 10.94 mmol)was added to a mixture of2-(tert-butoxycarbonyl)-5-(N-methylsulfamoyl)isoindoline-1-carboxylicacid (3 g, 8.42 mmol), HATU (4.16 g, 10.94 mmol) and DIPEA (2.94 mL,16.84 mmol) in DCM (50 mL) under nitrogen. The resulting mixture wasstirred at room temperature for 2 hours. The reaction mixture wasquenched with saturated NH₄Cl (75 mL), extracted with DCM (3×75 mL), theorganic layer was dried over Na₂SO₄, filtered and evaporated to affordorange solid. The crude product was purified by flash silicachromatography, elution gradient 30 to 50% EtOAc in petroleum ether.Pure fractions were evaporated to dryness to afford tert-butyl1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)-5-(N-methylsulfamoyl)isoindoline-2-carboxylate(3.00 g, 59.6%) as a yellow solid.

LC/MS: m/z=598 [M+H]⁺. ¹H NMR (300 MHz, DMSO-d₆, mixture of rotamers,1.8*:1) δ 1.36*, 1.48 (s, 9H), 2.43 (d, 3H), 4.63-4.87 (m, 2H),5.60-5.77 (m, 1H), 7.49-7.85 (m, 8H), 8.66*, 8.67 (s, 1H), 10.75 (s,1H).

Intermediate 4: 9H-Fluoren-9-yl1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-5-(methylsulfonyl)-1,3-dihydro-2H-isoindole-2-carboxylate

Step 1: 5-(Methylthio)isoindolin-1-one

5-Bromoisoindolin-1-one (15 g, 70.74 mmol) and sodium methyl mercaptide(12.40 g, 176.85 mmol) were mixed together in DMF (150 mL) and heated to100° C. for 1 h. The reaction mixture was cooled to room temperature andpoured into water (160 mL). The product extracted with EtOAc (400 mL).The layers were then separated and the aqueous was extracted with EtOAc(3×200 mL). The combined organic extracts were washed with brine (3×100mL). The organic extracts were combined, dried using a phase separatorcartridge and concentrated in vacuo. 5-(Methylthio)isoindolin-1-one(12.00 g, 95%) was obtained as a yellow solid. The material was used inthe next step without further purification.

LC/MS: m/z=180 [M−H]⁻. ¹H NMR (500 MHz, DMSO-d₆) δ 2.54 (s, 3H), 4.33(s, 2H), 7.33 (d, 1H), 7.44 (s, 1H), 7.56 (d, 1H), 8.43 (s, 1H).

Step 2: tert-Butyl 5-(methylthio)-1-oxoisoindoline-2-carboxylate

5-(Methylthio)isoindolin-1-one (12.68 g, 70.74 mmol) was suspended inacetonitrile (500 mL) and DMAP (12.10 g, 99.04 mmol) was added in oneportion. Boc-anhydride (21.61 g, 99.04 mmol) was then added and thereaction stirred for 20 min at room temperature. The acetonitrile wasremoved in vacuo. The residue was dissolved in EtOAc and washed with0.5M aq HCl (3×200 ml). The organic extract was dried using a phaseseparator cartridge and concentrated in vacuo. tert-Butyl5-(methylthio)-1-oxoisoindoline-2-carboxylate (15.60 g, 79%) wasobtained as a brown oil that solidified on standing. The material wasused in the next step without further purification.

¹H NMR (500 MHz, DMSO-d₆) δ 1.51 (s, 9H), 2.55 (s, 3H), 4.74 (s, 2H),7.37 (d, 1H), 7.49 (s, 1H), 7.64 (d, 1H).

Step 3: tert-Butyl 5-(methylsulfonyl)-1-oxoisoindoline-2-carboxylate

tert-Butyl 5-(methylthio)-1-oxoisoindoline-2-carboxylate (15.58 g, 55.77mmol) was dissolved in DCM (500 mL) and to this mCPBA (≥77%) (30.0 g,133.85 mmol) was added portionwise (an exotherm to ca. 38° C. wasobserved). The reaction was stirred at room temperature for 20 min. Thereaction was washed twice with 1M aq NaOH. The organic layer was driedusing a phase separator cartridge and concentrated in vacuo to affordtert-butyl 5-(methylsulfonyl)-1-oxoisoindoline-2-carboxylate (15.56 g,90%) as a yellow solid.

The material was used in the next step without further purification.

LC/MS: m/z=310 [M−H]⁻. ¹H NMR (500 MHz, DMSO-d₆) δ 1.53 (s, 9H), 3.31(s, 3H), 4.88 (s, 2H), 8.00 (d, 1H), 8.08 (d, 1H), 8.25 (s, 1H).

Step 4: tert-Butyl 1-hydroxy-5-(methylsulfonyl)isoindoline-2-carboxylate

tert-Butyl 5-(methylsulfonyl)-1-oxoisoindoline-2-carboxylate (15.56 g,49.98 mmol) was dissolved in DCM (375 mL), cooled in an ice bath andkept under a nitrogen atmosphere. DIBAL-H (85 mL, 84.96 mmol) 1Msolution in THF was added gradually over 10 min. The reaction wasstirred at this temperature for 15 min. Sat. aq Rochelle's salt (100 ml)was added and the resultant mixture was stirred for 20 min whilstwarming to room temperature. DCM (200 mL) was added and the layersseparated. The aqueous layer was extracted with DCM. The combinedorganic extracts were dried using a phase separator cartridge andconcentrated in vacuo. The product was obtained as a pink-brown gum/foamwhich was used crude in the next step.

LC/MS: m/z=312 [M−H]⁻.

Step 5: tert-Butyl 1-methoxy-5-(methylsulfonyl)isoindoline-2-carboxylate

tert-Butyl 1-hydroxy-5-(methylsulfonyl)isoindoline-2-carboxylate (15.66g, 49.98 mmol) was dissolved in MeOH (300 mL) and to this PPTs (1.256 g,5.00 mmol) was added and the reaction stirred at room temperature. After20 min LCMS indicated that no starting material remained and one producthad formed but the desired mass ion was not seen. The reaction wasquenched by addition of triethylamine (111 mL, 799.68 mmol) andconcentrated in vacuo to afford a dark purple oil. This was used crudein the next step.

Step 6: tert-Butyl 1-cyano-5-(methylsulfonyl)isoindoline-2-carboxylate

tert-Butyl 1-methoxy-5-(methylsulfonyl)isoindoline-2-carboxylate (16.36g, 49.98 mmol) was dissolved in DCM (375 mL). This was cooled to −78° C.before TMS-CN (10.05 mL, 74.97 mmol) and BF₃. OEt₂ (9.50 mL, 74.97 mmol)was added. The reaction was stirred at −78° C. for 15 min. Sat aq NaHCO₃and DCM was added and the reaction allowed to warm to room temperature.The two layers were separated and the aqueous extracted with DCM. Thecombined organic extracts were dried using a phase separator cartridgeand concentrated in vacuo. The material was purified by flashchromatography eluting with 40-50% EtOAc in heptane. tert-Butyl1-cyano-5-(methylsulfonyl)isoindoline-2-carboxylate (10.6 g, 65.8%) wasobtained as a slightly pink solid.

LC/MS: m/z=321 [M−H]⁻. ¹H NMR (500 MHz, DMSO-d₆, mixture of rotamers,1:1) δ 1.50, 1.51 (s, 9H), 3.24, 3.25 (s, 3H), 4.74, 4.76 (s, 2H), 6.17,6.19 (s, 1H), 7.83 (d, 1H), 7.96-8.05 (m, 2H).

Step 7: 5-(Methylsulfonyl)isoindoline-1-carboxylic acid, hydrochloridesalt

6M aq HCl (110 mL, 660.00 mmol) was added to tert-butyl1-cyano-5-(methylsulfonyl)isoindoline-2-carboxylate (10.6 g, 32.88 mmol)and the mixture was heated at 70° C. for 2.5 h. The reaction was cooledto room temperature and concentrated to dryness to afford a dark solid,which was used in the next step without further purification.

LC/MS: m/z=240 [M−H]⁻.

Step 8:2-[(9H-Fluoren-9-yloxy)carbonyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxylicacid

To 5-(methylsulfonyl)isoindoline-1-carboxylic acid, HCl (9.13 g, 32.88mmol) in dioxane (230 mL)/water (230 mL) was added potassium carbonate(22.72 g, 164.40 mmol) and 9-fluorenylmethyl chloroformate (7.66 g,29.59 mmol). The reaction was stirred at room temperature overnight. Thedioxane was removed in vacuo. The aqueous was then acidified with 1M aqHCl and extracted with EtOAc. These organic extracts were combined,dried using a phase separator and concentrated in vacuo. The materialwas used crude in the next step.

LC/MS: m/z=462 [M−H]⁻.

Step 9: 9H-Fluoren-9-yl1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-5-(methylsulfonyl)-1,3-dihydro-2H-isoindole-2-carboxylate

T3P (50% solution in EtOAc, 37.7 mL, 63.40 mmol) was added to a mixtureof2-[(9H-fluoren-9-yloxy)carbonyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxylicacid (14.69 g, 31.7 mmol),2-(4-aminophenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol (6.57 g, 25.36 mmol)and triethylamine (8.84 mL, 63.40 mmol) in DCM (300 mL). This wasstirred at room temperature for 30 min. The reaction mixture was washedwith water and the layers separated using a phase separator cartridge.The DCM was removed in vacuo to afford a black tar. The first attempt topurify by flash chromatography was unsuccessful because the mainimpurity crystallised and blocked the column. The column had to beflushed with 1:1 EtOAc:methanol to unblock it. The product containingsolution obtained was concentrated in vacuo. This was then purified byflash chromatography eluting with 30%-50% EtOAc in heptane to afford(9H-fluoren-9-yl)methyl1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)-5-(methylsulfonyl)isoindoline-2-carboxylate(10.64 g, 47.6%).

LC/MS: m/z=705 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆, mixture of rotamers,1:1) δ 3.22, 3.23 (s, 3H), 4.14-4.39 (m, 3H), 4.88-5.03 (m, 2H), 5.72,5.81 (s, 1H), 6.93-6.99 (m, 1H), 7.21-7.48 (m, 3H), 7.56-7.83 (m, 8H),7.9-7.95 (m, 2H), 8.03-8.09 (m, 1H), 8.64, 8.66 (s, 1H), 10.82, 10.87(s, 1H).

Intermediate 5: tert-Butyl1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-5-(methylsulfonyl)-1,3-dihydro-2H-isoindole-2-carboxylate

Step 1: 5-(Methylsulfonyl)isoindoline-1-carboxylic acid, hydrochloridesalt

6M aq HCl (110 mL, 660.00 mmol) was added to tert-butyl1-cyano-5-(methylsulfonyl)isoindoline-2-carboxylate (10.6 g, 32.88 mmol)with stirring, and the mixture was heated at 70° C. for 3 h. Thereaction was concentrated to 13.3 g of a sticky black solid, which wasused as such in the next step.

¹H NMR (400 MHz, DMSO-d₆) δ 3.25 (s, 3H), 4.61 (q, 1H), 4.69 (q, 1H),5.75 (s, 1H), 7.81 (d, 1H), 7.99 (d, 1H), 8.04 (s, 1H).

Step 2:2-(tert-Butoxycarbonyl)-5-(methylsulfonyl)isoindoline-1-carboxylic acid

The hydrochloride salt of 5-(methylsulfonyl)isoindoline-1-carboxylicacid (7.78 g, 28 mmol) was dissolved in water (130 mL) and 1,4-dioxane(200 mL) and 2M aq potassium carbonate (70.0 mL, 140.00 mmol) was added.Di-tert-butyl dicarbonate (6.11 g, 28.00 mmol) was added in one portion,and the solution was stirred at room temperature overnight. The dioxanewas removed in vacuo and DCM (100 mL) was added. A black precipitateformed in the aqueous which was removed by filtration. The aqueoussolution was washed a second time with DCM and the organic washesdiscarded.

The aqueous solution was then chilled with stirring on an ice water bathbefore adding EtOAc (100 mL). The pH was gradually adjusted to 2 by theslow addition of chilled 3.8M aq HCl; the biphasic mixture was stirredfor a few minutes before the EtOAc phase was separated. The aqueoussolution was washed with EtOAc (2×100 mL). The combined EtOAc extractswere washed with water (1×100 mL) and brine (50 mL) before drying overMgSO₄. This was filtered and concentrated in vacuo to afford2-(tert-butoxycarbonyl)-5-(methylsulfonyl)isoindoline-1-carboxylic acid(4.55 g, 47.5%) as solid.

LC/MS: m/z=681 [2M−H]⁻. ¹H NMR (400 MHz, DMSO-d₆, mixture of rotamers,1.6*:1) δ 1.41*, 1.46 (s, 9H), 3.21, 3.22* (s, 3H), 4.68-4.8 (m, 2H),5.44 (s, 1H), 7.60*, 7.63 (d, 1H), 7.87-7.92 (m, 1H), 7.95, 7.98* (s,1H).

Step 3: tert-Buyl1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-5-(methylsulfonyl)-1,3-dihydro-2H-isoindole-2-carboxylate

2-(tert-Butoxycarbonyl)-5-(methylsulfonyl)isoindoline-1-carboxylic acid(4.40 g, 12.89 mmol) and2-(4-aminophenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol (3.34 g, 12.89 mmol)were combined in ethyl acetate (50 mL) to give a suspension, before theaddition of triethylamine (5.39 mL, 38.67 mmol) gave a dark brownsolution. The solution was chilled by stirring on an ice/water bathbefore the addition of T3P (50% in EtOA, 15.35 mL, 25.78 mmol) bydropping funnel. The addition was controlled to ensure temperature didnot exceed 5° C. After one hour the reaction solution was washed withwater (2×50 mL). The combined water washes were extracted with EtOAc (50mL). The combined organic extracts were washed with 0.1M aq HCl (2×50mL) and brine (25 mL) before drying over MgSO₄. This was filtered andconcentrated in vacuo. The residue was purified by flash chromatographyeluting with 0-60% EtOAc in n-heptane to give the title compound (4.95g, 66%) as a solid.

LC/MS: m/z=581 [M−H]⁻. ¹H NMR (400 MHz, DMSO-d₆, mixture of rotamers,1.8*:1) δ 1.35*, 1.47 (s, 9H), 3.20, 3.21* (s, 3H), 4.69-4.88 (m, 2H),5.61*, 5.63 (s, 1H), 7.6-7.76 (m, 5H), 7.86-7.92 (m, 1H), 7.98, 8.01*(s, 1H), 8.63*, 8.65 (s, 1H), 10.75 (s, 1H).

Intermediate 6:2-Acetyl-5-(cyclopropylsulfamoyl)-2,3-dihydro-1H-isoindole-1-carboxylicacid

Step 1: N-Cyclopropyl-1-oxoisoindoline-5-sulfonamide

Cyclopropanamine (1.848 g, 32.38 mmol) was added to1-oxoisoindoline-5-sulfonyl chloride (2.5 g, 10.79 mmol, prepared asdescribed for intermediate 3, step 1 and 2) in DCM (30 mL) undernitrogen. The resulting mixture was stirred at room temperature for 2hours. The reaction mixture was quenched with water (125 mL), extractedwith DCM (3×100 mL), the organic layer was dried over Na₂SO₄, filteredand evaporated to afford N-cyclopropyl-1-oxoisoindoline-5-sulfonamide(1.60 g, 58.8%) as a yellow solid. The product was used in the next stepdirectly without further purification.

LC/MS: m/z=253 [M+H]⁺

Step 2: tert-Butyl5-(N-(tert-butoxycarbonyl)-N-cyclopropylsulfamoyl)-1-oxoisoindoline-2-carboxylate

Di-tert-butyl dicarbonate (1.938 g, 8.88 mmol) was added toN-cyclopropyl-1-oxoisoindoline-5-sulfonamide (1.6 g, 6.34 mmol) and DMAP(1.085 g, 8.88 mmol) in MeCN (20 mL) under nitrogen. The resultingmixture was stirred at room temperature for 2 hours. The reactionmixture was quenched with water (100 mL), extracted with EtOAc (3×75mL), the organic layer was dried over Na₂SO₄, filtered and evaporated toafford yellow solid. The crude product was purified by flash silicachromatography, elution gradient 30 to 40% EtOAc in petroleum ether.Pure fractions were evaporated to dryness to afford tert-butyl5-(N-(tert-butoxycarbonyl)-N-cyclopropylsulfamoyl)-1-oxoisoindoline-2-carboxylate(1.10 g, 38.3%) as a pale yellow oil.

LC/MS: m/z=397 [M+H-tBu]⁺. ¹H NMR (300 MHz, DMSO-d₆) δ 0.88-0.92 (m,2H), 1.11-1.14 (m, 2H), 1.39 (s, 9H), 1.61 (s, 9H), 2.82-2.87 (m, 1H),4.87 (s, 2H), 8.05-8.06 (m, 2H), 8.13 (s, 1H).

Step 3: tert-Butyl5-(N-(tert-butoxycarbonyl)-N-cyclopropylsulfamoyl)-1-hydroxyisoindoline-2-carboxylate

DIBAL-H (1M in THF) (4.42 mL, 4.42 mmol) was added to tert-butyl5-(N-(tert-butoxycarbonyl)-N-cyclopropylsulfamoyl)-1-oxoisoindoline-2-carboxylate(1 g, 2.21 mmol) in DCM (25 mL) cooled to 0° C. under nitrogen. Theresulting mixture was stirred at 0° C. for 1 hour. The reaction mixturewas quenched with saturated aq. Rochelle's salt (25 mL), extracted withEtOAc (3×100 mL), the organic layer was dried over Na₂SO₄, filtered andevaporated to afford tert-butyl5-(N-(tert-butoxycarbonyl)-N-cyclopropylsulfamoyl)-1-hydroxyisoindoline-2-carboxylate(0.92 g, 92%) as a pale yellow oil. The crude product was used in thenext step directly without further purification.

LC/MS: m/z=437 [M-OH]⁺.

Step 4: tert-Butyl5-(N-(tert-butoxycarbonyl)-N-cyclopropylsulfamoyl)-1-methoxyisoindoline-2-carboxylate

PPTs (50.9 mg, 0.20 mmol) was added to tert-butyl5-(N-(tert-butoxycarbonyl)-N-cyclopropylsulfamoyl)-1-hydroxyisoindoline-2-carboxylate(920 mg, 2.02 mmol) in MeOH (2 mL) under nitrogen. The resulting mixturewas stirred at room temperature for 2 hours. The reaction was quenchedby addition of Et₃N (4.51 mL, 32.38 mmol) and concentrated in vacuo toafford tert-butyl5-(N-(tert-butoxycarbonyl)-N-cyclopropylsulfamoyl)-1-methoxyisoindoline-2-carboxylate(940 mg, 99%) as a dark purple oil. The crude product was used to thenext step directly without further purification.

LC/MS: m/z=437 [M−MeO]⁺

Step 5: tert-Butyl5-(N-(tert-butoxycarbonyl)-N-cyclopropylsulfamoyl)-1-cyanoisoindoline-2-carboxylate

BF₃.Et₂O (0.38 mL, 3.01 mmol) was added to tert-butyl5-(N-(tert-butoxycarbonyl)-N-cyclopropylsulfamoyl)-1-methoxyisoindoline-2-carboxylate(940 mg, 2.01 mmol) and trimethylsilanecarbonitrile (299 mg, 3.01 mmol)in DCM (25 mL) cooled to −78° C. under nitrogen. The resulting mixturewas stirred at −78° C. for 30 minutes. The reaction mixture was quenchedwith saturated NaHCO₃ (25 mL), extracted with DCM (3×25 mL), the organiclayer was dried over Na₂SO₄, filtered and evaporated to afford dark oil.The crude product was purified by flash silica chromatography, elutiongradient 0 to 60% EtOAc in petroleum ether. Pure fractions wereevaporated to dryness to afford tert-butyl5-(N-(tert-butoxycarbonyl)-N-cyclopropylsulfamoyl)-1-cyanoisoindoline-2-carboxylate(240 mg, 25.8%) as a solid.

LC/MS: m/z=464 [M+H]⁺. ¹H NMR (300 MHz, CDCl₃) δ 0.82-0.85 (m, 2H),1.03-1.10 (m, 2H), 1.40 (s, 9H), 1.56 (d, 9H), 2.77-2.82 (m, 1H),4.77-4.80 (m, 2H), 5.80 (d, 1H), 7.59-7.66 (m, 1H), 7.93-7.99 (m, 2H).

Step 6: 5-(N-cyclopropylsulfamoyl)isoindoline-1-carboxylic acid

tert-Butyl5-(N-(tert-butoxycarbonyl)-N-cyclopropylsulfamoyl)-1-cyanoisoindoline-2-carboxylate(240 mg, 0.52 mmol) was added to 6M aq HCl (2.4 mL, 14.40 mmol). Theresulting mixture was stirred at 70° C. for 2 hours. The reactionmixture was concentrated under reduced pressure to afford5-(N-cyclopropylsulfamoyl)isoindoline-1-carboxylic acid (110 mg, 75%) assolid, which was used without furthet purification.

LC/MS: m/z=283 [M+H]⁺.

Step 7:2-Acetyl-5-(cyclopropylsulfamoyl)-2,3-dihydro-1H-isoindole-1-carboxylicacid

Acetic anhydride (39.8 mg, 0.39 mmol) was added to5-(N-cyclopropylsulfamoyl)-isoindoline-1-carboxylic acid (110 mg, 0.39mmol) and Et₃N (0.217 mL, 1.56 mmol) in DCM (2 mL) under nitrogen. Theresulting solution was stirred at room temperature for 2 hours. Thereaction mixture was concentrated under vacuum to afford the crude2-acetyl-5-(cyclopropylsulfamoyl)-2,3-dihydro-1H-isoindole-1-carboxylicacid (110 mg, 87%), which was used without further purification.

LC/MS: m/z=325 [M+H]⁺.

Intermediate 7: Tert-Butyl5-(Cyclopropylsulfonyl)-1-{[4-(1,1,1,3,3,3-Hexafluoro-2-Hydroxypropan-2-Yl)Phenyl]Carbamoyl}-1,3-Dihydro-2H-Isoindole-2-Carboxylate

Step 1: 5-mercaptoisoindolin-1-one

Sodium 2-methylbutan-2-olate (31.2 g, 282.96 mmol) was added to5-bromoisoindolin-1-one (30 g, 141.48 mmol) and phenylmethanethiol (35.1g, 282.96 mmol) in DMF (300 mL) under nitrogen. The resulting mixturewas stirred at 100° C. for 12 hours. The reaction mixture was quenchedwith water (300 mL), extracted with EtOAc (3×300 mL), the organic layerwas dried over Na₂SO₄, filtered and evaporated to afford5-(benzylthio)isoindolin-1-one (6.00 g, 16.61%) as a yellow solid. Thewater layer was acidified with 2M HCl and the mixture was extracted withEtOAc (3×150 mL). The organic layer was dried over Na₂SO₄, filtered andevaporated to dryness to afford 5-mercaptoisoindolin-1-one (15.00 g,64.2%) as a solid.

LC/MS: m/z=166 [M+H]⁺. ¹H NMR (300 MHz, DMSO-d₆) δ 4.32 (s, 2H), 5.88(s, 1H), 7.37-7.40 (m, 1H), 7.49-7.54 (m, 2H), 8.45 (s, 1H).

Step 2: 5-(Cyclopropylthio)isoindolin-1-one

5-Mercaptoisoindolin-1-one (8 g, 48.42 mmol) was added tobromocyclopropane (8.79 g, 72.63 mmol) and NaH (2.32 g, 96.85 mmol) inDMF (100 mL) under nitrogen. The resulting mixture was stirred at 100°C. for 12 hours. The reaction mixture was quenched with water (300 mL),extracted with EtOAc (3×300 mL), the organic layer was dried overNa₂SO₄, filtered and evaporated to afford yellow solid. The crudeproduct was purified by flash silica chromatography, elution gradient 30to 50% EtOAc in petroleum ether. Pure fractions were evaporated todryness to afford 5-(cyclopropylthio)isoindolin-1-one (5.00 g, 50.3%) asa solid.

LC/MS: m/z=206 [M+H]⁺.

Step 3: 5-(Cyclopropylsulfonyl)isoindolin-1-one

mCPBA (10.51 g, 60.89 mmol) was added to5-(cyclopropylthio)isoindolin-1-one (5 g, 24.36 mmol) in DCM (100 mL)cooled to 0° C. over a period of 5 minutes under nitrogen. The resultingmixture was stirred at room temperature for 2 hours. The reactionmixture was quenched with saturated NaHCO₃ (200 mL), extracted with DCM(3×200 mL), the organic layer was dried over Na₂SO₄, filtered andevaporated to afford 5-(cyclopropylsulfonyl)isoindolin-1-one (6.00 g,crude) as a white solid.

LC/MS: m/z=238 [M+H]⁺.

Step 4: tert-Butyl5-(cyclopropylsulfonyl)-1-oxoisoindoline-2-carboxylate

Boc-anhydride (8.81 mL, 37.93 mmol) was added to5-(cyclopropylsulfonyl)isoindolin-1-one (6 g, 25.29 mmol) and DMAP (4.63g, 37.93 mmol) in DCM (120 mL) under nitrogen. The resulting solutionwas stirred at room temperature for 4 hours. The reaction mixture wasquenched with saturated NH₄Cl (100 mL), extracted with DCM (3×100 mL),the organic layer was dried over Na₂SO₄, filtered and evaporated toafford yellow solid. The crude product was purified by flash silicachromatography, elution gradient 0 to 50% EtOAc in petroleum ether. Purefractions were evaporated to dryness to afford tert-butyl5-(cyclopropylsulfonyl)-1-oxoisoindoline-2-carboxylate (7.10 g, 83%) asa solid.

LC/MS: m/z=401 [M+Na+MeCN]⁺. ¹H NMR (400 MHz, CDCl₃) δ 1.10-1.13 (m,2H), 1.39-1.43 (m, 2H), 1.62 (s, 9H), 2.48-2.54 (m, 1H), 4.87 (s, 2H),8.02-8.10 (m, 3H).

Step 5: tert-Butyl5-(cyclopropylsulfonyl)-1-hydroxyisoindoline-2-carboxylate

DIBAL-H (42.1 mL, 42.09 mmol) was added dropwise to tert-butyl5-(cyclopropylsulfonyl)-1-oxoisoindoline-2-carboxylate (7.1 g, 21.04mmol) in DCM (140 mL) cooled to 0° C. over a period of 10 minutes undernitrogen. The resulting solution was stirred at 0° C. for 1 hour. Thereaction mixture was quenched with saturated aq. Rochelle's salt (200mL), extracted with DCM (3×200 mL), the organic layer was dried overNa₂SO₄, filtered and evaporated to afford tert-butyl5-(cyclopropylsulfonyl)-1-hydroxyisoindoline-2-carboxylate (6.80 g).

LC/MS: m/z=266 [M-OH-tBu]⁺.

Step 6: tert-Butyl5-(cyclopropylsulfonyl)-1-methoxyisoindoline-2-carboxylate

PPTs (0.067 g, 0.27 mmol) was added to tert-butyl5-(cyclopropylsulfonyl)-1-hydroxyisoindoline-2-carboxylate (0.9 g, 2.65mmol) in MeOH (20 mL) under nitrogen. The resulting solution was stirredat room temperature for 1 hour. The reaction mixture was quenched withEt₃N (50 mL), The resulting mixture was concentrated under reducedpressure to afford crude tert-butyl5-(cyclopropylsulfonyl)-1-methoxyisoindoline-2-carboxylate (5.80 g,83%).

LC/MS: m/z=266 [M-MeO-tBu]⁺.

Step 7: tert-Butyl1-cyano-5-(cyclopropylsulfonyl)isoindoline-2-carboxylate

BF₃.Et₂O (3.12 mL, 24.62 mmol) was added dropwise to tert-butyl5-(cyclopropylsulfonyl)-1-methoxyisoindoline-2-carboxylate (5.8 g, 16.41mmol) and TMS-CN (3.30 mL, 24.62 mmol) in DCM (120 mL) at −78° C. undernitrogen. The resulting solution was stirred at −78° C. for 1 hour. Thereaction mixture was quenched with saturated NaHCO₃ (150 mL), extractedwith DCM (3×100 mL), the organic layer was dried over Na₂SO₄, filteredand evaporated to afford dark solid. The crude product was purified byflash silica chromatography, elution gradient 0 to 50% EtOAc inpetroleum ether. Pure fractions were evaporated to dryness to affordtert-butyl 1-cyano-5-(cyclopropylsulfonyl)isoindoline-2-carboxylate(2.400 g, 42.0.

LC/MS: m/z=366 [M+H+NH₃]+. ¹H NMR (300 MHz, CDCl₃) δ 1.06-1.15 (m, 2H),1.35-1.51 (m, 2H), 1.62 (s, 9H), 2.48-2.54 (m, 1H), 4.82-4.89 (m, 2H),5.82-5.88 (m, 1H), 7.66-7.74 (m, 1H), 7.89-8.07 (m, 2H).

Step 8: 5-(Cyclopropylsulfonyl)isoindoline-1-carboxylic acid

A mixture of tert-butyl1-cyano-5-(cyclopropylsulfonyl)isoindoline-2-carboxylate (2.38 g, 6.83mmol) in HCl (6M, 24 mL, 144.00 mmol) was stirrd at 70° C. for 3 hours.The reaction mixture was concentrated under reduced pressure to afford5-(cyclopropylsulfonyl)isoindoline-1-carboxylic acid 2.2 g of a darksolid, which was used without further purification.

LC/MS: m/z=268 [M+H]+.

Step 9:2-(tert-Butoxycarbonyl)-5-(cyclopropylsulfonyl)isoindoline-1-carboxylicacid

Boc₂O (1.91 mL, 8.23 mmol) was added to5-(cyclopropylsulfonyl)isoindoline-1-carboxylic acid (2.2 g, 8.23 mmol)and Et₃N (4.59 mL, 32.92 mmol) in DCM (40 mL) under nitrogen. Theresulting solution was stirred at room temperature for 12 hours. Thereaction mixture was acidified with 1M HCl. The resulting mixture wasextracted with DCM (3×50 mL), the organic layer was dried over Na₂SO₄,filtered and evaporated to afford dark oil. The crude product waspurified by flash silica chromatography, elution gradient 0 to 10% MeOHin DCM. Pure fractions were evaporated to dryness to afford2-(tert-butoxycarbonyl)-5-(cyclopropylsulfonyl)isoindoline-1-carboxylicacid (2.20 g, 72.8 LC/MS: m/z=268 [M+H-Boc]⁺. ¹H NMR (300 MHz, DMSO-d₆)δ 1.00-1.27 (m, 4H), 1.45 (s, 9H), 2.82-2.88 (m, 1H), 4.68-4.78 (m, 2H),5.40 (s, 1H), 7.60-7.66 (m, 1H), 7.82-7.93 (m, 2H).

Step 10: Tert-Butyl5-(Cyclopropylsulfonyl)-1-{[4-(1,1,1,3,3,3-Hexafluoro-2-Hydroxypropan-2-Yl)Phenyl]Carbamoyl}-1,3-Dihydro-2H-Isoindole-2-Carboxylate

DIPEA (1.426 mL, 8.17 mmol) was added to2-(tert-butoxycarbonyl)-5-(cyclopropylsulfonyl)isoindoline-1-carboxylicacid (1 g, 2.72 mmol), HATU (1.138 g, 2.99 mmol) and2-(4-aminophenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol (0.705 g, 2.72 mmol)in DCM (10 mL) under nitrogen. The resulting solution was stirred atroom temperature for 1 hour. The reaction mixture was quenched withsaturated NH₄Cl (20 mL), extracted with DCM (3×25 mL), the organic layerwas dried over Na₂SO₄, filtered and evaporated to afford dark oil. Thecrude product was purified by flash silica chromatography, elutiongradient 0 to 50% EtOAc in petroleum ether. Pure fractions wereevaporated to dryness to afford the title compound (1.3 g, 77%) as apale yellow solid.

LC/MS: m/z=609 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆, mixture of rotamers,1.8*:1) δ 1.04-1.21 (m, 4H), 1.35*, 1.47 (s, 9H), 2.84-2.86 (m, 1H),4.73-4.86 (m, 2H), 5.61*, 5.63 (s, 1H), 7.61-7.78 (m, 5H), 7.83-7.89 (m,1H), 7.94-8.01 (m, 1H), 8.65*, 8.67 (s, 1H), 10.76 (s, 1H).

Intermediate 8: tert-Butyl1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-5-[(2-methoxyethyl)sulfonyl]-1,3-dihydro-2H-isoindole-2-carboxylate

Step 1: 5-(2-Methoxyethylthio)isoindolin-1-one

1-Bromo-2-methoxyethane (12.62 g, 90.79 mmol) was added to5-mercaptoisoindolin-1-one (10 g, 60.53 mmol) and K₂CO₃ (16.73 g, 121.06mmol) in DMF (200 mL) under nitrogen. The resulting mixture was stirredat room temperature for 12 hours. The reaction mixture was quenched withwater (200 mL), extracted with EtOAc (2×200 mL), the organic layer waswashed with water (2×200 mL) and brine (1×200 mL), dried over Na₂SO₄,filtered and evaporated to afford brown oil. The crude product waspurified by flash silica chromatography, elution gradient 30 to 50%EtOAc in petroleum ether. Pure fractions were evaporated to dryness toafford 5-((2-methoxyethyl)thio)isoindolin-1-one (9.60 g, 71%).

LC/MS: m/z=224 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 3.25 (t, 2H), 3.27(s, 3H), 3.56 (t, 2H), 4.34 (s, 2H), 7.39-7.58 (m, 3H), 8.49 (s, 1H).

Step 2: 5-((2-Methoxyethyl)sulfonyl)isoindolin-1-one

mCPBA (15.58 g, 90.29 mmol) was added portionwise to5-((2-methoxyethyl)thio)isoindolin-1-one (9.6 g, 42.99 mmol) in DCM (60mL) under nitrogen. The resulting mixture was stirred at roomtemperature for 3 hours. The reaction mixture was quenched withsaturated Na₂CO₃ (200 mL), extracted with DCM (6×150 mL), the organiclayer was dried over Na₂SO₄, filtered and evaporated to afford5-((2-methoxyethyl)sulfonyl)isoindolin-1-one (8.20 g, 75%) as paleyellow solid. The crude product was used to the next step directly.

LC/MS: m/z=256 [M+H]⁺. ¹H NMR (300 MHz, DMSO-d₆) δ 3.09 (s, 3H),3.61-3.71 (m, 4H), 4.50 (s, 2H), 7.91 (d, 1H), 8.00 (d, 1H), 8.14 (s,1H), 8.96 (s, 1H).

Step 3: tert-Butyl5-(2-methoxyethylsulfonyl)-1-oxoisoindoline-2-carboxylate

DMAP (5.81 g, 47.59 mmol) was added to5-((2-methoxyethyl)sulfonyl)isoindolin-1-one (8.1 g, 31.73 mmol) and(Boc)₂O (11.05 mL, 47.59 mmol) in MeCN (160 mL) under nitrogen. Theresulting solution was stirred at room temperature for 2 hours. Thereaction mixture was quenched with saturated NH₄Cl (200 mL), extractedwith DCM (3×200 mL), the organic layer was dried over Na₂SO₄, filteredand evaporated to afford brown oil. The crude product was purified byflash silica chromatography, elution gradient 0 to 50% EtOAc inpetroleum ether. Pure fractions were evaporated to dryness to affordtert-butyl 5-((2-methoxyethyl)sulfonyl)-1-oxoisoindoline-2-carboxylate(7.20 g, 63.2%) as a brown solid.

LC/MS: m/z=300 [M+H-tBu]⁺. ¹H NMR (300 MHz, DMSO-d₆) δ 1.55 (s, 9H),3.08 (s, 3H), 3.65-3.72 (m, 4H), 4.90 (s, 2H), 7.98-8.06 (m, 2H), 8.22(s, 1H).

Step 4: tert-Butyl1-hydroxy-5-((2-methoxyethyl)sulfonyl)isoindoline-2-carboxylate

DIBAL-H (5.76 g, 40.52 mmol) was added to tert-butyl5-((2-methoxyethyl)sulfonyl)-1-oxoisoindoline-2-carboxylate (7.2 g,20.26 mmol) in DCM (140 mL) cooled to 0° C. under nitrogen. Theresulting solution was stirred at room temperature for 5 hours. Thereaction mixture was quenched with sat Rochelle's salt (50 mL),extracted with DCM (3×50 mL), the organic layer was dried over Na₂SO₄,filtered and evaporated to afford tert-butyl1-hydroxy-5-((2-methoxyethyl)sulfonyl)isoindoline-2-carboxylate (6.50 g,90%).

LC/MS: m/z=340 [M-OH]⁺.

Step 5: tert-Butyl1-methoxy-5-((2-methoxyethyl)sulfonyl)isoindoline-2-carboxylate

PPTs (0.457 g, 1.82 mmol) was added to tert-butyl1-hydroxy-5-((2-methoxyethyl)sulfonyl)isoindoline-2-carboxylate (6.5 g,18.19 mmol) in MeOH (130 mL) at room temperature under nitrogen. Theresulting solution was stirred at room temperature for 5 hours. Thereaction mixture was quenched with Et₃N (150 mL), the organic layer wasfiltered and evaporated to afford tert-butyl1-methoxy-5-((2-methoxyethyl)sulfonyl)isoindoline-2-carboxylate (6.50 g,96%) as brown oil.

LC/MS: m/z=340 [M-MeO]⁺.

Step 6: tert-Butyl1-cyano-5-(2-methoxyethylsulfonyl)isoindoline-2-carboxylate

BF₃.Et₂O (3.79 mL, 29.88 mmol) was added dropwise to tert-butyl1-methoxy-5-((2-methoxyethyl)sulfonyl)isoindoline-2-carboxylate (7.4 g,19.92 mmol) and TMS-CN (4.01 mL, 29.88 mmol) in DCM (148 mL) cooled to−78° C. under nitrogen. The resulting solution was stirred at −78° C.for 45 minutes. The reaction mixture was quenched with saturated NaHCO₃(150 mL), extracted with DCM (3×150 mL), the organic layer was driedover Na₂SO₄, filtered and evaporated to afford purple oil. The crudeproduct was purified by flash silica chromatography. Pure fractions wereevaporated to dryness to afford tert-butyl1-cyano-5-((2-methoxyethyl)sulfonyl)isoindoline-2-carboxylate (3.20 g,43.8%).

LC/MS: m/z=384 [M+H+NH₃]+. ¹H NMR (300 MHz, DMSO-d₆) δ 1.52 (s, 9H),3.11 (s, 3H), 3.64 (s, 4H), 4.77 (s, 2H), 6.21 (s, 1H), 7.82-8.00 (m,3H).

Step 7: 5-((2-Methoxyethyl)sulfonyl)isoindoline-1-carboxylic acid

A mixture of tert-butyl1-cyano-5-((2-methoxyethyl)sulfonyl)isoindoline-2-carboxylate (3.2 g,8.73 mmol) in HCl (6M, 0.2 mL, 1.20 mmol) was heated to 70° C. for 2hours. The reaction mixture was concentrated under vacuum to afford thecrude 5-((2-methoxyethyl)sulfonyl)isoindoline-1-carboxylic acid (3.2 g),which was used without further purification.

LC/MS: m/z=286 [M+H]⁺.

Step8:2-(tert-Butoxycarbonyl)-5-(2-methoxyethylsulfonyl)isoindoline-1-carboxylicacid

Boc-anhydride (2.60 mL, 11.22 mmol) was added to5-((2-methoxyethyl)sulfonyl)-isoindoline-1-carboxylic acid (3.2 g, 11.22mmol) and Et₃N (6.25 mL, 44.86 mmol) in DCM (64 mL) under nitrogen. Theresulting solution was stirred at room temperature for 4 hours. Thereaction mixture was acidified with 1M HCl. The resulting mixture wasextracted with DCM (3×60 ml), the organic layer was dried over Na₂SO₄,filtered and evaporated to afford dark solid. The crude product waspurified by flash silica chromatography, elution gradient 0 to 10% MeOHin DCM. Pure fractions were evaporated to dryness to afford2-(tert-butoxycarbonyl)-5-((2-methoxyethyl)sulfonyl)isoindoline-1-carboxylicacid (2.80 g, 64.8%).

LC/MS: m/z=286 [M+H-Boc]+.

¹H NMR (300 MHz, DMSO-d₆, mixture of rotamers, 1.3*:1) δ 1.43*, 1.48 (s,9H), 3.11 (s, 3H), 3.63 (s, 4H), 4.73-4.76 (m, 2H), 5.47 (s, 1H),7.60-7.96 (m, 3H), 13.28 (1H, brs).

Step 9: tert-Butyl1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-5-[(2-methoxyethyl)sulfonyl]-1,3-dihydro-2H-isoindole-2-carboxylate

DIPEA (3.81 mL, 21.79 mmol) was added to2-(tert-butoxycarbonyl)-5-((2-methoxyethyl)sulfonyl)isoindoline-1-carboxylicacid (2.8 g, 7.26 mmol),2-(4-aminophenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol (1.883 g, 7.26 mmol)and HATU (3.04 g, 7.99 mmol) in DCM (56 mL) under nitrogen. Theresulting solution was stirred at room temperature for 1 hour. Thereaction mixture was quenched with saturated aqueous NH₄Cl (20 mL),extracted with DCM (3×100 mL), the organic layer was dried over Na₂SO₄,filtered and evaporated to afford dark solid. The crude product waspurified by flash silica chromatography, elution gradient 0 to 60% EtOAcin petroleum ether. Pure fractions were evaporated to dryness to affordtert-butyl1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)-5-((2-methoxyethyl)sulfonyl)isoindoline-2-carboxylate(3.53 g, 96%).

LC/MS: m/z=571 [M+H-tBu]+. ¹H NMR (300 MHz, DMSO-d₆, mixture ofrotamers, 1.8*:1) δ 1.34*, 1.48 (s, 9H), 3.09 (s, 3H), 3.58-3.60 (m,4H), 4.66-4.89 (m, 2H), 5.60*, 5.62 (s, 1H), 7.59-7.78 (m, 5H),7.81-7.87 (m, 1H), 7.91-7.99 (m, 1H), 8.63*, 8.64 (s, 1H), 10.74 (1H,s).

Intermediate 9: (9H-Fluoren-9-yl)methyl1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenylcarbamoyl)-5-(2-hydroxyethylsulfonyl)isoindoline-2-carboxylate

Step 1: (9H-Fluoren-9-yl)methyl1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenylcarbamoyl)-5-(2-methoxyethylsulfonyl)isoindoline-2-carboxylate

9-Fluorenylmethyl chloroformate (73.7 mg, 0.28 mmol) was added toN-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-5-((2-methoxyethyl)sulfonyl)isoindoline-1-carboxamide(100 mg, 0.19 mmol, prepared as described in Example 700) and sat. aq.NaHCO₃ (4 mL) in DCM (2 mL). The resulting mixture was stirred at roomtemperature for 6 hours. The reaction mixture was quenched with water(10 mL), extracted with DCM (3×10 mL), the organic layer was dried overNa₂SO₄, filtered and evaporated to afford brown oil. The crude productwas purified by flash silica chromatography, elution gradient 30 to 50%EtOAc in petroleum ether. Pure fractions were evaporated to dryness toafford (9H-fluoren-9-yl)methyl1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)-5-((2-methoxyethyl)sulfonyl)isoindoline-2-carboxylate(120 mg, 84%).

LC/MS: m/z=749 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆, mixture of rotamers,1.1*:1) δ 3.11*, 3.12 (s, 3H), 3.60-3.64 (m, 4H), 4.14-4.42 (m, 3H),4.78-5.03 (m, 2H), 5.72, 5.82* (s, 1H), 6.92-7.00 (m, 1H), 7.22-7.50 (m,3H), 7.55-7.84 (m, 8H), 7.86-7.96 (m, 2H), 8.00-8.05 (m, 1H), 8.67,8.69* (s, 1H), 10.84, 10.88* (s, 1H).

Step 2: (9H-Fluoren-9-yl)methyl1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenylcarbamoyl)-5-(2-hydroxyethylsulfonyl)isoindoline-2-carboxylate

Tribromoborane (1088 mg, 4.34 mmol) was added dropwise to(9H-fluoren-9-yl)methyl1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)-5-((2-methoxyethyl)sulfonyl)isoindoline-2-carboxylate(650 mg, 0.87 mmol) in DCM (20 mL) cooled to −40° C. over a period of 20minutes under nitrogen. The resulting solution was stirred at 0° C. for2 hours. The reaction mixture was quenched with ice (50 mL), extractedwith DCM (3×75 mL), the organic layer was dried over Na₂SO₄, filteredand evaporated to afford pale yellow solid. The crude product waspurified by flash silica chromatography, elution gradient 0 to 80% EtOAcin petroleum ether. Pure fractions were evaporated to dryness to afford(9H-fluoren-9-yl)methyl1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)-5-((2-hydroxyethyl)sulfonyl)isoindoline-2-carboxylate(442 mg, 69.3%).

LC/MS: m/z=735 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆, mixture of rotamers,1.2*:1) δ 3.46-3.49 (m, 2H), 3.68-3.71 (m, 2H), 4.16-4.38 (m, 3H),4.88-5.03 (m, 3H), 5.72, 5.82* (s, 1H), 6.94-7.00 (m, 1H), 7.23-7.32 (m,1H), 7.34-7.49 (m, 2H), 7.56-7.85 (m, 8H), 7.87-7.96 (m, 2H), 8.01-8.06(m, 1H), 8.67, 8.69* (s, 1H), 10.85, 10.90* (s, 1H).

Intermediate 10:5-((2-((tert-Butyldimethylsilyl)oxy)ethyl)sulfonyl)-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)isoindoline-1-carboxamide

Step 1: (9H-Fluoren-9-yl)methyl5-((2-((tert-butyldimethylsilyl)oxy)ethyl)sulfonyl)-1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)isoindoline-2-carboxylate

tert-Butylchlorodimethylsilane (451 mg, 2.99 mmol) was added to(9H-fluoren-9-yl)methyl1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)-5-((2-hydroxyethyl)sulfonyl)isoindoline-2-carboxylate(440 mg, 0.60 mmol), 2,6-dimethylpyridine (193 mg, 1.80 mmol) in DCM (10mL) under nitrogen. The resulting solution was stirred at 25° C. for 4hours. The reaction mixture was quenched with water (15 mL), extractedwith DCM (3×20 mL), the organic layer was dried over Na₂SO₄, filteredand evaporated to afford pale yellow solid. The crude product waspurified by flash silica chromatography, elution gradient 0 to 70% EtOAcin petroleum ether. Pure fractions were evaporated to dryness to afford(9H-fluoren-9-yl)methyl5-((2-((tert-butyldimethylsilyl)oxy)ethyl)sulfonyl)-1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)isoindoline-2-carboxylate(320 mg, 62.9%).

LC/MS: m/z=849 [M+H]⁺.

Step 2:5-((2-((tert-Butyldimethylsilyl)oxy)ethyl)sulfonyl)-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)isoindoline-11-carboxamide

Diethylamine (267 mg, 3.65 mmol) was added to (9H-fluoren-9-yl)methyl5-((2-((tert-butyldimethylsilyl)oxy)ethyl)sulfonyl)-1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)isoindoline-2-carboxylate(310 mg, 0.37 mmol) in DCM (2 mL) under nitrogen. The resulting solutionwas stirred at room temperature for 2 hours. The crude product waspurified by flash silica chromatography, elution gradient 0 to 70% EtOAcin petroleum ether. Pure fractions were evaporated to dryness to afford5-((2-((tert-butyldimethylsilyl)oxy)ethyl)sulfonyl)-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)isoindoline-1-carboxamide(210 mg, 92%).

LC/MS: m/z=627 [M+H]+.

Intermediate 11: 2-(4-amino-3-fluorophenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol

2-Fluoroaniline (3 g, 27.00 mmol), 1,1,1,3,3,3-hexafluoropropan-2-onesesquihydrate (4.23 ml, 34.60 mmol) and 4-methylbenzenesulfonic acidhydrate (0.54 g, 2.84 mmol) were mixed in a vial under nitrogen. Themixture was heated to 90° C. overnight. The reaction contents were thendiluted with 600 mL ethyl acetate and washed with NaHCO₃(sat.). Theethyl acetate phase was then washed with brine, dried using a phaseseparator, and concentrated in vacuo. Flash chromatography on silica geleluting with 0 to 20% EtOAc in heptanes gave impure product, which waspurified again under the same conditions to afford2-(4-amino-3-fluorophenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol (2.3 g,31%). LC/MS: m/z=276 [M−H]⁻. ¹H NMR (500 MHz, DMSO) δ 5.55 (s, 2H), 6.82(t, 1H), 7.15 (d, 1H), 7.19 (d, 1H), 8.44 (s, 1H).

Intermediate 12:2-(4-Amino-2-fluorophenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol

To 3-fluoroaniline (3 g, 27.00 mmol) in a vial was added1,1,1,3,3,3-hexafluoropropan-2-one sesquihydrate (4.23 ml, 34.60 mmol)and 4-methylbenzenesulfonic acid hydrate (0.54 g, 2.84 mmol). The tubewas then purged with nitrogen, sealed and heated overnight at 90° C. Thereaction contents were then diluted with ethyl acetate and washed 3×with NaHCO₃(sat.). The ethyl acetate phase was then washed with brine,dried using a phase separator, and concentrated in vacuo. The desiredproduct was isolated by flash chromatography on silica using 0 to 20%ethyl acetate in heptane. This resulted in a solid that wasrecrystallised using hexanes and ethyl acetate.2-(4-Amino-2-fluorophenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol (1.22 g,16.3%) was obtained as a solid.

LC/MS: m/z=276 [M−H]⁻. ¹H NMR (500 MHz, DMSO) δ 5.78 (s, 2H), 6.33 (dd,1H), 6.44 (dd, 1H), 7.35 (t, 1H), 8.33 (s, 1H).

Intermediate 13: tert-Butyl1-{[3-fluoro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-5-(methylsulfonyl)-1,3-dihydro-2H-isoindole-2-carboxylate

2-(tert-Butoxycarbonyl)-5-(methylsulfonyl)isoindoline-1-carboxylic acid(345 mg, 1.01 mmol) was suspended in DCM (5 mL) and to this2-(4-amino-2-fluorophenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol (280 mg,1.01 mmol) and triethylamine (0.282 mL, 2.02 mmol) was added. To thesolution obtained T3P (643 mg, 2.02 mmol, 50% in EtOAc) was then added.The reaction was stirred at rt for 30 mins. LCMS indicated completeconversion to product. The reaction was diluted with DCM and washed with0.5M HCl. The layers were separated using a phase separator andconcentrated in vacuo. The residue was purified on silica eluting with40% EtOAc in heptane. Pure fractions were combined and concentrated invacuo to afford tert-butyl1-((3-fluoro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)-5-(methylsulfonyl)isoindoline-2-carboxylate(422 mg, 69.5%) as a solid.

LC/MS: m/z=601 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆, mixture of rotamers,2*:1) δ 1.34*, 1.47 (s, 9H), 3.21, 3.22* (s, 3H), 4.71-4.86, (m, 2H),5.6*, 5.62 (s, 1H), 7.51 (td, 1H), 7.63-7.71 (m, 2H), 7.75-7.81 (m, 1H),7.85-7.91 (m, 1H), 7.98, 8.02* (s, 1H), 8.84*, 8.86 (s, 1H), 10.94 (s,1H).

Intermediate 14: tert-Butyl1-{[2-fluoro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-5-(methylsulfonyl)-1,3-dihydro-2H-isoindole-2-carboxylate

2-(tert-Butoxycarbonyl)-5-(methylsulfonyl)isoindoline-1-carboxylic acid(345 mg, 1.01 mmol) was suspended in DCM (5 mL) and to this2-(4-amino-3-fluorophenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol (280 mg,1.01 mmol) and triethylamine (0.282 mL, 2.02 mmol) was added. To theresulting solution T3P (1.203 mL, 2.02 mmol) 50% in EtOAc was thenadded. The reaction was stirred at rt for 30 mins. LCMS indicatedcomplete conversion to product. The reaction was diluted with DCM andwashed with 0.5M HCl. The layers were separated using a phase separatorand concentrated in vacuo. The residue was purified on silica elutingwith 40% EtOAc in heptane. Completely pure fractions were combined andconcentrated in vacuo to afford tert-butyl1-((2-fluoro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)-5-(methylsulfonyl)isoindoline-2-carboxylate(402 mg, 66.3%) as a solid.

LC/MS: m/z=601 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆, mixture of rotamers,2*:1) δ 1.38*, 1.47 (s, 9H), 3.21, 3.23* (s, 3H), 4.7-4.85 (m, 2H),5.81*, 5.85 (s, 1H), 7.42-7.58 (m, 2H), 7.67*, 7.72 (d, 1H), 7.88-8.06(m, 3H), 8.92 (s, 1H), 10.60, 10.63* (s, 1H).

Intermediate 15: tert-Butyl1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-5-[(3-methoxy-3-oxopropyl)sulfonyl]-1,3-dihydro-2H-isoindole-2-carboxylate

Step 1: tert-Butyl 5-bromo-1-oxoisoindoline-2-carboxylate

(Boc)₂O (69.5 g, 318.33 mmol) was added slowly to5-bromoisoindolin-1-one (45 g, 212.22 mmol) and DMAP (38.9 g, 318.33mmol) in acetonitrile (1000 mL) at room temperature over a period of 30minutes under nitrogen. The resulting solution was stirred at thistemperature for 12 hours. The solvent was removed under reducedpressure. The residue was treated with water (500 mL), extracted withDCM (3×500 mL), the organic layer was dried over Na₂SO₄, filtered andevaporated to afford brown oil. The crude product was purified by flashsilica chromatography, elution gradient 0 to 10% EtOAc in petroleumether. Pure fractions were evaporated to dryness to afford tert-butyl5-bromo-1-oxoisoindoline-2-carboxylate (55.0 g, 83%).

LC/MS: m/z=256,258 [M-tBu+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 1.62 (s, 9H),4.76 (s, 2H), 7.63-7.66 (m, 2H), 7.78 (d, J=8.0 Hz, 1H).

Step 2: tert-Butyl 5-bromo-1-hydroxyisoindoline-2-carboxylate

Lithium tri-tert-butoxyaluminum hydride (61.1 g, 240.26 mmol) was addedslowly to tert-butyl 5-bromo-1-oxoisoindoline-2-carboxylate (50 g,160.17 mmol) in THF (800 mL) at 0° C. over a period of 45 minutes undernitrogen. The resulting solution was stirred at 25° C. for 12 hours. Thereaction mixture was quenched with ice (500 mL), extracted with EtOAc(3×250 mL), the organic layer was dried over Na₂SO₄, filtered andevaporated to afford brown oil. The crude product was purified by flashsilica chromatography, elution gradient 10 to 20% EtOAc in petroleumether. Pure fractions were evaporated to dryness to afford tert-butyl5-bromo-1-hydroxyisoindoline-2-carboxylate (40.0 g, 79%).

LC/MS: m/z=240,242 [M-tBu-OH]⁺.

Step 3: tert-Butyl 5-bromo-1-methoxyisoindoline-2-carboxylate

PPTs (3.20 g, 12.73 mmol) was added slowly to tert-butyl5-bromo-1-hydroxyisoindoline-2-carboxylate (20 g, 63.66 mmol) in MeOH(400 mL) at room temperature over a period of 15 minutes under nitrogen.The resulting solution was stirred at this temperature for 2 hours. Thereaction mixture was treated with Et₃N (100 mL). The solvent was removedunder reduced pressure to afford tert-butyl5-bromo-1-methoxyisoindoline-2-carboxylate (20.00 g, 96%). The productwas used in the next step directly without further purification.

¹H NMR (300 MHz, CDCl₃, mixture of rotamers, 1:1) δ 1.55 (s, 9H), 3.23,3.32 (s, 3H), 4.57-4.75 (m, 2H), 6.23, 6.33 (s, 1H), 7.29-7.34 (m, 1H),7.42-7.50 (m, 2H).

Step 4: tert-Butyl 5-bromo-1-cyanoisoindoline-2-carboxylate

BF₃.Et₂O (11.58 mL, 91.41 mmol) was added dropwise to tert-butyl5-bromo-1-methoxyisoindoline-2-carboxylate (20 g, 60.94 mmol) and TMS-CN(12.25 mL, 91.41 mmol) in DCM (400 mL) at −78° C. over a period of 45minutes under nitrogen. The resulting solution was stirred at −78° C.for 2 hours. The reaction mixture was treated with ice/water (300 mL),extracted with DCM (3×200 mL), the organic layer was dried over Na₂SO₄,filtered and evaporated to afford brown oil. The crude product waspurified by flash silica chromatography, elution gradient 10 to 20%EtOAc in petroleum ether. Pure fractions were evaporated to dryness toafford tert-butyl 5-bromo-1-cyanoisoindoline-2-carboxylate (15.0 g,76%).

¹H NMR (300 MHz, CDCl₃, mixture of rotamers, 1.5*:1) δ 1.54, 1.58* (s,9H), 4.68, 4.72* (s, 2H), 5.65*, 5.70 (s, 1H), 7.28-7.41 (m, 1H),7.42-7.58 (m, 2H).

Step 5: 5-Bromoisoindoline-1-carboxylic acid

tert-Butyl 5-bromo-1-cyanoisoindoline-2-carboxylate (7 g, 21.66 mmol)was added slowly to 6M HCl (140 mL) at room temperature over a period of35 minutes under nitrogen. The resulting mixture was stirred at 70° C.for 3 hours. The solvent was removed under reduced pressure to afford5-bromoisoindoline-1-carboxylic acid (5.0 g, 95%). The product was usedin the next step directly without further purification.

LC/MS: m/z=242,244 [M+H]⁺. ¹H NMR (300 MHz, DMSO-d₆) δ 4.52 (d, J=15.0Hz, 1H), 4.61 (d, J=15.1 Hz, 1H), 5.57 (s, 1H), 7.49 (d, J=8.4 Hz, 1H),7.61 (dd, J=8.4, 1.8 Hz, 1H), 7.69 (d, J=1.8 Hz, 1H), 9.54 (brs, 1H),11.29 (brs, 1H).

Step 6: 5-Bromo-2-(tert-butoxycarbonyl)isoindoline-1-carboxylic acid

(Boc)₂O (5.41 g, 24.79 mmol) was added slowly to5-bromoisoindoline-1-carboxylic acid (5 g, 20.66 mmol) and Et₃N (11.52mL, 82.62 mmol) in DCM (100 mL) at 0° C. over a period of 30 minutesunder nitrogen. The resulting mixture was stirred at room temperaturefor 12 hours. The reaction mixture was treated with water (100 mL),extracted with DCM (3×50 mL), the organic layer was dried over Na₂SO₄,filtered and evaporated to afford brown oil. The crude product waspurified by flash silica chromatography, elution gradient 10 to 20%EtOAc in petroleum ether. Pure fractions were evaporated to dryness toafford 5-bromo-2-(tert-butoxycarbonyl)isoindoline-1-carboxylic acid (3.0g, 42.4%). ¹H NMR (300 MHz, CDCl₃, mixture of rotamers, 1.6*: 1) δ1.47*, 1.49 (s, 9H), 4.61-4.83 (m, 2H), 5.25-5.32 (m, 1H), 7.32-7.43 (m,3H).

Step 7: tert-Butyl 5-bromo-1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenylcarbamoyl)isoindoline-2-carboxylate

Et₃N (5.50 mL, 39.45 mmol) was added to5-bromo-2-(tert-butoxycarbonyl)isoindoline-1-carboxylic acid (4.5 g,13.15 mmol), 2-(4-aminophenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol (3.41g, 13.15 mmol) and T3P (12.55 g, 39.45 mmol) in DCM (100 mL) undernitrogen. The resulting solution was stirred at room temperature for 2hours. The reaction mixture was treated with saturated NH₄Cl (100 mL),extracted with DCM (3×100 mL), the organic layer was dried over Na₂SO₄,filtered and evaporated to afford yellow solid. The crude product waspurified by flash C18-flash chromatography, elution gradient 0 to 60%MeCN in water. Pure fractions were evaporated to dryness to affordtert-butyl5-bromo-1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)isoindoline-2-carboxylate(5.70 g, 74.3%).

LC/MS: m/z=583,585 [M+H]⁺. ¹H NMR (300 MHz, DMSO-d₆, mixture ofrotamers, 1.7*:1) δ 1.34*, 1.45 (s, 9H), 4.61-4.77 (m, 2H), 5.43-5.47(m, 1H), 7.36 (dd, J=10.8, 8.1 Hz, 1H), 7.50 (dd, J=8.1, 1.8 Hz, 1H),7.61-7.74 (m, 5H), 8.61*, 8.63 (s, 1H), 10.63, 10.64* (s, 1H).

Step 8: tert-Butyl1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenylcarbamoyl)-5-(3-methoxy-3-oxopropylthio)isoindoline-2-carboxylate

DIPEA (5.14 mL, 29.40 mmol) was added to tert-butyl5-bromo-1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)isoindoline-2-carboxylate(5.7 g, 9.77 mmol), methyl 3-mercaptopropanoate (1.174 g, 9.77 mmol),Pd₂(dba)₃ (0.447 g, 0.49 mmol) and Xantphos (0.565 g, 0.98 mmol) in1,4-dioxane (120 mL) under nitrogen. The resulting mixture was stirredat 80° C. for 2 hours. The reaction mixture was quenched with water (100mL), extracted with DCM (3×125 mL), the organic layer was dried overNa₂SO₄, filtered and evaporated to afford white solid. The crude productwas purified by flash silica chromatography, elution gradient 0 to 25%EtOAc in petroleum ether. Pure fractions were evaporated to dryness toafford tert-butyl1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)-5-((3-methoxy-3-oxopropyl)thio)isoindoline-2-carboxylate(5.5 g, 90%).

LC/MS: m/z=623 [M+H]⁺. ¹H NMR (300 MHz, CDCl₃) δ 1.54 (s, 9H), 2.65 (t,J=7.5 Hz, 2H), 3.19 (t, J=7.5 Hz, 2H), 3.70 (s, 3H), 4.77-4.90 (m, 2H),5.48-5.65 (m, 1H), 7.31-7.63 (m, 7H), 9.38 (brs, 1H).

Intermediate 16: tert-Butyl1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-5-[(2-methylpropyl)sulfonyl]-1,3-dihydro-2H-isoindole-2-carboxylate

Step 1: tert-Butyl1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-5-[(2-methylpropyl)sulfanyl]-1,3-dihydro-2H-isoindole-2-carboxylate

A solution of tert-butyl5-bromo-1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)isoindoline-2-carboxylate(150 mg, 0.26 mmol) in dioxane (3 mL) was degassed before Xantphos(14.88 mg, 0.03 mmol), DIPEA (0.054 mL, 0.31 mmol). Pd₂(dba)₃ (11.77 mg,0.01 mmol) and 2-methylpropane-1-thiol (162 mg, 1.80 mmol) were added.The reaction was heated to 80° C. for 40 min. The reaction was judged tobe complete by LCMS. The reaction was cooled to room temperature andconcentrated in vacuo. The residue was purified by flash chromatographyeluting with 0-40% EtOAc in heptane. tert-Butyl1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-5-[(2-methylpropyl)sulfanyl]-1,3-dihydro-2H-isoindole-2-carboxylate(130 mg, 85%) was obtained as a foam.

LC/MS: m/z=591 [M−H]⁻. ¹H NMR (500 MHz, DMSO-d₆, mixture of rotamers,3*:1) 0.98 (d, 6H), 1.34*, 1.45 (s, 9H), 1.73-1.83 (m, 1H), 2.82-2.89(m, 2H), 4.53-4.74 (m, 2H), 5.43*, 5.46 (d, 1H), 7.23-7.26 (m, 1H),7.28-7.4 (m, 2H), 7.6-7.66 (m, 2H), 7.7-7.75 (m, 2H), 8.61*, 8.63 (s,1H), 10.60, 10.61* (s, 1H).

Step 2: tert-Butyl1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-5-[(2-methylpropyl)sulfonyl]-1,3-dihydro-2H-isoindole-2-carboxylate

tert-Butyl1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-5-[(2-methylpropyl)sulfanyl]-1,3-dihydro-2H-isoindole-2-carboxylate(127 mg, 0.21 mmol) was dissolved in DCM (5 mL) and to this mCPBA (≥77%)(115 mg, 0.51 mmol) was added. The reaction was stirred at roomtemperature for 20 min. After this time LCMS indicated thatapproximately 20% of the sulphoxide remained. mCPBA (≥77%) (30 mg, 0.13mmol) was added and the reaction stirred at rt for 10 min. LCMSindicated complete clean conversion to the sulphone had been achieved.The reaction was diluted with DCM and washed twice with 1M aqueous NaOH.The DCM was dried using a phase separator cartridge and concentrated invacuo to afford tert-butyl1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-5-[(2-methylpropyl)sulfonyl]-1,3-dihydro-2H-isoindole-2-carboxylate.(130 mg, 97%) as a foam. The material was used in the next step withoutpurification.

LC/MS: m/z=625 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆, mixture of rotamers,2*:1) δ 0.92-1 (m, 6H), 1.35*, 1.47 (s, 9H), 2-2.08 (m, 1H), 3.2 (t,2H), 4.69-4.86 (m, 2H), 5.61*, 5.63 (d, 1H), 7.61-7.76 (m, 5H),7.84-7.88 (m, 1H), 7.95, 7.98* (s, 1H), 8.65 (br s, 1H), 10.76, 10.77*(s, 1H).

Intermediate 17:2-Acetyl-5-bromo-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)isoindoline-1-carboxamide

Step 1:5-Bromo-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)isoindoline-1-carboxamide

tert-Butyl5-bromo-1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)-isoindoline-2-carboxylate(300 mg, 0.51 mmol) was dissolved in DCM (4 mL) and to this TFA (2 mL,25.96 mmol) was added. The reaction was stirred at room temperature for1 h. The reaction was concentrated in vacuo and the residue obtained wasdissolved in methanol. This was loaded onto a O1 g Isolute™ SCXcartridge (previously flushed with methanol). The cartridge was flushedwith methanol and then the product was eluted with 7M NH₃ in methanol.The methanolic ammonia was removed in vacuo to afford5-bromo-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)isoindoline-1-carboxamide(180 mg, 72.4%). The material was used in the next step withoutpurification.

LC/MS: m/z=483/485 [M+H]⁺.

Step 2:2-Acetyl-5-bromo-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)isoindoline-1-carboxamide

5-Bromo-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)isoindoline-1-carboxamide(180 mg, 0.37 mmol) was suspended in DCM (2 mL) and to thistriethylamine (0.104 mL, 0.75 mmol)), acetic acid (0.043 mL, 0.75 mmol)and T3P (50% solution in EtOAc) (0.444 mL, 0.75 mmol) were added. Thereaction was stirred at room temperature for 30 min. The reaction wasdiluted with DCM and washed with 0.5M aqueous HCl and then saturatedaqueous NaHCO₃. The layers were separated using a phase separatorcartridge and the DCM removed in vacuo. The yield was assumedquantitative and the material was used without further purification.

LC/MS: m/z=523/525 [M−H]⁻

Intermediate 18: (1-(tert-Butyldimethylsilyloxy)cyclopropyl)methylmethanesulphonate

Step 1: 1-(Benzyloxymethyl)cyclopropanol

Ethylmagnesium bromide in Et₂O (154 mL, 463.36 mmol) was added dropwiseto ethyl 2-(benzyloxy)acetate (20 g, 102.98 mmol) and titanium (IV)isopropoxide (30.18 mL, 102.98 mmol) in Et₂O (200 mL) cooled to 0′C overa period of 30 minutes under nitrogen. The reaction mixture was quenchedwith saturated NH₄Cl (200 mL) in a bath of ice, extracted with EtOAc(3×250 mL), the organic layer was dried over Na₂SO₄, filtered andevaporated to afford grey oil. The crude product was purified by flashsilica chromatography, elution gradient 0 to 20% EtOAc in petroleumether. Pure fractions were evaporated to dryness to afford1-((benzyloxy)methyl)cyclopropan-1-ol (15.0 g, 82%). ¹H NMR (300 MHz,DMSO-d₆) δ 0.47-0.52 (m, 2H), 0.56-0.60 (m, 2H), 3.46 (s, 2H), 4.54 (s,2H), 5.39 (s, 1H), 7.23-7.40 (m, 5H).

Step 2: 1-(Benzyloxymethyl)cyclopropoxy)(tert-butyl)dimethylsilane

Imidazole (2.86 g, 42.08 mmol) was added to1-((benzyloxy)methyl)cyclopropan-1-ol (5 g, 28.05 mmol) and TBDMSCl(4.65 g, 30.86 mmol) in DCM (4 mL) cooled to 0° C. under nitrogen. Theresulting mixture was stirred at room temperature for 12 hours. Thereaction mixture was quenched with water (20 mL), extracted with DCM(3×20 mL), the organic layer was dried over Na₂SO₄, filtered andevaporated to afford pale yellow oil. The crude product was purified byflash silica chromatography, elution gradient 0 to 5% EtOAc in petroleumether. Pure fractions were evaporated to dryness to afford(1-((benzyloxy)methyl)cyclopropoxy)(tert-butyl)dimethylsilane (5.30 g,64.6%). ¹H NMR (300 MHz, DMSO-d₆) δ 0.09 (s, 6H), 0.60-0.65 (m, 4H),0.82 (s, 9H), 3.47 (s, 2H), 4.51 (s, 2H), 7.29-7.37 (m, 5H).

Step 3: (1-tert-Butyldimethylsilyloxy)cyclopropyl)methanol

Pd—C (40 mg, 0.38 mmol) was added to(1-((benzyloxy)methyl)cyclopropoxy)(tert-butyl)dimethylsilane (5.3 g,18.12 mmol) in MeOH (100 mL) under nitrogen. The resulting mixture wasstirred at room temperature for 12 hours under hydrogen. The reactionmixture was filtered through celite. The solvent was removed underreduced pressure. The crude product was purified by flash silicachromatography, elution gradient 0 to 5% EtOAc in petroleum ether. Purefractions were evaporated to dryness to afford(1-((tert-butyldimethylsilyl)oxy)cyclopropyl)methanol (2.3 g, 62.7%).

¹H NMR (300 MHz, DMSO-d₆) δ 0.10 (s, 6H), 0.53-0.57 (m, 4H), 0.82 (s,9H), 3.43 (d, J=5.7 Hz, 2H), 4.65 (t, J=5.7 Hz, 1H).

Step 4: (2-(9H-Fluoren-9-yl)methyl 1-methyl5-(benzylthio)isoindoline-1,2-dicarboxylate

Et₃N (1.891 mL, 13.56 mmol) was added to(1-((tert-butyldimethylsilyl)oxy)cyclopropyl)methanol (1.83 g, 9.04mmol) and MsC1 (0.846 mL, 10.85 mmol) in DCM (30 mL) cooled to 0° C.under nitrogen. The resulting solution was stirred at room temperaturefor 3 hours. The reaction mixture was quenched with water (25 mL),extracted with DCM (2×25 mL), the organic layer was dried over Na₂SO₄,filtered and evaporated to afford(1-((tert-butyldimethylsilyl)oxy)cyclopropyl)methyl methanesulfonate(1.85 g, 72.9%).

¹H NMR (300 MHz, CDCl₃) δ 0.17 (s, 6H), 0.76-0.95 (m, 13H), 3.09 (s,3H), 4.22 (s, 2H).

Intermediate 19: (1-Cyanocyclopropyl)methyl 4-methylbenzenesulphonate

Et₃N (8.97 mL, 64.36 mmol) was added to1-(hydroxymethyl)cyclopropane-1-carbonitrile (5 g, 51.48 mmol) and TsCl(11.78 g, 61.78 mmol) in DCM (100 mL) cooled to 0° C. under nitrogen.The resulting solution was stirred at room temperature for 2 hours. Thereaction mixture was quenched with water (20 mL), extracted with DCM(3×20 mL), the organic layer was dried over Na₂SO₄, filtered andevaporated to afford white solid. The crude product was purified byflash silica chromatography, elution gradient 0 to 100% DCM in petroleumether. Pure fractions were evaporated to dryness to afford(1-cyanocyclopropyl)methyl 4-methylbenzenesulfonate (5.20 g, 40%).

LC/MS: m/z=252 [M+H]⁺. ¹H NMR (300 MHz, CDCl₃) δ 1.09 (dd, J=7.5, 5.7Hz, 2H), 1.38 (dd, J=7.5, 5.4 Hz, 2H), 2.48 (s, 3H), 4.01 (s, 2H), 7.40(d, J=8.1 Hz, 2H), 7.84 (d, J=8.1 Hz, 2H).

Intermediate 20: 9H-Fluoren-9-yl5-{[(1-cyanocyclopropyl)methyl]sulfonyl}-1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-1,3-dihydro-2H-isoindole-2-carboxylate

Step 1: tert-Butyl 5-(benzylthio)1-oxoisoindoline-2-carboxylate

(Boc)₂O (87.20 g, 400.00 mmol) was added to5-(benzylthio)isoindolin-1-one (68.00 g, 266.7 mmol) and DMAP (48.80 g,400 mmol) in MeCN (900 mL) under nitrogen. The resulting mixture wasstirred at room temperature for 3 hours. The solvent was removed underreduced pressure. The crude product was purified by crystallisation fromMeCN to afford tert-butyl 5-(benzylthio)-1-oxoisoindoline-2-carboxylate(60.0 g, 63%). LC/MS: m/z=300 [M-tBu+H]⁺. ¹H NMR (300 MHz, DMSO-d₆) δ1.50 (s, 9H), 4.37 (s, 2H), 4.72 (s, 2H), 7.25-7.64 (m, 8H).

Step 2: tert-Butyl 5-(benzylthio)1-hydroxyisoindoline-2-carboxylate

Lithium tri-tert-butoxyaluminum hydride (32.2 g, 126.60 mmol) was addedto tert-butyl 5-(benzylthio)-1-oxoisoindoline-2-carboxylate (30 g, 84.40mmol) in THF (750 mL) cooled to 0° C. under nitrogen. The resultingsolution was stirred at room temperature for 2 hours. The reactionmixture was quenched with saturated NH₄Cl (500 mL), extracted with EtOAc(3×500 mL), the organic layer was dried over Na₂SO₄, filtered andevaporated to afford tert-butyl5-(benzylthio)-1-hydroxyisoindoline-2-carboxylate (29.6 g, 98%).

LC/MS: m/z=340 [M-OH]⁺. ¹H NMR (300 MHz, DMSO-d₆) δ 1.48 (s, 9H), 4.27(s, 2H), 4.45-4.48 (m, 2H), 6.03-6.25 (m, 2H), 7.24-7.40 (m, 8H).

Step 3: tert-Butyl 5-(benzylthio)1-methoxyisoindoline-2-carboxylate

Silver (I) oxide (77 g, 331.22 mmol) was added to tert-butyl5-(benzylthio)-1-hydroxyisoindoline-2-carboxylate (29.6 g, 82.80 mmol)and MeI (31.1 mL, 496.83 mmol) in toluene (650 mL) under nitrogen. Theresulting mixture was stirred at 80° C. for 4 hours. The reactionmixture was filtered through celite. The solvent was removed underreduced pressure. The product tert-butyl5-(benzylthio)-1-methoxyisoindoline-2-carboxylate (29.6 g, 96%) was usedin the next step directly without further purification.

LC/MS: m/z=340 [M-MeO]⁺. ¹H NMR (400 MHz, DMSO-d₆, mixture of rotamers,1:1) δ 1.47 (s, 9H), 3.14 (brs, 3H), 4.27 (s, 2H), 4.44-4.57 (m, 2H),6.14, 6.19 (s, 1H), 7.22-7.38 (m, 8H).

Step 4: tert-Butyl 5-(benzylthio)1-cyanoisoindoline-2-carboxylate

BF₃.Et₂O (15.15 mL, 119.52 mmol) was added dropwise to tert-butyl5-(benzylthio)-1-methoxyisoindoline-2-carboxylate (29.6 g, 79.68 mmol)and trimethylsilanecarbonitrile (11.86 g, 119.52 mmol) in DCM (600 mL)cooled to −78′C under nitrogen. The resulting solution was stirred at−78° C. for 1 hour. The reaction mixture was quenched with saturatedNaHCO₃ (5 mL), extracted with DCM (3×10 mL), the organic layer was driedover Na₂SO₄, filtered and evaporated to afford red oil. The crudeproduct was purified by flash silica chromatography, elution gradient 0to 5% EtOAc in petroleum ether. Pure fractions were evaporated todryness to afford tert-butyl5-(benzylthio)-1-cyanoisoindoline-2-carboxylate (15.50 g, 53.1%).

LC/MS: m/z=430 [M+Na+MeCN]⁺. ¹H NMR (300 MHz, DMSO-d₆, mixture ofrotamers, 1.1*:1) δ 1.49, 1.50* (s, 9H), 4.30 (s, 2H), 4.61*, 4.63 (s,2H), 5.99, 6.00* (s, 1H), 7.22-7.47 (m, 8H).

Step 5: Methyl 5-(benzylthio)isoindoline-1-carboxylate

Hydrogen chloride (12N, 43 mL, 516.00 mmol) was added slowly totert-butyl 5-(benzylthio)-1-cyanoisoindoline-2-carboxylate (19 g, 51.91mmol) in MeOH (30 mL) cooled to 0° C. The resulting mixture was stirredat room temperature for 18 hours. The reaction mixture was basified with2M NaOH (200 mL), extracted with DCM (3×200 mL), the organic layer wasdried over Na₂SO₄, filtered and evaporated to afford dark oil. The crudeproduct was purified by flash silica chromatography, elution gradient 0to 10% MeOH in DCM. Pure fractions were evaporated to dryness to affordmethyl 5-(benzylthio)isoindoline-1-carboxylate (8.0 g, 51.5%).

LC/MS: m/z=300 [M+H]⁺. ¹H NMR (300 MHz, DMSO-d₆) δ 3.65 (s, 3H),4.02-4.24 (m, 4H), 4.89 (s, 1H), 7.18-7.37 (m, 8H).

Step 6: 2-(9H-Fluoren-9-yl)methyl 1-methyl5-(benzylthio)isoindoline-1,2-dicarboxylate

K₂CO₃ (44.6 g, 322.83 mmol) was added to (9H-fluoren-9-yl)methylcarbonochloridate (3.48 g, 13.45 mmol), methyl5-(benzylthio)-1H-isoindole-1-carboxylate (4 g, 13.45 mmol) in1,4-dioxane (15 mL) and water (60.0 mL) at 0° C. under air. Theresulting solution was stirred at room temperature for 2 hours. Thereaction mixture was treated with water (75 mL), extracted with DCM(3×75 mL), the organic layer was dried over Na₂SO₄, filtered andevaporated to afford black solid. The crude product was purified byflash silica chromatography, elution gradient 0 to 5% EtOAc in petroleumether. Pure fractions were evaporated to dryness to afford2-((9H-fluoren-9-yl)methyl)-1-methyl-5-(benzylthio)isoindoline-1,2-dicarboxylate(4.50 g, 64.1%).

LC/MS: m/z=522 [M+H]⁺. ¹H NMR (300 MHz, DMSO-d₆, mixture of rotamers,1.1*:1) δ 3.59, 3.66* (s, 3H), 4.19-4.50 (m, 5H), 4.64-4.74 (m, 2H),5.41, 5.48* (s, 1H), 7.21-7.93 (m, 16H).

Step 7: 2-(9H-Fluoren-9-yl)methyl 1-methyl5-(chlorosulphonyl)isoindoline-1,2-dicarboxylate

Formic acid (60 mL, 1604.35 mmol) was added to2-((9H-fluoren-9-yl)methyl) 1-methyl5-(benzylthio)isoindoline-1,2-dicarboxylate (5.08 g, 9.74 mmol), NCS(6.50 g, 48.69 mmol) and sodium chloride (2.85 g, 48.69 mmol) in DCM(140 mL) and water (60 mL) under nitrogen. The resulting solution wasstirred at 25° C. for 2 hours. The reaction mixture was treated withwater (150 mL), extracted with DCM (3×200 mL), the organic layer wasdried over Na₂SO₄, filtered and evaporated to afford2-((9H-fluoren-9-yl)methyl) 1-methyl5-(chlorosulfonyl)isoindoline-1,2-dicarboxylate (4.40 g, 90%). Theproduct was used in the next step directly without further purification.

LC/MS: m/z=498 [M+H]⁺.

Step 8: 2-(9H-Fluoren-9-yl)methyl 1-methyl5-mercaptoisoindoline-1,2-dicarboxylate

Ph₃P (9.48 g, 36.15 mmol) was added to 2-((9H-fluoren-9-yl)methyl)1-methyl 5-(chlorosulfonyl)isoindoline-1,2-dicarboxylate (6 g, 12.05mmol) in DMF (18 mL) and DCM (180 mL) at 0° C. under nitrogen. Theresulting solution was stirred at 30° C. for 4 hours. The reactionmixture was quenched with water (100 mL), extracted with DCM (3×100 mL),the organic layer was dried over Na₂SO₄, filtered and evaporated toafford brown oil. The crude product was purified by flash C18-flashchromatography, elution gradient 0 to 60% MeCN in water. Pure fractionswere evaporated to dryness to afford 2-((9H-fluoren-9-yl)methyl)1-methyl 5-mercaptoisoindoline-1,2-dicarboxylate (1.6 g, 30.8%).

LC/MS: m/z=432 [M+H]⁺. ¹H NMR (300 MHz, CDCl₃, mixture of rotamers,1.1*:1) δ 3.53, 3.55* (s, 1H), 3.67, 3.79* (s, 3H), 4.24, 4.36* (t,J=6.7 Hz, 1H), 4.43-4.59 (m, 2H), 4.74-4.91 (m, 2H), 5.39-5.43,5.52-5.56 (m, 1H), 7.18-7.25 (m, 2H), 7.28-7.48 (m, 5H), 7.55-7.72 (m,2H), 7.76-7.82 (m, 2H).

Step 9: 2-(9H-Fluoren-9-yl)methyl 1-methyl5-((1-cyanocyclopropyl)methylthio)isoindoline-1,2-dicarboxylate

K₂CO₃ (4.68 g, 14.37 mmol) was added to 2-((9H-fluoren-9-yl)methyl)1-methyl 5-mercaptoisoindoline-1,2-dicarboxylate (3.1 g, 7.18 mmol) and(1-cyanocyclopropyl)methyl 4-methylbenzenesulfonate (2.72 g, 10.78 mmol)in DMF (100 mL) at 0° C. under nitrogen. The resulting solution wasstirred at room temperature for 2 hours. The reaction mixture wasquenched with water (100 mL), extracted with DCM (3×125 mL), the organiclayer was dried over Na₂SO₄, filtered and evaporated to afford whitesolid. The crude product was purified by flash silica chromatography,elution gradient 0 to 25% EtOAc in petroleum ether. Pure fractions wereevaporated to dryness to afford 2-((9H-fluoren-9-yl)methyl) 1-methyl5-(((1-cyanocyclopropyl)methyl)thio)isoindoline-1,2-dicarboxylate (3.39g, 92%).

LC/MS: m/z=511 [M+H]⁺. ¹H NMR (300 MHz, CDCl₃, mixture of rotamers,1.1*:1) δ 0.89-0.93 (m, 2H), 1.29-1.34 (m, 2H), 3.07, 3.08* (s, 2H),3.67, 3.81* (s, 3H), 4.22, 4.33* (t, J=6.7 Hz, 1H), 4.39-4.60 (m, 2H),4.74-4.94 (m, 2H), 5.40, 5.60* (brs, 1H), 7.29-7.47 (m, 7H), 7.54-7.71(m, 2H), 7.74-7.83 (m, 2H).

Step 10: 2-(9H-Fluoren-9-yl)methyl 1-methyl5-((1-cyanocyclopropyl)methylsulfonyl)isoindoline-1,2-dicarboxylate

mCPBA (3.44 g, 19.92 mmol) was added to 2-((9H-fluoren-9-yl)methyl)1-methyl5-(((1-cyanocyclopropyl)methyl)thio)isoindoline-1,2-dicarboxylate (3.39g, 6.64 mmol) in DCM (100 mL) under nitrogen. The resulting solution wasstirred at room temperature for 2 hours. The reaction mixture wastreated with saturated NaHCO₃ (100 mL), extracted with DCM (3×150 mL),the organic layer was dried over Na₂SO₄, filtered and evaporated toafford white solid. The crude product was purified by flash silicachromatography, elution gradient 0 to 30% EtOAc in petroleum ether. Purefractions were evaporated to dryness to afford2-((9H-fluoren-9-yl)methyl) 1-methyl5-(((1-cyanocyclopropyl)methyl)sulfonyl)isoindoline-1,2-dicarboxylate(3.20 g, 89%).

LC/MS: m/z=543 [M+H]⁺. ¹H NMR (300 MHz, CDCl₃, mixture of rotamers,1.1*:1) δ 1.19-1.27 (m, 2H), 1.39-1.49 (m, 2H), 3.22, 3.24* (s, 2H),3.64, 3.79* (s, 3H), 4.22, 4.34* (t, J=6.7 Hz, 1H), 4.42-4.65 (m, 2H),4.79-5.03 (m, 2H), 5.51, 5.69* (brs, 1H), 7.28-7.49 (m, 4H), 7.53-7.85(m, 5H), 7.90-8.02 (m, 2H).

Step 11:2-(((9H-Fluoren-9-yl)methoxy)carbonyl)-5-((1-cyanocyclopropyl)methylsulfonyl)isoindoline-1-carboxylicacid

Lithium iodide (0.740 g, 5.53 mmol) was added to2-((9H-fluoren-9-yl)methyl) 1-methyl5-(((1-cyanocyclopropyl)methyl)sulfonyl)isoindoline-1,2-dicarboxylate (3g, 5.53 mmol) in EtOAc (100 mL) under nitrogen. The resulting solutionwas stirred at 70° C. for 15 hours. The reaction mixture was treatedwith 0.1M HCl (50 mL), extracted with EtOAc (3×100 mL), the organiclayer was dried over Na₂SO₄, filtered and evaporated to afford whitesolid. The crude product was purified by flash silica chromatography,elution gradient 0 to 10% MeOH in DCM. Pure fractions were evaporated todryness to afford2-(((9H-fluoren-9-yl)methoxy)carbonyl)-5-(((1-cyanocyclopropyl)methyl)sulfonyl)isoindoline-1-carboxylicacid (2.2 g, 75%).

LC/MS: m/z=529 [M+H]⁺. ¹H NMR (300 MHz, DMSO-d₆) δ 1.01-1.05 (m, 2H),1.30-1.34 (m, 2H), 3.70 (s, 2H), 4.10-4.39 (m, 3H), 4.78-4.86 (m, 2H),5.23-5.39 (m, 1H), 7.32-7.95 (m, 11H).

Step 12: (9H-Fluoren-9-yl)methyl5-{[(1-cyanocyclopropyl)methyl]sulfonyl}-1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-1,3-dihydro-2H-isoindole-2-carboxylate

DIPEA (0.991 mL, 5.68 mmol) was added to2-(((9H-fluoren-9-yl)methoxy)carbonyl)-5-(((1-cyanocyclopropyl)methyl)sulfonyl)isoindoline-1-carboxylicacid (1 g, 1.89 mmol),2-(4-aminophenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol (0.981 g, 3.78 mmol)and HATU (1.439 g, 3.78 mmol) in DCM (20 mL) under nitrogen. Theresulting solution was stirred at room temperature for 2 hours. Thereaction mixture was treated with saturated NH₄Cl (20 mL), extractedwith DCM (3×25 mL), the organic layer was dried over Na₂SO₄, filteredand evaporated to afford (9H-fluoren-9-yl)methyl5-(((1-cyanocyclopropyl)methyl)sulfonyl)-1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)isoindoline-2-carboxylate(1.200 g, 82%), which was used in the next step without furtherpurification.

LC/MS: m/z=770 [M+H]⁺. ¹H NMR (300 MHz, DMSO-d₆) δ 0.99-1.07 (m, 2H),1.29-1.34 (m, 2H), 3.73 (s, 2H), 4.15-4.39 (m, 3H), 4.93-5.05 (m, 2H),5.75-5.85 (m, 1H), 6.95-8.08 (m, 15H), 8.67 (s, 1H), 10.86-10.92 (m,1H).

Intermediate 21: tert-Butyl5-{[(1-{[tert-butyl(dimethyl)silyl]oxy}cyclopropyl)methyl]sulfonyl}-1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-1,3-dihydro-2H-isoindole-2-carboxylate

Step 1: tert-Butyl5-{[(1-{[tert-butyl(dimethyl)silyl]oxy}cyclopropyl)methyl]sulfanyl}-1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-1,3-dihydro-2H-isoindole-2-carboxylate

(1-((tert-Butyldimethylsilyl)oxy)cyclopropyl)methyl methanesulfonate(1.8 g, 6.42 mmol) was added to tert-butyl1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)-5-((3-methoxy-3-oxopropyl)thio)isoindoline-2-carboxylate(2.7 g, 4.34 mmol) and potassium 2-methylpropan-2-olate (1.947 g, 17.35mmol) in THF (70 mL) at −78° C. under nitrogen. The resulting solutionwas stirred at 60° C. for 3 hours. The reaction mixture was treated withwater (75 mL), extracted with DCM (3×100 mL), the organic layer wasdried over Na₂SO₄, filtered and evaporated to afford white solid. Thecrude product was purified by flash silica chromatography, elutiongradient 0 to 25% EtOAc in petroleum ether. Pure fractions wereevaporated to dryness to afford tert-butyl5-(((1-((tert-butyldimethylsilyl)oxy)cyclopropyl)methyl)thiohi)-1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)isoindoline-2-carboxylate(2.60 g, 83%).

LC/MS: m/z=721 [M+H]⁺. ¹H NMR (300 MHz, DMSO-d₆, mixture of rotamers,1.5*:1) δ 0.10 (s, 6H), 0.61-0.68 (m, 2H), 0.72-0.77 (m, 2H), 0.82 (s,9H), 1.35*, 1.46 (s, 9H), 3.22, 3.23* (s, 2H), 4.54-4.77 (m, 2H),5.39-5.49 (m, 1H), 7.21-7.43 (m, 3H), 7.56-7.77 (m, 4H), 8.61*, 8.63 (s,1H), 10.60 (s, 1H).

Step 2: tert-Butyl5-{[(1-{[tert-butyl(dimethyl)silyl]oxy}cyclopropyl)methyl]sulfonyl}-1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-1,3-dihydro-2H-isoindole-2-carboxylate

mCPBA (1.867 g, 10.82 mmol) was added to tert-butyl5-(((1-((tert-butyldimethylsilyl)oxy)cyclopropyl)methyl)thio)-1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)isoindoline-2-carboxylate(2.6 g, 3.61 mmol) in DCM (50 mL) under nitrogen. The resulting solutionwas stirred at rt for 1 hour. The reaction mixture was treated withsaturated Na₂CO₃ (50 mL), extracted with DCM (3×75 mL), the organiclayer was dried over Na₂SO₄, filtered and evaporated to afford whitesolid. The crude product was purified by flash silica chromatography,elution gradient 0 to 25% EtOAc in petroleum ether. Pure fractions wereevaporated to dryness to afford tert-butyl5-(((1-((tert-butyldimethylsilyl)oxy)cycloplfonyl)-1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)isoindoline-2-carboxylate(2.2 g, 81%).

LC/MS: m/z=753 [M+H]⁺. ¹H NMR (300 MHz, DMSO-d₆, mixture of rotamers,1.8*:1) δ−0.12, −0.08* (s, 6H), 0.61 (s, 9H), 0.66-0.79 (m, 4H), 1.37*,1.48 (s, 9H), 3.45-3.65 (m, 2H), 4.66-4.90 (m, 2H), 5.60*, 5.62 (brs,1H), 7.59-7.78 (m, 5H), 7.82-7.98 (m, 2H), 8.61*, 8.62 (s, 1H), 10.71(s, 1H).

Intermediate 22: (R)-tert-Butyl1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)-5-(methylsulfonyl)isoindoline-2-carboxylate

A 2 L reactor, equipped with a thermometer, was charged with(R)-2-(tert-butoxycarbonyl)-5-(methylsulfonyl)isoindoline-1-carboxylicacid (110 g, 307.08 mmol) under nitrogen. EtOAc (1000 mL) was added andthe resulting mixture was stirred for 1 min. The vessel was then chargedwith 2-(4-aminophenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol (84 g, 307.08mmol), the resulting mixture was cooled to +10 OC and then pyridine(27.3 mL, 337.79 mmol) was added. The reaction was cooled to +5 OC, andT3P (50% in EtOAc, 274 mL, 460.62 mmol) was added at 5° C. over 15 min.The temperature rose to 13.3° C. over the addition, and the resultingsolution was allowed to reach room temperature over 20 minutes and leftstirring overnight at room temperature. The mixture was cooled to +5 OC,and an aqueous solution of citric acid (iN) was added, followed by 500mL of EtOAc. Stirring was continued for 15 min, then stirring wasstopped and the layers separated. The organic layer was washed withaqueous citric acid (1000 mL), and then twice with saturated aqueousNaHCO₃ (1000 mL), followed by brine (1000 mL). The organic layer wasseparated and concentrated under reduced pressure (bath temperature 32°C.). The crude material was dissolved in 550 mL of EtOH at rt, and water(440 mL) was slowly added dropwise over 15 min. Seed crystals (20 mg),were added, and the mixture was left overnight at 20° C. The precipitatewas isolated by filtration, washed with a 4:1 mixture of H₂O/EtOH (220mL), and dried under high vacuum. The title compound (132 g,quantitative) was used in the next step without further purification.

LC/MS: m/z=581 [M−H]⁻, 583 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆, mixture ofrotamers, 1.9*:1) δ 1.34*, 1.46 (s, 9H), 3.20, 3.21* (s, 3H), 4.69-4.88(m, 2H), 5.60*, 5.62 (s, 1H), 7.6-7.76 (m, 5H), 7.86-7.92 (m, 1H), 7.98,8.01* (s, 1H), 8.68*, 8.69 (s, 1H), 10.76 (s, 1H).

The seed crystals were obtained from (R)-tert-butyl1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)-5-(methylsulfonyl)isoindoline-2-carboxylate(0.5 g, 0.86 mmol, prepared as described above for the large scalepreparation of intermediate 22). This material was dissolved in ethanol(2.5 ml). Water (2 ml) was added until the point the mixture just becameturbid. Spontaneous crystalization occured after about 30 seconds, and(R)-tert-butyl1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)-5-(methylsulfonyl)isoindoline-2-carboxylatewas obtained after filtration and drying as a colorless solid (0.38 g,76%).

Intermediate 23: (1-Fluorocyclopropyl)methyl methanesulphonate

Step 1: (1-Fluorocyclopropyl)methanol

LiAlH₄ (0.912 g, 24.02 mmol) was added dropwise to1-fluorocyclopropane-1-carboxylic acid (2.5 g, 24.02 mmol) in THF (1 mL)cooled to 0° C. under nitrogen. The resulting solution was stirred at rtfor 2 hours. The reaction mixture was quenched with Na₂SO₄. 10H₂O,extracted with Et₂O (3×20 mL), the organic layer was dried over Na₂SO₄,filtered and evaporated to afford pale yellow oil. The crude product waspurified by flash silica chromatography, elution gradient 0 to 20% EtOAcin petroleum ether. Pure fractions were evaporated to dryness to afford(1-fluorocyclopropyl) methanol (0.700 g, 32.3%) as a colourless oil.

¹H NMR (400 MHz, DMSO-d₆): δ 0.63-0.69 (m, 2H), 0.88-0.97 (m, 2H), 3.62(dd, 2H), 5.00 (t, 1H).

Step 2: (1-Fluorocyclopropyl)methyl methanesulphonate

Et₃N (0.464 mL, 3.33 mmol) was added to (1-fluorocyclopropyl)methanol(150 mg, 1.66 mmol) and MsCl (0.195 mL, 2.50 mmol) in DCM (2 mL) cooledto 0° C. under nitrogen. The resulting solution was stirred at roomtemperature for 1 hour. The reaction mixture was quenched with water (5mL), extracted with DCM (3×5 mL), the organic layer was dried overNa₂SO₄, filtered and evaporated to afford (1-fluorocyclopropyl)methylmethanesulfonate (250 mg, 89%) as pale yellow oil.

¹H NMR (300 MHz, CDCl₃) δ 0.86-0.93 (m, 2H), 1.21-1.32 (m, 2H), 3.13 (s,3H), 4.50 (d, 2H).

Intermediate 24: tert-Butyl5-{[(1-fluorocyclopropyl)methyl]sulfonyl}-1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-1,3-dihydro-2H-isoindole-2-carboxylate

Step 1: tert-Butyl5-{[(1-fluorocyclopropyl)methyl]sulfanyl}-1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-1,3-dihydro-2H-isoindole-2-carboxylate

KO^(t)Bu in THF (2.168 mL, 2.17 mmol) was added to tert-butyl1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)-5-((3-methoxy-3-oxopropyl)thio)isoindoline-2-carboxylate (450 mg, 0.72 mmol) and(1-fluorocyclopropyl)methyl methanesulfonate (243 mg, 1.45 mmol) in THF(10 mL) cooled to 0° C. under nitrogen. The resulting solution wasstirred at 60° C. for 1 hour. The reaction mixture was quenched withwater (20 mL), extracted with EtOAc (3×20 mL), the organic layer wasdried over Na₂SO₄, filtered and evaporated to afford tert-butyl5-(((1-fluorocyclopropyl)methyl)thio)-14-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)isoindoline-2-carboxylate (400 mg, 91%) as an oil. LC/MS:m/z=609 [M+H]⁺. ¹H NMR (300 MHz, DMSO-d₆, mixture of rotamers, 1.6*:1) δ0.70-0.78 (m, 2H), 0.99-1.14 (m, 2H), 1.35*, 1.47 (s, 9H), 3.51, 3.52*(d, 2H), 4.50-4.76 (m, 2H), 5.47*, 5.48 (s, 1H), 7.31-7.39 (m, 2H),7.44-7.49 (m, 1H), 7.59-7.69 (m, 2H), 7.70-7.79 (m, 2H), 8.63*, 8.65 (s,1H), 10.64 (s, 1H).

Step 2: tert-Butyl5-{[(1-fluorocyclopropyl)methyl]sulfonyl}-1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-1,3-dihydro-2H-isoindole-2-carboxylate

mCPBA (247 mg, 1.43 mmol) was added slowly to tert-butyl5-(((1-fluorocyclopropyl)methyl)thio)-1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)isoindoline-2-carboxylate(290 mg, 0.48 mmol) in DCM (15 mL) at 0° C. under nitrogen. Theresulting solution was stirred at room temperature for 3 hours. Thereaction mixture was quenched with water (15 mL), extracted with DCM(3×10 mL), the organic layer was dried over Na₂SO₄, filtered andevaporated to afford brown oil. The crude product was purified by flashsilica chromatography, elution gradient 10 to 20% EtOAc in petroleumether. Pure fractions were evaporated to dryness to afford tert-butyl5-(((1-fluorocyclopropyl)methyl)sulfonyl)-1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)isoindoline-2-carboxylate(200 mg, 65.5%) as a solid.

LC/MS: m/z=641 [M+H]⁺. ¹H NMR (300 MHz, DMSO-d₆, mixture of rotamers,1.2*:1) δ 0.69-0.77 (m, 2H), 0.93-1.07 (m, 2H), 1.36*, 1.47 (s, 9H),3.95-4.04 (m, 2H) 4.72-4.87 (m, 2H), 5.62*, 5.63 (s, 1H), 7.60-7.69 (m,3H), 7.70-7.77 (m, 2H), 7.85-7.92 (m, 1H), 7.94-8.03 (m, 1H), 8.64*,8.66 (s, 1H), 10.75 (s, 1H).

Example 100:5-(Ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide

(9H-Fluoren-9-yl)methyl5-(ethylsulfonyl)-1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)isoindoline-2-carboxylate(5.4 g, 7.51 mmol) was suspended in acetonitrile (200 mL). Diethylamine(62.8 mL, 601.12 mmol) was added and the reaction stirred at roomtemperature for 20 min. The reaction was evaporated to dryness and theresidue dissolved in methanol. This was loaded on an Isolute™ SCXcartridge (previously flushed with methanol). The SCX was then flushedwith methanol and the product eluted with 2M ammonia in methanol. Themethanolic ammonia was removed in vacuo to afford5-(ethylsulfonyl)-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)isoindoline-1-carboxamide(3.20 g, 86%).

A sample for biological screening was triturated with diethyl ether andthe solid obtained was collected by filtration and washed with ether.

HRMS: calculated for (C₂₀H₁₈F₆N₂O₄S+H)⁺497.0970; found: (ESI [M+H]⁺)497.0977. ¹H NMR (500 MHz, DMSO-d₆) δ 1.09 (t, 3H), 3.27 (q, 2H), 3.94(s, 1H), 4.29-4.48 (m, 2H), 5.09 (s, 1H), 7.60 (d, 2H), 7.7-7.84 (m,5H), 8.62 (s, 1H), 10.33 (s, 1H).

Example 101:5-(Ethylsulfonyl)-2-formyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide

T3P (50% in EtOAc) (0.134 mL, 0.23 mmol) was added to a solution of5-(ethylsulfonyl)-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)isoindoline-1-carboxamide(80 mg, 0.16 mmol), formic acid (9.64 mg, 0.21 mmol) and triethylamine(0.045 mL, 0.32 mmol) in dichloromethane (2 mL). The resulting mixturewas stirred at room temperature for 1 h. The reaction mixture waspartitioned between DCM and sat aq NaHCO₃. The layers were separated ina phase separator cartridge and the organic layer was concentrated invacuo. The residue was purified by flash chromatography eluting with60%-100% EtOAc in heptane.5-(Ethylsulfonyl)-2-formyl-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)isoindoline-1-carboxamide(67.0 mg, 79%) was obtained as a solid. HRMS: calculated for(C₂₁H₁₈F₆N₂O₅S+H)⁺525.0919; found: (ESI [M+H]⁺) 525.0891. ¹H NMR (500MHz, DMSO-d₆, mixture of rotamers, 2*:1) δ 1.09, 1.10* (t, 3H),3.27-3.31 (m, 2H), 4.74-4.91, 5.05-5.17* (m, 2H), 5.77*, 5.99 (s, 1H),7.61-7.67 (m, 2H), 7.7-7.78 (m, 3H), 7.83-7.9 (m, 1H), 7.97-8.03 (m,1H), 8.39, 8.48* (s, 1H), 8.65 (s, 1H), 10.76*, 10.86 (s, 1H).

Example 102:2-[(1-Cyanocyclopropyl)acetyl]-5-(ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide

Using the same procedure described in example 101, but using2-(1-cyanocyclopropyl)acetic acid, the title compound (15.6 mg, 16%) wasobtained after purification by RP-HPLC (chromatographic conditions:gradient 5-95% ACN in 0.1M HCO₂H, pH3; column: Waters Sunfire C18 ODB 5μ19×150 mm).

HRMS: calculated for (C₂₆H₂₃F₆N₃O₅S+H)⁺604.1341; found: (ESI [M+H]⁺)604.1368.

¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 2*:1) δ 0.87-1.26*(m,7H), 2.75-2.94, 3.01-3.12* (m, 2H), 3.27-3.32 (m, 2H), 4.97, 5.20* (s,2H), 5.76-5.8 (m, 1H), 7.6-7.66 (m, 2H), 7.69-7.76 (m, 3H), 7.84-7.89(m, 1H), 7.94-7.98 (m, 1H), 8.69 (s, 1H), 10.74*, 10.76 (s, 1H).

Example 103:2-Acetyl-5-(ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide

Using the same procedure as in Example 101 but acetic acid instead offormic acid, the title compound (1.0 g, 81%) was obtained afterpurification by flash chromatography eluting with 50% to 100% EtOAc inheptane.

HRMS: calculated for (C₂₂H₂₀F₆N₂O₅S+H)⁺539.1075; found: (ESI [M+H]⁺)539.1077.

¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 4*:1) δ 1.09, 1.10* (t,3H), 1.99, 2.15* (s, 3H), 3.27-3.32 (m, 2H), 4.77-4.91, 5-5.09* (m, 2H),5.73*, 5.93 (s, 1H), 7.6-7.66 (m, 2H), 7.69-7.8 (m, 3H), 7.84-7.87 (m,1H), 7.96*, 7.98 (s, 1H), 8.66*, 8.69 (s, 1H), 10.71*, 10.94 (s, 1H).

The (1R) and the (1S) enantiomers of2-acetyl-5-(ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide(1230 mg) were separated by a preparative SFC system equipped with aChiralpak AS column 30% EtOH 100 in CO₂ (120 bar); flow: 150 mL/min;injection volume was 1 mL of a 200 mg/mL ethanol solution.

Isomer 1 (peak 1): 624 mg, 99.9% ee by analytical chiral SFC (analyticalconditions: Chiralpak AS column, 150×4.6 mm, 3 μm, 3.5 ml/min, 35% EtOHin CO₂, 120 bar, 40° C.). [α]D₅₈₉+99° (c=1, CH₃CN).

HRMS: calculated for (C₂₂H₂₀F₆N₂O₅S+H)⁺539.1075; found: (ESI [M+H]⁺)539.1082.

¹H NMR (500 MHz, DMSO-d₆, mixture of rotamers, 4*:1) δ 1.10 (t, 3H),1.99, 2.15* (s, 3H), 3.27-3.32 (m, 2H), 4.77-4.91*, 5-5.09 (m, 2H),5.73*, 5.93 (s, 1H), 7.6-7.66 (m, 2H), 7.69-7.8 (m, 3H), 7.84-7.87 (m,1H), 7.96*, 7.98 (s, 1H), 8.66*, 8.69 (s, 1H), 10.71*, 10.94 (s, 1H).

Isomer 2 (peak 2): 612 mg, 99.8% ee by analytical chiral SFC (analyticalconditions: Chiralpak AS column, 150×4.6 mm, 3 μm, 3.5 ml/min, 35% EtOHin CO₂, 120 bar, 40° C.). [α]D₅₈₉-100° (c=1, CH₃CN).

HRMS: calculated for (C₂₂H₂₀F₆N₂O₅S+H)⁺539.1075; found: (ESI [M+H]⁺)539.1077.

¹H NMR (500 MHz, DMSO-d₆, mixture of rotamers, 4*:1) δ 1.10 (t, 3H),1.99, 2.15* (s, 3H), 3.27-3.32 (m, 2H), 4.77-4.91*, 5-5.09 (m, 2H),5.73*, 5.93 (s, 1H), 7.6-7.66 (m, 2H), 7.69-7.8 (m, 3H), 7.84-7.87 (m,1H), 7.96*, 7.98 (s, 1H), 8.66*, 8.69 (s, 1H), 10.71*, 10.94 (s, 1H).

Example 104:2-[Cyclopropyl(difluoro)acetyl]-5-(ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide

Using the same procedure described in example 101, but using2-cyclopropyl-2,2-difluoroacetic acid, the title compound (18.5 mg,37.4%) was obtained after purification by RP-HPLC (chromatographicconditions: gradient 5-95% ACN in 0.1M HCO₂H, pH3; column: WatersSunfire C18 ODB 5 t 19×150 mm).

HRMS: calculated for (C₂₅H₂₂F₅N₂O₅S+H)⁺615.1200; found: (ESI [M+H]⁺)615.1200.

¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 5*:1) δ 0.55-0.8 (m, 4H),1.09, 1.10* (t, 3H), 1.69-1.82 (m, 1H), 3.29 (q, 2H), 4.92-5.1,5.18-5.29* (m, 2H), 5.91*, 6.17 (s, 1H), 7.61-7.83 (m, 5H), 7.86-7.89(m, 1H), 7.99*, 8.02 (s, 1H), 8.69 (s, 1H), 10.90, 10.96* (s, 1H).

Example 105:2-[(1-Cyanocyclopropyl)carbonyl]-5-(ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide

Using the same procedure described in example 101, but using using1-cyanocyclopropanecarboxylic acid, the title compound (25.2 mg, 70.7%)was obtained after purification by preparative SFC (chromatographicconditions: MeOH/NH₃ 20 mM; column: Phenomenex Luna Hilic 5 30×250 mm).

HRMS: calculated for (C₂₅H₂₁F₆N₃O₅S+H)⁺590.1184; found: (ESI [M+H]⁺)590.1232.

¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 6*:1, only data for themajor rotamer reported) δ 1.11 (t, 3H), 1.53-1.64 (m, 2H), 1.66-1.76 (m,2H), 3.30 (q, 2H), 5.35-5.4 (m, 2H), 5.85 (s, 1H), 7.61-7.67 (m, 2H),7.7-7.76 (m, 3H), 7.87-8 (m, 1H), 8.08 (s, 1H), 8.68 (s, 1H), 10.88 (s,1H).

Examples 106-117

Examples 106-117 (Table 1) were prepared using a similar procedures tothose described in the preceding examples.

-   Example 106:    5-(Ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 107:    5-(Ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(1-hydroxycyclopropyl)acetyl]-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 108:    5-(Ethylsulfonyl)-2-(3-fluoropropanoyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 109:    2-(Cyclobutylacetyl)-5-(ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 110:    5-(Ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(oxetan-2-ylcarbonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 111:    2-(3-Cyanopropanoyl)-5-(ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 112:    5-(Ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(1-methoxycyclopropyl)acetyl]-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 113:    5-(Ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(tetrahydrofuran-3-ylcarbonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 114:    5-(Ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(tetrahydrofuran-2-ylcarbonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 115:    2-{[1-(Dimethylamino)cyclopropyl]acetyl}-5-(ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 116:    2-(Cyanoacetyl)-5-(ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 117:    5-(Ethylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-{[1-(hydroxymethyl)cyclopropyl]carbonyl}-2,3-dihydro-1H-isoindole-1-carboxamide

TABLE 1 Example No. Structure NMR + MS 106

HRMS: calculated for (C₂₅H₂₆F₆N₂O₆S + H)⁺ 597.1494; found (ESI [M + H]⁺)597.1484. ¹H NMR (500 MHz DMSO-d₆, mixture of rotamers, 5*:1) δ 1.10 (t,3H), 1.22, 1.26* (s, 6H), 2.52-2.64 (m, 2H), 3.27-3.31 (m, 2H), 4.80 (s,1H), 4.82-4.96, 5.08-5.19* (m, 2H), 5.78*, 6.10 (s, 1H), 7.6-7.67 (m,2H), 7.7-7.81 (m, 3H), 7.84-7.88 (m, 1H), 7.95*, 7.98 (s, 1H), 8.65*,8.67 (s, 1H), 10.66 *, 10.97 (s, 1H). 107

HRMS: calculated for (C₂₅H₂₄F₆N₂O₆S + H)⁺ 595.1337; found (ESI [M + H]⁺)595.1337. ¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 5*:1) δ0.53-0.63 (m, 4H), 1.09, 1.10 (t, 3H), 2.6-2.67 (m, 1H), 2.78-2.88 (m,1H), 3.30 (q, 2H), 4.79-4.99, 5.12* (m, 2H), 5.35*, 5.36 (s, 1H), 5.77*,6.08 (s, 1H), 7.55-7.68 (m, 2H), 7.7-7.83 (m, 3H), 7.83- 7.88 (m, 1H),7.96*, 7.99 (s, 1H), 8.68 (s, 1H), 10.69*, 10.94 (s, 1H). 108

HRMS: calculated for (C₂₃H₂₁F₇N₂O₅S + H)⁺ 571.1138; found (ESI [M + H]⁺)511.1130. ¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 4*:1) δ 1.09,1.10* (t, 3H), 2.83- 3.05 (m, 2H), 3.28-3.32 (m, 2H), 4.66-4.78 (m, 2H),4.81-4.97, 5.04-5.11* (m, 2H), 5.77*, 5.98 (s, 1H), 7.6-7.67 (m, 2H),7.7- 7.82 (m, 3H), 7.84-7.88 (m, 1H), 7.96*, 7.99 (s, 1H), 8.69*, 8.71(s, 1H), 10.76*, 10.97 (s, 1H). 109

HRMS: calculated for (C₂₆H₂₆F₆N₂O₅S + H)⁺ 593.1545; found (ESI [M + H]⁺)593.1556. ¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 4*:1) δ 1.09,1.10* (t, 3H), 1.55- 1.75 (m, 2H), 1.77-1.89 (m, 2H), 2-2.25 (m, 2H),2.59 (d, 2H), 2.6-2.71 (m, 1H), 3.26- 3.32 (m, 2H), 4.72-4.93,4.99-5.07* (m, 2H), 5.72*, 5.94 (s, 1H), 7.64 (m, 2H), 7.68- 7.8 (m,3H), 7.82-7.87 (m, 1H), 7.94*, 7.97 (s, 1H), 8.68 (br s, 1H), 10.70*,10.94 (s, 1H). 110

HRMS: calculated for (C₂₄H₂₂F₆N₂O₆S + H)⁺ 581.1181; found (ESI [M + H]⁺)581.1161. Mixture of diastereomers and rotamers; only majordiastereomer/rotamer reported: ¹H NMR (500 MHz, DMSO-d₆) δ 1.10 (t, 3H),2.71-2.85 (m, 1H), 2.85-2.99 (m, 1H), 3.25-3.3 (m, 2H), 4.46-4.54 (m,1H), 4.6- 4.68 (m, 1H), 4.83-4.91 (m, 1H), 4.99-5.06 (m, 1H), 5.42-5.54(m, 1H), 5.82 (s, 1H), 7.59-7.66 (m, 2H), 7.71-7.81 (m, 3H), 7.84- 7.88(m, 1H), 7.95 (s, 1H), 8.65 (s, 1H), 10.81 (s, 1H). 111

HRMS: calculated for (C₂₄H₂₁F₆N₃O₅S + H)⁺ 578.1184; found (ESI [M + H]⁺)578.1190. ¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 5*:1) δ 1.09,1.10* (t, 3H), 2.67- 2.71 (m, 2H), 2.82-2.97 (m, 2H), 3.31 (q, 2H),4.81-4.98, 5.02-5.07* (m, 2H), 5.77*, 5.96 (s, 1H), 7.59-7.67 (m, 2H),7.7-7.82 (m, 3H), 7.83-7.88 (m, 1H), 7.97*, 8.00 (s, 1H), 8.68 (s, 1H),10.75*, 10.96 (s, 1H). 112

HRMS: calculated for (C₂₆H₂₆F₆N₂O₆S + H)⁺ 609.1494; found (ESI [M + H]⁺)609.1484. ¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 6*:1) δ0.54-0.79 (m, 4H), 1.09, 1.10 (t, 3H), 2.75-2.92 (m, 2H), 3.14, 3.24*(s, 3H), 3.30 (q, 2H), 4.77-4.96, 5.07-5.18* (m, 2H), 5.75*, 6.01 (s,1H), 7.6-7.67 (m, 2H), 7.68-7.82 (m, 3H), 7.84-7.88 (m, 1H), 7.97*, 7.99(s, 1H), 8.66 (br s, 1H), 10.74*, 10.98 (s, 1H). 113

HRMS: calculated for (C₂₅H₂₄F₆N₂O₆S + H)⁺ 595.1337; found (ESI [M + H]⁺)595.1331. Mixture of diastereomers and rotamers; only majordiastereomer/rotamer reported: ¹H NMR (600 MHz, DMSO-d₆) δ 1.04-1.13 (m,3H), 1.95-2.24 (m, 2H), 3.27-3.32 (m, 2H), 3.42-3.45 (m, 1H), 3.63-3.83(m, 4H), 5.04-5.16 (m, 2H), 5.74-5.79 (m, 1H), 7.58- 7.68 (m, 2H),7.69-7.81 (m, 3H), 7.84- 7.88 (m, 1H), 7.94 (s, 1H), 8.68 (s, 1H),10.73- 10.8 (m, 1H). 114

HRMS: calculated for (C₂₅H₂₄F₆N₂O₆S + H)⁺ 595.1337; found (ESI [M + H]⁺)595.1349. Mixture of diastereomers and rotamers; only majordiastereomer/rotamer reported: ¹H NMR (600 MHz, DMSO-d₆) δ 1.04-1.15 (m,3H), 1.72-2.24 (m, 4H), 3.22-3.31 (m, 2H), 3.75-3.89 (m, 2H), 4.66-4.79(m, 1H), 5.04-5.24 (m, 2H), 5.75-5.81 (m, 1H), 7.6- 7.65 (m, 2H),7.68-7.76 (m, 3H), 7.84- 7.88 (m, 1H), 7.93-7.96 (m, 1H), 8.67 (s, 1H),10.76-10.81 (m, 1H). 115

HRMS: calculated for (C₂₇H₂₉F₆N₃O₅S + H)⁺ 622.1810; found: 622.1790. ¹HNMR (600 MHz, DMSO-d₆, mixture of rotamers, 7*:1) δ 0.41-0.68 (m, 4H),1.09, 1.10* (t, 3H), 2.20, 2.32* (s, 6H), 2.58-2.63 (m, 1H), 2.79-2.87(m, 1H), 3.29 (q, 2H), 4.74-4.93, 5.06-5.18* (m, 2H), 5.72*, 5.97 (s,1H), 7.59-7.77 (m, 5H), 7.82-7.88 (m, 1H), 7.98, 7.99* (s, 1H), 8.69*8.72 (s, 1H), 10.79*, 11.01 (s, 1H). 116

HRMS: calculated for (C₂₃H₁₉F₆N₃O₅S + H)⁺ 564.1028; found (ESI [M + H]⁺)564.1046. ¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 6*:1, onlymajor rotamer reported) δ 1.10 (m, 3H), 3.30 (q, 2H), 4.15-4.3 (m, 2H),4.96-5.08 (m, 2H), 5.78 (d, 1H), 7.64 (d, 2H), 7.7-7.75 (m, 3H),7.86-7.89 (m, 1H), 7.99 (s, 1H), 8.70 (s, 1H), 10.81 (s, 1H). 117

HRMS: calculated for (C₂₅H₂₄F₆N₂O₆S + H)⁺ 595.1337; found (ESI [M + H]⁺)595.1354. ¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 9:1, only majorrotamer reported) δ 0.69-0.76 (m, 1H), 0.79-0.83 (m, 1H), 0.85- 0.9 (m,1H), 0.93-0.98 (m, 1H), 1.10 (t, 3H), 3.29 (q, 2H), 3.59 (dd, 1H), 3.71(dd, 1H), 5.04 (t, 1H), 5.21 (d, 1H), 5.32 (d, 1H), 5.78 (s, 1H), 7.62(d, 2H), 7.68-7.74 (m, 3H), 7.85 (d, 1H), 7.96 (s, 1H), 8.67 (s, 1H),10.63 (s, 1H).

Example 200:5-[(Cyclopropylmethyl)sulfonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide

9H-Fluoren-9-yl5-[(cyclopropylmethyl)sulfonyl]-1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-1,3-dihydro-2H-isoindole-2-carboxylate(3.2 g, 4.30 mmol) was dissolved in acetonitrile (140 mL). Diethylamine(35.9 mL, 343.76 mmol) was added and the reaction stirred at roomtemperature for 20 min. The reaction was evaporated to dryness and theresidue dissolved in methanol. This was loaded onto Isolute™ SCX(previously flushed with methanol). The resin was flushed with methanoland the product was then eluted with 2M ammonia in methanol. Themethanolic ammonia was removed in vacuo to afford5-((cyclopropylmethyl)sulfonyl)-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)isoindoline-1-carboxamide(1.918 g, 85%). A sample purified for biological screening was obtainedafter purification by RP-HPLC (chromatographic conditions: gradient5-95% ACN in 0.2% NH₃, pH10; column: Waters Xbridge, C18 5 ODB 19×150mm).

HRMS: calculated for (C₂₂H₂₀F₆N₂O₄S+H)⁺523.1126; found: (ESI [M+H]⁺)523.1105.

¹H NMR (600 MHz, DMSO-d₆) δ 0.05-0.15 (m, 2H), 0.42-0.47 (m, 2H),0.77-0.84 (m, 1H), 3.20-3.27 (m, 2H), 3.96 (br s, 1H), 4.28-4.43 (m,2H), 5.09 (s, 1H), 7.60 (d, 2H), 7.71 (d, 1H), 7.75-7.85 (m, 4H), 8.65(br s, 1H), 10.33 (s, 1H).

Example 201:2-Acetyl-5-[(cyclopropylmethyl)sulfonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide

5-[(Cyclopropylmethyl)sulfonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide(300 mg, 0.57 mmol) was dissolved in DCM (15 mL) and to thistriethylamine (0.160 mL, 1.15 mmol) and acetic acid (0.036 mL, 0.63mmol) was added followed by T3P (50% in EtOAc, 0.479 mL, 0.80 mmol). Thereaction was stirred at room temperature for 30 min. The reactionmixture was partitioned between DCM and water, the layers were separatedusing a phase separator cartridge and the solvent was removed in vacuo.The compound was purified by RP-HPLC (chromatographic conditions:gradient 5-95% ACN in 0.1M HCO₂H, pH3; column: Waters Sunfire C18 ODB 5μ19×150 mm) to give2-acetyl-5-[(cyclopropylmethyl)sulfonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide(189 mg, 58.3%).

HRMS: calculated for (C₂₄H₂₂F₆N₂O₅S+H)⁺565.1232; found: (ESI [M+H]⁺)565.1252.

¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 4*:1) δ 0.02-0.18 (m,2H), 0.41-0.52 (m, 2H), 0.77-0.88 (m, 1H), 1.99*, 2.15 (s, 3H),3.21-3.31 (m, 2H), 4.76-4.92, 4.98-5.1* (m, 2H), 5.73*, 5.93 (s, 1H),7.6-7.66 (m, 2H), 7.68-7.79 (m, 3H), 7.85-7.88 (m, 1H), 7.96*, 7.99 (s,1H), 8.67 (s, 1H), 10.70*, 10.94 (s, 1H).

The (1R) and the (1S) enantiomers of2-Acetyl-5-[(cyclopropylmethyl)sulfonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide(120 mg) were separated by a preparative SFC system equipped with aChiralpak IB column 30% IPA in CO₂ (120 bar); flow: 80 mL/min; injectionvolume was 1 mL of a 30 mg/mL ethanol solution.

Isomer 1 (peak 1) 41 mg, 95.4% ee by analytical chiral SFC (analyticalconditions: Chiralpak IB column, 150×4.6 mm, 3 m, 3.5 ml/min, 30% IPA inCO₂, 120 bar, 40° C.). HRMS: calculated for (C₂₄H₂₂F₆N₂O₅S+H)⁺565.1232;found: (ESI [M+H]⁺) 565.1234.

¹H NMR (500 MHz, MeOD, mixture of rotamers, 4*:1) δ 0.1-0.18 (m, 2H),0.47-0.56 (m, 2H), 0.9-1.01 (m, 1H), 2.14, 2.27* (s, 3H), 3.11-3.21 (m,2H), 4.96-5.22 (m, 2H), 5.81*, 5.91 (s, 1H), 7.65-7.77 (m, 5H), 7.9-7.95(m, 1H), 8.01 (s, 1H).

Isomer 2 (peak 2) 41 mg, 87.3% ee by analytical chiral SFC (analyticalconditions: Chiralpak IB column, 150×4.6 mm, 3 m, 3.5 ml/min, 30% IPA inCO₂, 120 bar, 40° C.). HRMS: calculated for (C₂₄H₂₂F₆N₂O₅S+H)⁺565.1232;found: (ESI [M+H]⁺) 565.1250.

¹H NMR (500 MHz, MeOD, mixture of rotamers, 4*:1) δ 0.1-0.18 (m, 2H),0.47-0.56 (m, 2H), 0.9-1.01 (m, 1H), 2.14, 2.27* (s, 3H), 3.1-3.21 (m,2H), 4.96-5.22 (m, 2H), 5.81*, 5.91 (s, 1H), 7.65-7.77 (m, 5H), 7.9-7.95(m, 1H), 8.01 (s, 1H).

Example 202:5-[(Cyclopropylmethyl)sulfonyl]-2-formyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide

Made using the same procedure as Example 201 but using formic acidinstead of acetic acid. The title compound (52 mg, mg, 70.5%) wasobtained after purification by RP-HPLC (chromatographic conditions:gradient 5-95% ACN in 0.1M HCO₂H, pH3; column: Waters Sunfire C18 ODB 5μ19×150 mm).

HRMS: calculated for (C₂₃H₂₀F₆N₂O₅S+H)⁺551.1075; found: (ESI [M+H]⁺)551.1089.

¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 2*:1) δ 0.07-0.17 (m,2H), 0.4-0.49 (m, 2H), 0.77-0.88 (m, 1H), 3.2-3.31 (m, 2H), 4.72-4.93,5.02-5.18* (m, 2H), 5.77*, 5.99 (s, 1H), 7.6-7.67 (m, 2H), 7.71-7.86 (m,3H), 7.86-7.9 (m, 1H), 7.96, 8.00* (s, 1H), 8.38, 8.48* (m, 1H), 8.67*,8.68 (s, 1H), 10.76*, 10.86 (s, 1H).

Example 203:5-[(Cyclopropylmethyl)sulfonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(methoxyacetyl)-2,3-dihydro-1H-isoindole-1-carboxamide

Made using the same procedure as Example 201 but using 2-methoxyaceticacid instead of acetic acid. The title compound (43.1 mg, 54%) wasobtained after purification by preparative SFC (chromatographicconditions: MeOH/NH₃ 20 mM, EP; column: Waters BEH 2-EP 5 μm 30×250 mm).

HRMS: calculated for (C₂₅H₂₄F₆N₂O₆S+H)⁺595.1337; found: (ESI [M+H]+)595.1380.

¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 4*:1) δ 0.05-0.18 (m,2H), 0.37-0.51 (m, 2H), 0.68-0.88 (m, 1H), 3.18-3.32 (m, 5H), 3.93-4.12,4.17-4.3* (m, 2H), 4.81-5.05 (m, 2H), 5.80*, 5.99 (s, 1H), 7.62-7.65 (m,2H), 7.7-7.79 (m, 3H), 7.85-7.89 (m, 1H), 7.97*, 8.00 (s, 1H), 8.67 (s,1H), 10.76*, 10.86 (s, 1H).

Example 204: Ethyl5-[(cyclopropylmethyl)sulfonyl]-1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-1,3-dihydro-2H-isoindole-2-carboxylate

Ethyl carbonochloridate (5.19 mg, 0.05 mmol) in acetonitrile (0.25 mL)was added to5-((cyclopropylmethyl)sulfonyl)-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)isoindoline-1-carboxamide(25 mg, 0.05 mmol) and DIPEA (0.025 mL, 0.14 mmol) in acetonitrile (1mL). The reaction was stirred at room temperature for 30 min. Theacetonitrile was removed in vacuo and the residue partioned between DCMand water. The layers were separated in a phase separator cartridge andthe organic layer was concentrated in vacuo. Purification by preparativeSFC (chromatographic conditions: MeOH/NH₃ 20 mM; column: Waters WatersBEH 2-EP 5 μm 30×250 mm) gave the title compound (12.0 mg, 42.2%).

HRMS: calculated for (C₂₅H₂₄F₆N₂O₆S+H)⁺595.1337; found: (ESI [M+H]⁺)595.1340.

¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 1:1) δ 0.04-0.16 (m, 2H),0.39-0.53 (m, 2H), 0.77-0.88 (m, 1H), 1.10, 1.26 (t, 3H), 3.19-3.31 (m,2H), 4.01-4.19 (m, 2H), 4.78-4.92 (m, 2H), 5.64-5.7 (m, 1H), 7.6-7.75(m, 5H), 7.83-7.88 (m, 1H), 7.96, 7.98 (s, 1H), 8.67 (s, 1H), 10.76,10.78 (s, 1H).

Example 205:5-[(Cyclopropylmethyl)sulfonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(1-methoxycyclopropyl)acetyl]-2,3-dihydro-1H-isoindole-1-carboxamide

Made using the same procedure as Example 201 but using2-(1-methoxycyclopropyl)acetic acid instead of acetic acid. The titlecompound (21.2 mg, 23.3%) was obtained after purification by RP-HPLC(chromatographic conditions: gradient 5-95% ACN in 0.1M HCO₂H, pH3;column: Waters Sunfire C18 ODB 5μ 19×150 mm).

HRMS: calculated for (C₂₈H₂₈F₆N₂O₆S+H)⁺635.1650; found: (ESI [M+H]⁺)635.1699.

¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 6*:1) δ 0.09-0.15 (m,2H), 0.41-0.48 (m, 2H), 0.56-0.77 (m, 4H), 0.79-0.87 (m, 1H), 2.76-2.92(m, 2H), 3.14, 3.24* (s, 3H), 3.25-3.31 (m, 2H), 4.8-4.96, 5.08-5.18*(m, 2H), 5.76*, 6.01 (s, 1H), 7.6-7.67 (m, 2H), 7.68-7.81 (m, 3H),7.85-7.89 (m, 1H), 7.98*, 7.99 (s, 1H), 8.66*, 8.69 (s, 1H), 10.73*,10.96 (s, 1H).

Examples 206-214

Examples 206-214 (Table 2) were prepared using a similar procedures tothose described in the preceding examples.

-   Example 206:    5-[(Cyclopropylmethyl)sulfonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(1-hydroxycyclopropyl)acetyl]-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 207:    5-[(Cyclopropylmethyl)sulfonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(3-hydroxy-3-methylbutanoyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 208:    5-[(Cyclopropylmethyl)sulfonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(tetrahydrofuran-2-ylcarbonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 209:    2-[(1-Cyanocyclopropyl)carbonyl]-5-[(cyclopropylmethyl)sulfonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 210:    5-[(Cyclopropylmethyl)sulfonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(tetrahydrofuran-3-ylcarbonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 211:    2-[Amino(cyclopropyl)acetyl]-5-[(cyclopropylmethyl)sulfonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 212:    5-[(Cyclopropylmethyl)sulfonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(1-methoxycyclopropyl)carbonyl]-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 213: Methyl    5-[(cyclopropylmethyl)sulfonyl]-1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-1,3-dihydro-2H-isoindole-2-carboxylate-   Example 214:    2-[Cyclopropyl(difluoro)acetyl]-5-[(cyclopropylmethyl)sulfonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide

TABLE 2 Example No. Structure NMR + MS 206

HRMS: calculated for (C₂₇H₂₆F₆N₂O₆S + H)⁺ 621.1494; found (ESI [M + H]⁺)621.1501. ¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 5*:1) δ0.07-0.14 (m, 2H), 0.4- 0.49 (m, 2H), 0.53-0.64 (m, 4H), 0.79-0.88 (m,1H), 2.57-2.66 (m, 1H), 2.79-2.89 (m, 1H), 3.22-3.32 (m, 2H), 4.77-4.99,5.05- 5.18* (m, 2H), 5.34*, 5.38 (s, 1H), 5.77*, 6.08 (s, 1H), 7.59-7.67(m, 2H), 7.68-7.81 (m, 3H), 7.86-7.89 (m, 1H), 7.96*, 7.99 (s, 1H), 8.67(s, 1H), 10.68*, 10.96 (s, 1H). 207

HRMS: calculated for (C₂₇H₂₈F₆N₂O₆S + H)⁺ 623.1650; found (ESI [M + H]⁺)623.1656. ¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 6:1, only datafor the major rotamer reported) δ 0.09-0.15 (m, 2H), 0.39-0.49 (m, 2H),0.75-0.88 (m, 1H), 1.26 (s, 6H), 2.55-2.61 (m, 2H), 3.21-3.3 (m, 2H), 5-5.18 (m, 2H), 5.77 (s, 1H), 7.58-7.67 (m, 2H), 7.68-7.8 (m, 3H),7.83-7.89 (m, 1H), 7.95 (s, 1H), 8.67 (s, 1H), 10.66 (s, 1H). 208

HRMS: calculated for (C₂₇H₂₆F₆N₂O₆S + H)⁺ 621.1494; found (ESI [M + H]⁺)621.1505. Mixture of diastereomers and rotamers; only majordiastereomer/rotamer reported: ¹H NMR (600 MHz, DMSO-d₆) δ 0.1-0.14 (m,2H), 0.42-0.49 (m, 2H), 0.75-0.88 (m, 1H), 1.72-2.23 (m, 4H), 3.2-3.3(m, 2H), 3.62-3.88 (m, 2H), 4.68-4.78 (m, 1H), 5.01- 5.22 (m, 2H),5.74-5.8 (m, 1H), 7.6-7.65 (m, 2H), 7.68-7.81 (m, 3H), 7.83-7.88 (m,1H), 7.94-8.01 (m, 1H), 8.68 (s, 1H), 10.76- 10.81 (m, 1H). 209

HRMS: calculated for (C₂₇H₂₃F₆N₃O₅S + H)⁺ 616.1341.1545; found (ESI [M +H]⁺) 616.1346. ¹H NMR (600 MHz, mixture of rotamers, 6:1, only data forthe major rotamer reported) δ 0.05-0.15 (m, 2H), 0.35-0.51 (m, 2H),0.74- 0.88 (m, 1H), 1.49-1.82 (m, 4H), 3.18- 3.32 (m, 2H), 5.33-5.4 (m,2H), 5.85 (s, 1H), 7.59-7.68 (m, 2H), 7.69-7.77 (m, 3H), 7.88- 8.02 (m,1H), 8.08 (s, 1H), 8.68 (s, 1H), 10.87 (s, 1H). 210

HRMS: calculated for (C₂₇H₂₆F₆N₂O₆S + H)⁺ 621.1494; found (ESI [M + H]⁺)621.1490. Mixture of diastereomers and rotamers; Only majordiastereomer/rotamer reported: ¹H NMR (600 MHz, DMSO-d₆) δ 0.06-0.17 (m,2H), 0.41-0.5 (m, 2H), 0.76-0.86 (m, 1H), 1.95-2.24 (m, 2H), 3.2-3.31(m, 2H), 3.42-3.45 (m, 1H), 3.62-3.84 (m, 4H), 5- 5.25 (m, 2H),5.65-5.83 (m, 1H), 7.6-7.67 (m, 2H), 7.69-7.75 (m, 3H), 7.86-7.89 (m,1H), 7.95 (s, 1H), 8.69 (s, 1H), 10.61-10.86 (m, 1H). 211

HRMS: calculated for (C₂₇H₂₇F₆N₃O₅S + H)⁺ 620.1653; found (ESI [M + H]⁺)620.1654. Mixture of diastereomers and rotamers; Only majordiastereomer/rotamer reported: ¹H NMR (600 MHz, DMSO-d₆) δ 0.08-0.16 (m,2H), 0.23-0.53 (m, 6H), 0.77-0.87 (m, 1H), 1.05-1.14 (m, 1H), 3.2-3.31(m, 3H), 5.02-5.24 (m, 2H), 5.73-5.82 (m, 1H), 7.6- 7.66 (m, 2H),7.67-7.82 (m, 3H), 7.85- 7.89 (m, 1H), 7.96 (s, 1H), 8.68 (s, 1H), 10.6-10.83 (m, 1H). 212

HRMS: calculated for (C₂₇H₂₆F₆N₂O₆S + H)⁺ 621.1494; found (ESI [M + H]⁺)621.1524. ¹H NMR (600 MHz, mixture of rotamers, 2*:1) δ 0.1-0.17 (m,2H), 0.43-0.5 (m, 2H), 0.77-0.86 (m, 1H), 0.87-1.19 (m, 4H), 3.2- 3.32(m, 2H), 3.16, 3.35* (s, 3H), 4.8-5.03, 5.19-5.28* (m, 2H), 5.89*, 6.21(s, 1H), 7.59- 7.66 (m, 2H), 7.69-7.82 (m, 3H), 7.85- 7.89 (m, 1H),7.99, 8.01* (s, 1H), 8.65, 8.67* (s, 1H), 10.79, 10.87* (s, 1H). 213

HRMS: calculated for (C₂₄H₂₂F₆N₂O₆S + H)⁺ 580.1181; found (ESI [M + H]⁺)580.1176. ¹H NMR (600 MHz, mixture of rotamers, 1.4*:1) δ 0.06-0.15 (m,2H), 0.39-0.49 (m, 2H), 0.76-0.85 (m, 1H), 3.19-3.3 (m, 2H), 3.63, 3.70*(s, 3H), 4.86 (s, 2H), 5.68*, 5.70 (s, 1H), 7.61-7.65 (m, 2H), 7.68-7.76(m, 3H), 7.84-7.88 (m, 1H), 7.96*, 7.98 (s, 1H), 8.68 (s, 1H), 10.76,10.78* (s, 1H). 214

HRMS: calculated for (C₂₇H₂₄F₈N₂O₅S + H)⁺ 641.1356; found (ESI [M + H]⁺)641.1341 ¹H NMR (600 MHz, , mixture of rotamers, 4*:1) δ 0.08-0.17 (m,2H), 0.39-0.51 (m, 2H), 0.54-0.86 (m, 5H), 1.7-1.83 (m, 1H), 3.19-3.3(m, 2H), 4.91-5.12, 5.16-5.31* (m, 2H), 5.91*, 6.17 (s, 1H), 7.61-7.66(m, 2H), 7.66-7.82 (m, 3H), 7.87-7.91 (m, 1H), 8.00*, 8.02 (s, 1H), 8.69(s, 1H), 10.89, 10.95* (s, 1H).

Example 300:N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfamoyl)-2,3-dihydro-1H-isoindole-1-carboxamide

tert-Butyl1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)-5-(N-methylsulfamoyl)isoindoline-2-carboxylate(380 mg, 0.64 mmol) was added to a solution of HCl in dioxane (15 mL,60.00 mmol) under nitrogen. The resulting mixture was stirred at roomtemperature for 2 hours. The reaction mixture was basified withsaturated NaHCO₃. The reaction mixture was quenched with water (50 mL),extracted with EtOAc (3×100 mL), the organic layer was dried overNa₂SO₄, filtered and evaporated to dryness to affordN-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-5-(N-methylsulfamoyl)isoindoline-1-carboxamide(300 mg, 95%) as an orange solid. LC/MS: m/z=498 [M+H]⁺.

HRMS: calculated for (C₁₉H₁₇F₆N₃O₄S+H)⁺498.0922; found (ESI [M+H]⁺)498.0918.

¹H NMR (300 MHz, DMSO-d₆) δ 2.41 (d, 3H), 4.39 (s, 2H), 5.08 (s, 1H),7.40-7.49 (m, 1H), 7.58-7.76 (m, 5H), 7.83 (d, 2H), 8.65 (s, 1H), 10.34(s, 1H).

Example 301:2-Acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfamoyl)-2,3-dihydro-1H-isoindole-1-carboxamide

Ac₂O (1 mL, 10.60 mmol) was added toN-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfamoyl)-2,3-dihydro-1H-isoindole-1-carboxamide(100 mg, 0.20 mmol) in DCM (10 mL) under nitrogen. The resulting mixturewas stirred at r.t for 2 hours. The reaction mixture was quenched withwater (50 mL), extracted with DCM (3×50 mL), the organic layer was driedover Na₂SO₄, filtered and evaporated to afford pale yellow solid. Thecrude product was purified by preparative HPLC (XBridge Prep C18 OBDcolumn, 5 j silica, 19 mm diameter, 100 mm length), using decreasinglypolar mixtures of water (containing 0.08% NH₄HCO₃) and MeCN as eluents.Fractions containing the desired compound were evaporated to dryness toafford2-acetyl-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-5-(N-methylsulfamoyl)isoindoline-1-carboxamide(50.0 mg, 46.1%). LC/MS: m/z=540 [M+H]⁺.

HRMS: calculated for (C₂₁H₁₉F₆N₃O₅S+H)⁺540.1028; found (ESI [M+H]⁺)540.1004.

¹H NMR (300 MHz, DMSO-d₆, mixture of rotamers, 4.3*:1) δ 1.98, 2.14* (s,3H), 2.42 (s, 3H), 4.77-5.10 (m, 2H), 5.71-5.98 (m, 1H), 7.52-7.88 (m,8H), 8.69 (s, 1H), 10.71-11.00 (m, 1H).

Example 302:2-Formyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfamoyl)-2,3-dihydro-1H-isoindole-1-carboxamide

N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfamoyl)-2,3-dihydro-1H-isoindole-1-carboxamide(90 mg, 0.18 mmol) was added to formic acid (12.49 mg, 0.27 mmol), HATU(103 mg, 0.27 mmol) and DIPEA (0.06 mL, 0.36 mmol) in DCM (5 mL) undernitrogen. The resulting mixture was stirred at room temperatrue for 2hours. The reaction mixture was quenched with saturated NH₄Cl (75 mL),extracted with DCM (3×100 mL), the organic layer was dried over Na₂SO₄,filtered and evaporated to afford yellow solid. The crude product waspurified by flash C18-flash chromatography, elution gradient 5 to 90%MeCN in water. Pure fractions were evaporated to dryness to afford thetitle compound (80 mg, 84%) as a white solid. LC/MS: m/z=526 [M+H]⁺.HRMS: calculated for (C₂₀H₁₇F₆N₃O₅S+H)⁺526.0871; found (ESI [M+H]⁺)526.0864.

¹H NMR (300 MHz, DMSO-d₆, mixture of rotamers, 2*:1) δ 2.43 (d, 3H),4.72-4.93, 5.03-5.19* (m, 2H), 5.75*, 5.96 (s, 1H), 7.51-7.87 (m, 8H),8.38, 8.49* (s, 1H), 8.68*, 8.69 (s, 1H), 10.77*, 10.87 (s, 1H).

Example 303:(R,S)—N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(2R)-2-hydroxybutanoyl]-5-(methylsulfamoyl)-2,3-dihydro-1H-isoindole-1-carboxamide

N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfamoyl)-2,3-dihydro-1H-isoindole-1-carboxamide(80.10 mg, 0.16 mmol) was added to (R)-2-hydroxybutanoic acid (21.77 mg,0.21 mmol), HATU (92.32 mg, 0.24 mmol) and DIPEA (0.056 mL, 0.32 mmol)in DMF (6 mL) under nitrogen. The resulting mixture was stirred at roomtemperature for 12 hours. The reaction mixture was diluted with DCM (75mL), and washed sequentially with water (1×75 mL), saturated brine (2×75mL). The organic layer was dried over Na₂SO₄, filtered and evaporated toafford crude product. The crude product was purified by preparative HPLC(XBridge Shield RP18 OBD column, 5p silica, 19 mm diameter, 150 mmlength), using decreasingly polar mixtures of water (containing 0.5%formic acid) and MeCN as eluents. Fractions containing the desiredcompound were evaporated to dryness to afford isomer 1 (15.0 mg, 16%)and isomer 2 (20.0 mg, 21.3%), both as solids.

Isomer 1: LC/MS: m/z=584 [M+H]⁺.

HRMS: calculated for (C₂₃H₂₃F₆N₃O₆S+H)⁺584.1290; found (ESI [M+H]⁺)584.1286.

¹H NMR (400 MHz, DMSO-d₆, mixture of rotamers, 3*:1) δ 0.80, 0.92* (t,3H), 1.53-1.71 (m, 2H), 2.39-2.41 (m, 3H), 3.90-3.97, 4.15-4.21* (m,1H), 4.75-4.98, 5.06-5.19* (m, 2H), 5.12 (s, 1H), 5.73*, 6.17 (s, 1H),7.45-7.54 (m, 1H), 7.58-7.67 (m, 3H), 7.69-7.76 (m, 4H), 7.82 (d, 1H),8.61-8.68 (m, 1H), 10.74*, 10.88 (s, 1H).

Isomer 2: LC/MS: m/z=584 [M+H]⁺.

HRMS: calculated for (C₂₃H₂₃F₆N₃O₆S+H)⁺584.1290; found (ESI [M+H]⁺)584.1299.

¹H NMR (isomer 2) (400 MHz, DMSO-d₆, mixture of rotamers, 7*:1) δ0.87-0.94 (m, 3H), 1.55-1.75 (m, 2H), 2.38-2.43 (m, 3H), 3.92-4.00,4.20-4.29* (m, 1H), 4.78-5.21 (m, 3H), 5.78*, 6.04 (s, 1H), 7.45-7.55(m, 1H), 7.57-7.77 (m, 6H), 7.79-7.86 (d, 1H), 8.67 (m, 1H), 10.76*,10.91 (s, 1H).

Example 304: Methyl1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-5-(methylsulfamoyl)-1,3-dihydro-2H-isoindole-2-carboxylate

N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfamoyl)-2,3-dihydro-1H-isoindole-1-carboxamide(90 mg, 0.18 mmol) was added to methyl carbonochloridate (51.3 mg, 0.54mmol) in DCM (5 mL) under nitrogen. The resulting mixture was stirred atroom temperature for 2 hours. The reaction mixture was quenched withwater (50 mL), extracted with DCM (3×50 mL), the organic layer was driedover Na₂SO₄, filtered and evaporated to afford orange solid. The crudeproduct was purified by flash C18-flash chromatography, elution gradient5 to 70% MeCN in water. Pure fractions were evaporated to dryness toafford methyl1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-5-(methylsulfamoyl)-1,3-dihydro-2H-isoindole-2-carboxylate(90 mg, 90%). LC/MS: m/z=556 [M+H]⁺.

HRMS: calculated for (C₂₁H₁₉F₆N₃O₆S+H)⁺556.0977; found (ESI [M+H]⁺)556.0994.

¹H NMR (300 MHz, DMSO-d6, mixture of rotamers, 1.3*:1) δ 2.41 (d, 3H),3.62, 3.70* (s, 3H), 4.84 (br.s, 2H), 5.65 (br.s, 1H), 7.45-7.54 (m,1H), 7.59-7.69 (m, 1H), 7.70-7.77 (m, 3H), 7.81-7.86 (m, 1H), 8.65 (s,1H), 10.72-10.78 (m, 1H).

Examples 305-313 Examples 305-313 (Table 3) were Prepared Using aSimilar Procedures to Those Described in the Preceding Examples

-   Example 305: Ethyl    1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-5-(methylsulfamoyl)-1,3-dihydro-2H-isoindole-2-carboxylate-   Example 306:    N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(1-methoxycyclopropyl)carbonyl]-5-(methylsulfamoyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 307, isomer 1: (R) or    (S)N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(2S)-2-hydroxybutanoyl]-5-(methylsulfamoyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 307, isomer 2: (R) or    (S)N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(2S)-2-hydroxybutanoyl]-5-(methylsulfamoyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 308:    N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(methoxyacetyl)-5-(methylsulfamoyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 309:    N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfamoyl)-2-(oxetan-2-ylcarbonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 310:    N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfamoyl)-2-[(2R)-tetrahydrofuran-2-ylcarbonyl]-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 311:    N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfamoyl)-2-[(2S)-tetrahydrofuran-2-ylcarbonyl]-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 312:    N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(2-methoxybutanoyl)-5-(methylsulfamoyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 313:    N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(hydroxyacetyl)-5-(methylsulfamoyl)-2,3-dihydro-1H-isoindole-1-carboxamide

TABLE 3 Example No. Structure NMR +MS 305

HRMS: calculated for (C₂₂H₂₁F₆N₃O₆S + H)⁺ 570.1133; found (ESI [M + H]⁺)570.1133. ¹H NMR (400 MHz, DMSO-d₆, mixture of rotamers, 1.2*:1) δ 1.10,1.26* (t, 3H), 2.42 (d, 3H), 3.99-4.21 (m, 2H), 4.75-4.93 (m, 2H), 5.66(s, 1H), 7.52 (s, 1H), 7.59-7.70 (m, 3H), 7.70-7.80 (m, 3H), 7.80-7.90(m, 1H), 8.68 (s, 1H), 10.77, 10.79* (s, 1H). 306

HRMS: calculated for (C₂₄H₂₃F₆N₃O₆S + H)⁺ 596.1290; found (ESI [M + H]⁺)596.1295. ¹H NMR (400 MHz, DMSO-d₆, mixture of rotamers, 2.2*:1) δ0.8-1.25 (m, 4H), 2.39- 2.46 (m, 3H), 3.19, 3.36* (s, 3H), 4.85-5.02,5.17-5.30* (m, 2H), 5.87*, 6.20 (s, 1H), 7.48- 7.58 (m, 1H), 7.59-7.81(m, 6H), 7.84- 7.93 (m, 1H), 8.66, 8.68* (s, 1H), 10.81, 10.88* (s, 1H).307 Isomer 1

HRMS: calculated for (C₂₃H₂₃F₆N₃O₆S + H)⁺ 584.1290; found (ESI [M + H]⁺)584.1292. ¹H NMR (300 MHz, DMSO-d₆, mixture of rotamers, 3*:1) δ 0.81,0.93* (t, 3H), 1.48- 1.80 (m, 2H), 2.42 (d, 3H), 3.88-3.99, 4.14- 4.26*(m, 1H), 4.76-5.51 (m, 3H), 5.74*, 6.18 (s, 1H), 7.45-7.56 (m, 1H),7.58-7.78 (m, 6H), 7.79-7.88 (m, 1H), 8.65 (s, 1H), 10.75*, 10.88 (s,1H). 307 Isomer 2

HRMS: calculated for (C₂₃H₂₃F₆N₃O₆S + H)⁺ 584.1290; found (ESI [M + H]⁺)584.1272. ¹H NMR (300 MHz, DMSO-d₆, mixture of rotamers, 7*:1) δ 0.93(t, 3H), 1.51-1.8 (m, 2H), 2.42 (s, 3H), 4.2-4.32 (m, 1H), 4.81- 5.24(m, 3H), 5.80*, 6.06 (s, 1H), 7.45-7.56 (m, 1H), 7.56-7.79 (m, 6H),7.79-7.88 (m, 1H), 8.48, 8.68* (s, 1H), 10.77 (s, 1H). 308

HRMS: calculated for (C₂₂H₂₁F₆N₃O₆S + H)⁺ 570.1133; found (ESI [M + H]⁺)570.1127. ¹H NMR (300 MHz, DMSO-d₆, mixture of rotamers, 5*:1) δ 2.43(d, 3H), 3.28, 3.38* (s, 3H), 3.93-4.13, 4.18-4.33* (m, 2H), 4.80- 5.09(m, 2H), 5.78*, 5.98 (s, 1H), 7.50-7.58 (m, 1H), 7.61-7.81 (m, 6H),7.83-7.90 (m, 1H), 8.68 (s, 1H), 10.77*, 10.87, (s, 1H). 309

HRMS: calculated for (C₂₃H₂₁F₆N₃O₆S + H)⁺ 582.1133; found (ESI [M + H]⁺)582.1131. Mixture of diastereomers/rotamers; ratio major*: minor =7.7:1.3:1; only major isomer reported: ¹H NMR (400 MHz, DMSO-d₆) δ 2.42(d, 3H), 2.71-3.04 (m, 2H), 4.44-4.71 (m, 2H), 4.79-5.08 (m, 2H),5.42-5.55 (m, 1H), 5.80 (s, 1H), 7.48-7.59 (m, 1H), 7.59-7.8 (m, 6H),7.80-7.89 (m, 1H), 8.70 (s, 1H), 10.83 (s, 1H). 310

HRMS: calculated for (C₂₄H₂₃F₆N₃O₆S + H)⁺ 596.1290; found (ESI [M + H]⁺)596.1307. Mixture of diastereomers/rotamers, 5*:4:1.3:1; only 2 majorisomers reported: ¹H NMR (400 MHz, DMSO-d₆) δ 1.7-2.27 (m, 4H), 2.4-2.45(m, 3H), 3.62-3.91 (m, 2H), 4.68-5.22 (m, 3H), 5.74, 4.76* (s, 1H),7.48-7.58 (m, 1H), 7.59-7.79 (m, 6H), 7.80- 7.89 (m, 1H), 8.68 (s, 1H),10.77, 10.80* (s, 1H). 311

HRMS: calculated for (C₂₄H₂₃F₆N₃O₆S + H)⁺ 596.1290; found (ESI [M + H]⁺)596.1311. Mixture of diastereomers/rotamers, 5*:5:2:1; only 2 majorisomers reported: ¹H NMR (400 MHz, DMSO-d₆) δ 1.71-2.26 (m, 4H),2.40-2.43 (m, 3H), 3.73-3.89 (m, 2H), 4.68-5.21 (m, 3H), 5.75, 5.76* (s,1H), 7.48-7.56 (m, 1H), 7.59-7.79 (m, 6H), 7.81- 7.88 (m, 1H), 8.68 (s,1H), 10.77, 10.80* (s, 1H). 312

HRMS: calculated for (C₂₄H₂₅F₆N₃O₆S + H)⁺ 598.1447; found (ESI [M + H]⁺)598.1470. ¹H NMR (300 MHz, DMSO-d₆, mixture of rotamers, 1.2*:1) δ0.89-1.00 (m, 3H), 1.63- 1.78 (m, 2H), 2.42 (d, J = 4.9 Hz, 3H), 3.27,3.30* (s, 3H), 3.91-4.13 (m, 1H), 4.93-5.27 (m, 2H), 5.78, 5.84* (s,1H), 7.47-7.56 (m, 1H), 7.59-7.79 (m, 6H), 7.80-7.88 (m, 1H), 8.65 (s,1H), 10.80, 10.83* (s, 1H). 313

HRMS: calculated for (C₂₁H₁₉F₆N₃O₆S + H)⁺ 556.0977; found (ESI [M + H]⁺)556.0972. ¹H NMR (300 MHz, DMSO-d₆, mixture of rotamers, 5*:1) δ 2.42(d, J = 4.6 Hz, 3H), 4.10-4.33 (m, 2H), 4.96 (s, 3H), 5.76*, 5.97 (s,1H), 7.47-7.55 (m, 1H), 7.58-7.79 (m, 6H), 7.80-7.89 (m, 1H), 8.65*,8.67 (s, 1H), 10.73*, 10.90 (s, 1H).

Example 314:N²—Cyclopropyl-N¹-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfamoyl)-1,3-dihydro-2H-isoindole-1,2-dicarboxamide

Et₃N (0.070 mL, 0.50 mmol) was added toN-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-5-(N-methylsulfamoyl)isoindoline-1-carboxamide(50 mg, 0.10 mmol) and methylcarbamic chloride (37.6 mg, 0.40 mmol) inDCM (4 mL) under nitrogen. The resulting solution was stirred at r.t.for 1 hour. The solvent was removed under reduced pressure. The crudeproduct was purified by preparative HPLC Column: XBridge Prep OBD C18Column 30×150 mm 5 um; Mobile Phase A: Water (10 mmol/L NH₄HCO₃), MobilePhase B: ACN; Flow rate: 60 mL/min; Gradient: 28% B to 43% B in 7 min.Fractions containing the desired compound were evaporated to dryness toaffordN²-Cyclopropyl-N¹-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfamoyl)-1,3-dihydro-2H-isoindole-1,2-dicarboxamide(25 mg, 45%) as a solid. HRMS: calculated for(C₂₁H₂₀F₆N₄O₅S+H)⁺555.1136; found: (ESI [M+H]⁺) 555.1147.

¹H NMR (300 MHz, DMSO d₆) δ 2.42 (d, 2H), 2.64 (d, 3H), 4.73 (d, 1H),4.82 (d, 1H), 5.64 (d, 1H), 6.58 (q, 1H), 7.49 (q, 1H), 7.59-7.67 (m,4H), 7.74 (d, 2H), 7.77 (d, 1H), 8.65 (s, 1H), 10.62 (s, 1H).

Example 400:N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide

9H-Fluoren-9-yl1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-5-(methylsulfonyl)-1,3-dihydro-2H-isoindole-2-carboxylate(10.64 g, 15.1 mmol) was dissolved in acetonitrile (300 mL) and to thisdiethylamine (126 mL, 1208 mmol) was added and the reaction stirred atroom temperature for 30 min. The reaction was evaporated to dryness andthe residue dissolved in methanol. This was loaded onto Isolute™ SCXresin previously flushed with methanol. The resin was flushed withmethanol and the product was then eluted with 2M ammonia in methanol.The methanolic ammonia was removed in vacuo to affordN-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-5-(methylsulfonyl)isoindoline-1-carboxamide(5.16 g, 70.8%).

A sample for biological screening was purified by RP-HPLC(chromatographic conditions: gradient 5-95% ACN in 0.1M HCO₂H, pH3;Column: Waters Sunfire C18 ODB 5μ 19×150 mm) to afford the titlecompound.

HRMS: calculated for (C₁₉H₁₆F₆N₂O₄S+H)⁺483.0813; found: (ESI [M+H]⁺)483.0811.

¹H NMR (600 MHz, DMSO-d₆) δ 3.18 (s, 3H), 4.37 (d, 1H), 4.41 (d, 1H),5.09 (s, 1H), 7.60 (d, 2H), 7.71 (d, 1H), 7.77-7.83 (m, 3H), 7.87 (s,1H), 8.65 (s, 1H), 10.33 (s, 1H).

Example 401:2-Acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide

N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide(4.2 g, 8.71 mmol) was dissolved in DCM (150 mL) and to thistriethylamine (2.427 mL, 17.41 mmol) and acetic acid (0.748 mL, 13.06mmol) was added followed by T3P (50% in EtOAc, 10.37 mL, 17.41 mmol).The reaction was stirred at room temperature for 30 min. The reactionwas partitioned between DCM and water, the layers were separated using aphase separator cartridge and the solvent was removed in vacuo.

The residue was purified on silica eluting with 50% to 100% EtOAc inheptane. Product fractions were combined, concentrated in vacuo and apink gum was obtained. This was triturated with diethyl ether and asolid was formed. This was collected by filtration and washed withdiethyl ether to afford2-acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide(3.32 g, 72.7%).

HRMS: calculated for (C₂₁H₈F₆N₂O₅S+H)⁺525.0919; found: (ESI [M+H]⁺)525.0927.

¹H NMR (500 MHz, DMSO-d₆, mixture of rotamers, 4*:1) δ 1.99, 2.15* (s,3H), 3.21, 3.22* (s, 3H), 4.76-4.94, 4.98-5.11* (m, 2H), 5.73*, 5.93 (s,1H), 7.6-7.81 (m, 5H), 7.87-7.92 (m, 1H), 8.00*, 8.03 (s, 1H), 8.64*,8.67 (s, 1H), 10.69*, 10.93 (s, 1H).

The (1R) and the (1S) enantiomers of2-acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide(4011 mg) were separated by a preparative SFC system equipped with aChiralpak AS column 25% EtOH 100 in CO₂ (120 bar); flow: 150 mL/min;injection volume was 2.5 mL of a 60 mg/mL ethanol/DMSO 9/1 solution.

Isomer 1 (peak 1): 1730 mg, 99.4% ee by analytical chiral SFC(analytical conditions: Chiralpak AS column, 150×4.6 mm, 3 μm, 3.5ml/min, 30% EtOH in CO₂, 120 bar, 40° C.). [α]D₅₈₉+13° (c=0.5,CHCl₃/DMSO 8/2).

HRMS: calculated for (C₂₁H₁₈F₆N₂O₅S+H)⁺525.0919; found: (ESI [M+H]⁺)525.0914.

¹H NMR (500 MHz, DMSO-d₆, mixture of rotamers, 4*:1) δ 1.99, 2.15* (s,3H), 3.21, 3.22* (s, 3H), 4.76-4.94, 4.98-5.11* (m, 2H), 5.73*, 5.93 (s,1H), 7.6-7.81 (m, 5H), 7.87-7.92 (m, 1H), 8.00*, 8.03 (s, 1H), 8.64*,8.67 (s, 1H), 10.69*, 10.93 (s, 1H). Isomer 2 (peak 2): 1980 mg, 99.5%ee by analytical chiral SFC (analytical conditions: Chiralpak AS column,150×4.6 mm, 3 m, 3.5 ml/min, 30% EtOH in CO₂, 120 bar, 40° C.). [α]D₅₈₉−11° (c=0.2, CHCl₃/DMSO 8/2).

HRMS: calculated for (C₂₁H₁₈F₆N₂O₅S+H)⁺525.0919; found: (ESI [M+H]⁺)525.0916.

¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 4*:1) δ 1.99, 2.15* (s,2H), 3.21, 3.22* (s, 2H), 4.76-4.94, 4.98-5.11* (m, 2H), 5.73*, 5.93 (s,1H), 7.6-7.81 (m, 5H), 7.87-7.92 (m, 1H), 8.00*, 8.03 (s, 1H), 8.64*,8.67 (s, 1H), 10.69*, 10.93 (s, 1H).

Example 402:N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2-(phenylacetyl)-2,3-dihydro-1H-isoindole-1-carboxamide

Prepared using the same procedure as Example 401 but using2-phenylacetic acid instead of acetic acid. The title compound (14.7 mg,47%) was obtained after purification by preparative SFC (chromatographicconditions: MeOH/NH₃ 20 mM; column: Phenomenex Luna Hilic 5 30×250 mm).

HRMS: calculated for (C₂₇H₂₂F₆N₂O₅S+H)⁺601.1232; found: (ESI [M+H]⁺)601.1224.

¹HNMR (400 MHz, DMSO-d₆, mixture of rotamers, 7*:1) δ ¹H NMR (600 MHz,DMSO-d₆) δ 3.21 (s, 3H), 3.81-3.91 (m, 2H), 4.77-4.99, 5.03-5.17* (m,2H), 5.79*, 6.05 (s, 1H), 7.18-7.36 (m, 5H), 7.6-7.68 (m, 2H), 7.69-7.76(m, 3H), 7.88-7.93 (m, 1H), 8.00*, 8.03 (s, 1H), 8.66*, 8.69 (s, 1H),10.76*, 10.99 (s, 1H).

Example 403: Methyl1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-5-(methylsulfonyl)-1,3-dihydro-2H-isoindole-2-carboxylate

To a suspension of 5-(methylsulfonyl)isoindoline-1-carboxylic acid, HCl(0.078 g, 0.28 mmol) in acetonitrile (3 mL) was added DIPEA (0.147 mL,0.84 mmol) and to this methyl carbonochloridate (0.027 g, 0.28 mmol) wasadded as a solution in acetonitrile (0.25 mL). After 30 mins thereaction was concentrated in vacuo. The residue was dissolved in DCM (4mL) and to this triethylamine (0.078 mL, 0.56 mmol),2-(4-aminophenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol (0.073 g, 0.28 mmol)and T3P (50% solution in EtOAc) 0.251 mL, 0.42 mmol) was added. Themixture was stirred at rt for 30 min. The reaction mixture diluted withDCM and washed with water. The layers were separated using a phaseseparator cartridge and the organic layer was concentrated in vacuo. Thetitle compound (41 mg, 27%) was obtained after purification bypreparative SFC (chromatographic conditions: MeOH/NH₃ 20 mM; column:Waters BEH 2-EP 5 μm 30×250 mm).

HRMS: calculated for (C₂₁H₁₈F₆N₂O₆S+H)⁺541.0868; found: (ESI [M+H]⁺)541.0875.

¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 1:1) δ 3.21 (s, 3H),3.63, 3.71 (s, 3H), 4.8-4.91 (m, 2H), 5.68, 5.70 (s, 1H), 7.57-7.79 (m,5H), 7.86-7.93 (m, 1H), 8.00, 8.02 (s, 1H), 10.80 (s, 1H).

Example 404:N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(1-methoxycyclopropyl)carbonyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide

Procedure A:

N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide(80 mg, 0.17 mmol) was added to a mixture of1-methoxycyclopropanecarboxylic acid (28.9 mg, 0.25 mmol), HATU (95 mg,0.25 mmol) and DIPEA (0.087 mL, 0.50 mmol) in DMF (5 mL) under nitrogen.The resulting mixture was stirred at room temperature for 12 hours. Thereaction mixture was quenched with saturated NH₄Cl (25 mL) and extractedwith EtOAc (3×50 mL). The organic layer was dried over Na₂SO₄, filteredand evaporated to afford pale yellow solid. The crude product waspurified by flash C18-flash chromatography, elution gradient 10 to 90%MeOH in water. Pure fractions were evaporated to dryness to afford thetitle compound (85 mg, 88%).

HRMS: calculated for (C₂₄H₂₂F₆N₂O₆S+H)⁺581.1181; found: (ESI [M+H])581.1199.

¹H NMR (300 MHz, DMSO-d₆, mixture of rotamers, 2.3*:1) δ 0.84-1.27 (m,4H), 3.20, 3.23* (s, 3H), 3.37 (s, 3H), 4.85-5.06, 5.18-5.34* (m, 2H),5.91*, 6.24 (s, 1H), 7.58-7.86 (m, 5H), 7.89-7.96 (m, 1H), 8.02-8.09 (m,1H), 8.66, 8.67* (s, 1H), 10.82 10.90* (s, 1H).

Procedure B:

The hydrochloride salt ofN-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide(1.2 g, 2.31 mmol) was dissolved in DCM (20 mL) and to thistriethylamine (0.967 mL, 6.94 mmol) and 1-methoxycyclopropanecarboxylicacid (0.295 g, 2.54 mmol) was added. T3P (50% in EtOAc, 2.75 mL, 4.63mmol) was then added. The reaction was stirred at room temperature for 1hr. LCMS indicated complete conversion to product. The reaction wasdiluted with DCM and washed with 0.5M HCl. The layers were separated andand the organic layer concentrated in vacuo.

The (1R) and the (1S) enantiomers ofN-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(1-methoxycyclopropyl)carbonyl]-5-(methylsulfonyl)-2,3-dihydro-H-isoindole-1-carboxamide(1400 mg) were separated by a preparative SFC system equipped with aCelluCoat column 20% EtOH in CO₂ (120 bar); flow: 150 mL/min; injectionvolume was 1 mL of a 140 mg/mL ethanol solution.

Isomer 1 (peak 1): 580 mg, 99.8% ee by analytical chiral SFC (analyticalconditions: CelluCoat column, 150×4.6 mm, 3 m, 3.5 ml/min, 25% EtOH inCO₂, 120 bar, 40° C.). [α]_(D) ⁵⁸⁹+97° (c=0.6, CH₃CN).

HRMS: calculated for (C₂₄H₂₂F₆N₂O₆S+H)⁺581.1181; found: (ESI [M+H]⁺)581.1173.

¹H NMR (500 MHz, DMSO-d₆, mixture of rotamers, 2*:1) δ 0.80-1.23 (m,4H), 3.17, 3.19* (s, 3H), 3.20, 3.21* (s, 3H), 4.82-5.05, 5.18-5.30* (m,2H), 5.90*, 6.22 (s, 1H), 7.59-7.83 (m, 5H), 7.86-7.94 (m, 1H), 8.03,8.06* (s, 1H), 10.80, 10.87* (s, 1H).

Isomer 2 (peak 2): 580 mg, 97.6% ee by analytical chiral SFC (analyticalconditions: CelluCoat column, 150×4.6 mm, 3 m, 3.5 ml/min, 25% EtOH inCO₂, 120 bar, 40° C.). [α]D₅₈₉ −95° (c=0.6, CH₃CN).

HRMS: calculated for (C₂₄H₂₂F₆N₂O₆S+H)⁺581.1181; found: (ESI [M+H])581.1163.

¹H NMR (500 MHz, DMSO-d₆, mixture of rotamers, 2*:1) δ 0.80-1.23 (m,4H), 3.17, 3.19* (s, 3H), 3.20, 3.21* (s, 3H), 4.82-5.05, 5.18-5.30* (m,2H), 5.90*, 6.22 (s, 1H), 7.59-7.83 (m, 5H), 7.86-7.94 (m, 1H), 8.03,8.06* (s, 1H), 10.80, 10.87* (s, 1H).

Example 405:2-[(1-Cyanocyclopropyl)carbonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide

Prepared using the same procedure as Example 404 B, but using1-cyanocyclopropanecarboxylic acid (332 mg, 2.99 mmol). After work-up,about 150 mg (10% of the crude product) were purified by preparative SFC(chromatographic conditions: MeOH/NH₃ 20 mM, EP; column: Waters BEH 2-EP5 μm 30×250 mm) to give the title compound (94 mg, 66%).

HRMS: calculated for (C₂₄H₁₉F₆N₃O₅S+H)⁺576.1028; found: (ESI [M+H]⁺)576.1002.

¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 5*:1) δ 1.50-1.65 (m,2H), 1.65-1.86 (m, 2H), 3.21, 3.22* (s, 3H), 4.85-5, 5.31-5.40* (m, 2H),5.85*, 6.44 (s, 1H), 7.61-7.76 (m, 5H), 7.91-7.95 (m, 1H), 8.03, 8.12*(s, 1H), 8.69 (br s, 1H), 10.88*, 11.21 (s, 1H).

The remaining material (1200 mg) was subjected to chiral separationusing a by a preparative SFC system equipped with a Chiralpak IC 25%EtOH 100 CO₂ (120 bar); flow: 70 mL/min; injection volume was 0.6 mL ofa 100 mg/mL ethanol solution to give the (1R) and the (1 S) enantiomers.

Isomer 1 (peak 1): 470 mg, 98.3% ee by analytical chiral SFC (analyticalconditions: Chiralpak IC, 150×4.6 mm, 3 m, 3.5 ml/min, 25% EtOH in CO₂,120 bar, 40° C.). [α]D₅₈₉+78.9° (c=1, CH₃CN).

HRMS: calculated for (C₂₄H₁₉F₆N₃O₅S+H)⁺576.1028; found: (ESI [M+H]⁺)576.1030.

¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 5*:1) δ 1.50-1.65 (m,2H), 1.65-1.86 (m, 2H), 3.21, 3.22* (s, 3H), 4.85-5, 5.31-5.40* (m, 2H),5.85*, 6.44 (s, 1H), 7.61-7.76 (m, 5H), 7.91-7.95 (m, 1H), 8.03, 8.12*(s, 1H), 8.69 (br s, 1H), 10.88*, 11.21 (s, 1H).

Isomer 2 (peak 2): 515 mg, 99.0% ee by analytical chiral SFC (analyticalconditions: Chiralpak IC, 150×4.6 mm, 3 m, 3.5 ml/min, 25% EtOH in CO₂,120 bar, 40° C.). [α]_(D) ⁵⁸⁹ −79.4° (c=1, CH₃CN).

HRMS: calculated for (C₂₄H₁₉F₆N₃O₅S+H)⁺576.1028; found: (ESI [M+H]⁺)576.1057.

¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 5*:1) δ 1.5-1.65 (m, 2H),1.65-1.86 (m, 2H), 3.21, 3.22* (s, 3H), 4.85-5, 5.31-5.4* (m, 2H),5.85*, 6.44 (s, 1H), 7.61-7.76 (m, 5H), 7.91-7.95 (m, 1H), 8.03, 8.12*(s, 1H), 8.69 (br s, 1H), 10.88*, 11.21 (s, 1H).

Example 406:2-Formyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide

N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide(50 mg, 0.10 mmol) was added to a solution of formic acid (6.20 mg, 0.13mmol), HATU (59.1 mg, 0.16 mmol) and DIPEA (0.054 mL, 0.31 mmol) in DCM(5 mL) under nitrogen. The resulting mixture was stirred at r.t for 2hours. The reaction mixture was quenched with saturated NH₄Cl (50 mL)and extracted with DCM (3×50 mL). The organic layer was dried overNa₂SO₄, filtered and evaporated to afford pale yellow solid, which waspurified by preparative HPLC (XBridge Prep C18 OBD column, 5p silica, 19mm diameter, 100 mm length), using decreasingly polar mixtures of water(containing 0.08% NH₄HCO₃) and MeCN as eluents. Fractions containing thedesired compound were evaporated to dryness to afford2-formyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide(35.0 mg, 66.2%) as a colorless solid. LC/MS: m/z=511 [M+H]⁺.

HRMS: calculated for (C₂₀H₁₆F₆N₂O₅S+H)⁺511.0762; found: (ESI [M+H]⁺)511.0744.

¹H NMR (300 MHz, DMSO-d₆, mixture of rotamers, 2*:1) δ 3.21, 3.22* (s,3H), 4.70-4.91, 5.01-5.18* (m, 2H), 5.76*, 5.99 (s, 1H), 7.59-7.95 (m,6H), 8.01-8.07 (m, 1H), 8.38, 8.48* (s, 1H), 8.66 (s, 1H), 10.77*, 10.88(s, 1H).

Example 407:N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2-(oxetan-2-ylcarbonyl)-2,3-dihydro-1H-isoindole-1-carboxamide

N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide(80 mg, 0.17 mmol) was added to a solution of oxetane-2-carboxylic acid(25.4 mg, 0.25 mmol), HATU (95 mg, 0.25 mmol) and DIPEA (0.087 mL, 0.50mmol) in DMF (5 mL) under nitrogen. The resulting mixture was stirred atroom temperature for 12 hours. The reaction mixture was quenched withsaturated NH₄Cl (25 mL) and extracted with EtOAc (3×50 mL). The organiclayer was dried over Na₂SO₄, filtered and evaporated to afford paleyellow solid. The crude product was purified by flash C18-flashchromatography, elution gradient 10 to 90% MeOH in water. Pure fractionswere evaporated to dryness to affordN-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2-(oxetan-2-ylcarbonyl)-2,3-dihydro-H-isoindole-1-carboxamide(20.0 mg, 21.3%) as a solid. LC/MS: m/z=567 [M+H]⁺.

HRMS: calculated for (C₂₃H₂₀F₆N₂O₆S+H)⁺567.1024; found: (ESI [M+H]⁺)567.1015.

¹H NMR (400 MHz, DMSO-d₆, mixture of diastereomers and rotamers; ratio13:2:2:1; data given for the major rotamer/diastereomer) δ 2.73-3.02 (m,2H), 3.22 (s, 3H), 4.47-4.68 (m, 2H), 4.82-5.07 (m, 2H), 5.43-5.55 (m,1H), 5.83 (s, 1H), 7.58-7.84 (m, 5H), 7.88-7.95 (m, 1H), 7.97-8.07 (m,1H), 8.68 (s, 1H), 10.84 (s, 1H).

Example 408:2-(3-Fluoro-2-methylpropanoyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide

Step 1:N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(3-methoxy-2-methylpropanoyl)-5-(methylsulfonyl)isoindoline-1-carboxamide

N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide(300 mg, 0.62 mmol) was added to a solution of3-methoxy-2-methylpropanoic acid (147 mg, 1.24 mmol), HATU (307 mg, 0.81mmol) and DIPEA (0.326 mL, 1.87 mmol) in DMF (10 mL) under nitrogen. Theresulting mixture was stirred at room temperature for 12 hours. Thereaction mixture was quenched with saturated NH₄Cl (50 mL), extractedwith EtOAc (3×50 mL), the organic layer was dried over Na₂SO₄, filteredand evaporated to afford pale yellow solid. The crude product waspurified by flash C18-flash chromatography, elution gradient 10 to 90%MeOH in water. Pure fractions were evaporated to dryness to affordN-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(3-methoxy-2-methylpropanoyl)-5-(methylsulfonyl)isoindoline-1-carboxamide(300 mg, 83%) as a solid.

LC/MS: m/z=583 [M+H]⁺. ¹HNMR (400 MHz, DMSO-d₆, mixture of diastereomersand rotamers; ratio 9.5:5:3:1; data given for the 2 majorrotamers/diastereomers) δ 1.06*, 1.09 (d, 3H), 3.02-3.10 (m, 1H),3.19-3.32 (m, 7H), 3.45-3.58 (m, 1H), 5.08-5.14 (m, 2H), 5.76, 5.77* (s,1H), 7.62-7.80 (m, 5H), 7.88-8.05 (m, 2H), 8.66 (s, 1H), 10.64, 10.73*(s, 1H).

Step 2:N-(4-(2-(Benzyloxy)-1,1,1,3,3,3-hexafluoropropan-2-yl)phenyl)-2-(3-methoxy-2-methylpropanoyl)-5-(methylsulfonyl)isoindoline-1-carboxamide

alpha-Bromotoluene (106 mg, 0.62 mmol) was added toN-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-2-(3-methoxy-2-methylpropanoyl)-5-(methylsulfonyl)isoindoline-1-carboxamide(300 mg, 0.52 mmol) and K₂CO₃ (142 mg, 1.03 mmol) in DMF (8 mL) undernitrogen. The resulting mixture was stirred at room temperature for 12hours. The reaction mixture was quenched with water (25 mL), extractedwith EtOAc (3×25 mL), the organic layer was dried over Na₂SO₄, filteredand evaporated to afford yellow solid. The crude product was purified byflash C18-flash chromatography, elution gradient 10 to 90% MeCN inwater. Pure fractions were evaporated to dryness to affordN-(4-(2-(benzyloxy)-1,1,1,3,3,3-hexafluoropropan-2-yl)phenyl)-2-(3-methoxy-2-methylpropanoyl)-5-(methylsulfonyl)isoindoline-1-carboxamide(220 mg, 63.5%).

LC/MS: m/z=673 [M+H]⁺. ¹HNMR (300 MHz, DMSO-d₆, mixture of diastereomersand rotamers; ratio 10:6:3:1; data given for the 2 majorrotamers/diastereomers) δ 1.06-1.10 (m, 3H), 2.97-3.13 (m, 1H),3.17-3.30 (m, 7H), 3.43-3.60 (m, 1H), 4.61 (s, 2H), 5.02-5.18 (m, 2H),5.72-5.83 (m, 1H), 7.31-8.04 (m, 12H), 10.75, 10.84* (s, 1H).

Step 3:N-(4-(2-(Benzyloxy)-1,1,1,3,3,3-hexafluoropropan-2-yl)phenyl)-2-(3-hydroxy-2-methylpropanoyl)-5-(methylsulfonyl)isoindoline-1-carboxamide

Boron tribromide (410 mg, 1.64 mmol) was added dropwise to a solution ofN-(4-(2-(benzyloxy)-1,1,1,3,3,3-hexafluoropropan-2-yl)phenyl)-2-(3-methoxy-2-methylpropanoyl)-5-(methylsulfonyl)isoindoline-1-carboxamide(220 mg, 0.33 mmol) in DCM (10 mL) cooled to −40° C. under nitrogen. Theresulting mixture was stirred at 0° C. for 5 hours.

The reaction mixture was quenched with ice water (25 mL), extracted withDCM (3×25 mL), the organic layer was dried over Na₂SO₄, filtered andevaporated to afford yellow solid. The crude product was purified byflash silica chromatography, elution gradient 0 to 10% MeOH in DCM. Purefractions were evaporated to dryness to affordN-(4-(2-(benzyloxy)-1,1,1,3,3,3-hexafluoropropan-2-yl)phenyl)-2-(3-hydroxy-2-methylpropanoyl)-5-(methylsulfonyl)isoindoline-1-carboxamide(130 mg, 60.3%).

LC/MS: m/z=659 [M+H]⁺. ¹HNMR (300 MHz, DMSO-d₆, mixture of diastereomersand rotamers; ratio 5:3:1.6:1; data given for the 2 majorrotamers/diastereomers) δ 0.97-1.18 (m, 3H), 2.88-3.05 (m, 1H),3.16-3.69 (m, 5H), 4.61 (s, 2H), 4.78-5.27 (m, 3H), 5.79 (s, 1H),7.31-8.12 (m, 12H), 10.61, 10.84* (s, 1H).

Step 4:N-(4-(2-(Benzyloxy)-1,1,1,3,3,3-hexafluoropropan-2-yl)phenyl)-2-(3-fluoro-2-methylpropanoyl)-5-(methylsulfonyl)isoindoline-1-carboxamide

DAST (0.047 mL, 0.36 mmol) was added dropwise to a soultion ofN-(4-(2-(benzyloxy)-1,1,1,3,3,3-hexafluoropropan-2-yl)phenyl)-2-(3-hydroxy-2-methylpropanoyl)-5-(methylsulfonyl)isoindoline-1-carboxamide(130 mg, 0.20 mmol) in DCM (8 mL) cooled to 0° C. under nitrogen. Theresulting mixture was stirred at room temperature for 2 hours. Thereaction mixture was quenched with water (15 mL), extracted with DCM(3×20 mL), the organic layer was dried over Na₂SO₄, filtered andevaporated to afford pale yellow solid. The crude product was purifiedby flash silica chromatography, elution gradient 0 to 20% MeOH in DCM.Pure fractions were evaporated to dryness to affordN-(4-(2-(benzyloxy)-1,1,1,3,3,3-hexafluoropropan-2-yl)phenyl)-2-(3-fluoro-2-methylpropanoyl)-5-(methylsulfonyl)isoindoline-1-carboxamide(100 mg, 77%).

LC/MS: m/z=661 [M+H]⁺. ¹HNMR (300 MHz, DMSO-d₆, mixture of diastereomersand rotamers; ratio 5:3:1.6:1; data given for the 2 majorrotamers/diastereomers) δ 1.02-1.17 (m, 3H), 3.12-3.29 (m, 4H),4.27-4.74 (m, 4H), 4.78-5.24 (m, 2H), 5.78, 5.81* (s, 1H), 7.33-8.06 (m,12H), 10.84, 10.90* (s, 1H).

Step 5:2-(3-Fluoro-2-methylpropanoyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide

N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide(100 mg, 0.15 mmol) and Pd—C (1,611 mg, 0.02 mmol) in MeOH (10 mL) werestirred under an atmosphere of hydrogen at room temperature for 12hours. The reaction mixture was filtered through celite. The solvent wasremoved under reduced pressure. The crude product was purified by flashC18-flash chromatography, elution gradient 10 to 90% MeCN in water. Purefractions were evaporated to dryness to afford2-(3-fluoro-2-methylpropanoyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide(60.0 mg, 69.5%).

HRMS: calculated for (C₂₃H₂₁F₇N₂O₅S+H)⁺571.1138; found: (ESI [M+H]⁺)571.1146.

¹H NMR (400 MHz, DMSO-d₆, mixture of diastereomers/rotamers, 8*:6:2:1,only data for 2 major isomers reported) δ 1.07-1.16 (m, 3H), 3.19-3.29(m, 4H), 4.32-4.71 (m, 2H), 4.79-5.21 (m, 2H), 5.77, 5.80* (s, 1H),7.59-7.83 (m, 5H), 7.89-7.95 (m, 1H), 7.98-8.05 (m, 1H), 8.68 (s, 1H),10.73, 10.79* (s, 1H).

Example 409:(R,S)—N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(2R)-2-hydroxybutanoyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide

N-(4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl)-5-(methylsulfonyl)isoindoline-1-carboxamide(90 mg, 0.19 mmol) was added to (R)-2-hydroxybutanoic acid (29.1 mg,0.28 mmol), HATU (142 mg, 0.37 mmol) and DIPEA (0.098 mL, 0.56 mmol) inDCM (10 mL) under nitrogen. The resulting mixture was stirred at rt for2 hours. The reaction mixture was quenched with saturated NH₄Cl (50 mL),extracted with DCM (3×50 mL), the organic layer was dried over Na₂SO₄,filtered and evaporated to affordN-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-2-((R)-2-hydroxybutanoyl)-5-(methylsulfonyl)isoindoline-1-carboxamide(100 mg, 94%). Half of this amount was purified by preparative HPLC(Waters XBridge Prep C18 OBD column, 5μ silica, 19 mm diameter, 100 mmlength), using decreasingly polar mixtures of water (containing 0.08%Formic acid) and MeCN as eluents. Fractions containing the desiredcompound were evaporated to dryness to afford:

Isomer 1, (20.0 mg, 38.0%).

HRMS: calculated for (C₂₃H₂₂F₆N₂O₆S+H)⁺569.1181; found (ESI [M+H]⁺)569.1193.

¹H NMR (400 MHz, DMSO-d₆, mixture of rotamers, 3*:1) δ 0.82, 0.94* (t,3H), 1.50-1.79 (m, 2H), 3.22, 3.23* (s, 3H), 3.91-4.00, 4.17-4.26* (m,1H), 4.76-5.02, 5.11-5.20* (m, 2H), 5.21-5.28*, 5.58-5.64 (d, 1H),5.79*, 6.28 (s, 1H), 7.60-7.68 (m, 2H), 7.70-7.83 (m, 3H), 7.91 (m, 1H),7.98-8.06 (m, 1H), 8.52, 8.86* (s, 1H), 10.85*, 11.13 (s, 1H).

Isomer 2, (20 mg, 38%).

HRMS: calculated for (C₂₃H₂₂F₆N₂O₆S—H)⁻ 567.1388; found (ESI [M+H]⁺)567.1379.

¹H NMR (400 MHz, DMSO-d₆, mixture of rotamers, 9*:1) δ 0.89-1.00 (m,3H), 1.51-1.80 (m, 2H), 3.22, 3.23* (s, 3H), 3.93-4.03, 4.23-4.33* (m,1H), 4.82-5.24 (m, 3H), 5.84, 6.11 (s, 1H), 7.60-7.81 (m, 5H), 7.88-7.95(m, 1H), 7.98-8.05 (m, 1H), 8.53, 8.71* (s, 1H), 10.82*, 10.95 (s, 1H).

Examples 410-433

Examples 410-433 (Table 4A) were prepared using a similar procedures tothose described in examples 401 to 409.

-   Example 410:    N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(3-methylbutanoyl)-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 411:    2-(Cyclopropylacetyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 412:    N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(1-hydroxycyclopropyl)acetyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 413:    2-[(3S)-3-Fluorobutanoyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 414:    N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(methoxyacetyl)-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 415:    2-(3-Fluoropropanoyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 416:    2-[(1-Ethoxycyclopropyl)carbonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 417:    N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(1-methoxycyclopropyl)acetyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 418:    2-[(3R)-3-Fluorobutanoyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 419:    N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(2-methoxy-2-methylpropanoyl)-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 420: Propan-2-yl    1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-5-(methylsulfonyl)-1,3-dihydro-2H-isoindole-2-carboxylate-   Example 421:    N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(3-hydroxy-3-methylbutanoyl)-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 422:    N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(2R)-2-hydroxy-3-methylbutanoyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 423:    N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(2S)-2-hydroxy-3-methylbutanoyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 424, isomer 1:    N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(2S)-2-hydroxybutanoyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 424, isomer 2:    N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(2S)-2-hydroxybutanoyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 425:    N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(3-hydroxy-2-methylpropanoyl)-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 426:    N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2-(oxetan-3-ylacetyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 427:    2-[(1-Cyanocyclopropyl)acetyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 428:    N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(1-hydroxycyclopropyl)carbonyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 429:    2-(3-Cyanopropanoyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 430:    N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(trans-3-hydroxycyclobutyl)carbonyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 431:    N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(cis-3-hydroxycyclobutyl)carbonyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 432:    N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(3R)-3-hydroxybutanoyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 433:    N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(3S)-3-hydroxybutanoyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide

TABLE 4A Example No. Structure NMR + MS 410

HRMS: calculated for (C₂₄H₂₄F₆N₂O₅S + H)⁺ 567.1388; found (ESI [M + H]⁺)567.1379. ¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 6*:1, only datafor major reported) δ 0.96 (d, 3H), 0.97 (d, 3H), 2.04-2.13 (m, 1H),2.27-2.41 (m, 2H), 3.22 (s, 3H), 5.04 (m, 2H), 5.76 (s, 1H), 7.6-7.68(m, 2H), 7.68- 7.78 (m, 3H), 7.86-7.92 (m, 1H), 7.98 (s, 1H), 8.66 (s,1H), 10.73 (s, 1H). 411

HRMS: calculated for (C₂₄H₂₂F₆N₂O₅S + H)⁺ 565.1232; found (ESI [M + H]⁺)565.1236. ¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 5*:1) δ 0-0.23(m, 2H), 0.38- 0.52 (m, 2H), 0.94-1.1 (m, 1H), 2.28-2.47 (m, 2H),0.94-1.1 (m, 1H), 2.28-2.47 (m, 2H), 3.21, 3.22* (s, 3H), 4.79-4.94,4.95- 5.04* (m, 2H), 5.75*, 5.90 (s, 1H), 7.61- 7.67 (m, 2H), 7.68-7.78(m, 3H), 7.88-7.92 (m, 1H), 7.98*, 8.03 (s, 1H), 8.66 (s, 1H), 10.71*,10.88 (s, 1H). 412

HRMS: calculated for (C₂₄H₂₂F₆N₂O₆S + H)⁺ 581.1181; found (ESI [M + H]⁺)581.1160. ¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 5*:1) δ0.40-0.65 (m, 4H), 2.58- 2.67 (m, 1H), 2.77-2.87 (m, 1H), 3.21, 3.22*(s, 3H), 4.77-4.98, 5.05-5.2* (m, 2H), 5.35*, 5.36 (s, 1H), 5.77*, 6.07(s, 1H), 7.6- 7.67 (m, 2H), 7.69-7.81 (m, 3H), 7.88-7.92 (m, 1H), 8.00*,8.03 (s, 1H), 8.66*, 8.69 (s, 1H), 10.68*, 10.94 (s, 1H). 413

HRMS: calculated for (C₂₃H₂₁F₇N₂O₅S + H)⁺ 571.1138; found (ESI [M + H]⁺)571.1179. ¹H NMR (400 MHz, DMSO-d₆, mixture of diastereomers androtamers; data reported for major diastereomer/rotamer) δ 1.34-1.46 (m,3H), 2.71-3.05 (m, 2H), 3.23 (s, 3H), 4.78- 5.24 (m, 3H), 5.78 (s, 1H),7.59-7.86 (m, 5H), 7.88-7.94 (m, 1H), 7.98-8.06 (m, 1H), 8.69 (s, 1H),10.71-11.11 (m, 1H). 414

HRMS: calculated for (C₂₂H₂₀F₆N₂O₆S + H)⁺ 555.1024; found (ESI [M + H]⁺)555.1031. ¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 4*:1) δ 3.21*,3.22 (s, 3H), 3.26, 3.36* (s, 3H), 3.92-4.16, 4.17-4.34* (m, 2H),4.8-5.08 (m, 2H), 5.79*, 5.99 (s, 1H), 7.61-7.66 (m, 2H), 7.71-7.8 (m,3H), 7.89- 7.92 (m, 1H), 8.00* 8.03 (s, 1H), 8.66 (s, 1H), 10.77*, 10.86(s, 1H). 415

HRMS: calculated for (C₂₂H₁₉F₇N₂O₆S + H)⁺ 557.0981; found (ESI [M + H]⁺)557.0993. ¹H NMR (300 MHz, DMSO-d₆, mixture of rotamers, 4.7*:1) δ ¹HNMR (300 MHz, DMSO) δ 2.85-3.06 (m, 2H), 3.24 (s, 3H), 4.60-4.85 (m,2H), 4.85-5.16 (m, 2H), 5.79*, 6.01 (s, 1H), 7.58-7.86 (m, 5H), 7.88-7.96 (m, 1H), 7.99-8.08 (m, 1H), 8.69*, 8.72 (s, 1H), 10.77*, 11.01 (s,1H). 416

HRMS: calculated for (C₂₅H₂₄F₆N₂O₆S + H)⁺ 595.1337; found (ESI [M + H]⁺)595.1368. ¹H NMR (300 MHz, DMSO-d₆, mixture of rotamers, 2.8:1*) δ0.91-1.27 (m, 7H), 3.23 (s, 3H), 3.40-3.76 (m, 2H), 4.80-5.08, 5.19-5.34* (m, 2H), 5.90*, 6.27 (s, 1H), 7.59- 7.96 (m, 6H), 8.01-8.13 (m,1H), 8.64, 8.66* (s, 1H), 10.81, 10.88* (s, 1H). 417

HR1S: calculated for (C₂₅H₂₄F₆N₂O₆S + H)⁺ 595.1337; found (ESI [M + H]⁺)595.1322. ¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 6*:1, only datafor major reported) δ 0.55-0.78 (m, 4H), 2.83-2.93 (m, 2H), 3.22 (s,3H), 3.24 (s, 3H), 5.08-5.17 (m, 2H), 5.75 (s, 1H), 7.57-7.67 (m, 2H),7.69-7.76 (m, 3H), 7.88-7.92 (m, 1H), 8.01 (s, 1H), 8.66 (s, 1H), 10.74(s, 1H). 418

HRMS: calculated for (C₂₃H₂₁F₇N₃O₅S + H)⁺ 571.1138; found (ESI [M + H]⁺)571.1144. ¹H NMR (300 MHz, DMSO-d₆, mixture of diastereomers androtamers; data reported for major diastereomer/rotamer) δ 1.39 (dd, 3H),2.67-3.06 (m, 2H), 3.22 (s, 3H), 4.76-5.25 (m, 3H), 5.77 (s, 1H),7.58-7.75 (m, 5H), 7.86-7.94 (m, 1H), 7.96-8.06 (m, 1H), 8.65 (s, 1H),10.71-10.78 (m, 1H). 419

HRMS: calculated for (C₂₄H₂₄F₆N₂O₆S + H)⁺ 583.1337; found (ESI [M + H]⁺)583.1340. ¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 10*:1, onlydata for major reported) δ 1.37 (s, 3H), 1.39 (s, 3H), 3.20 (s, 3H),3.26 (s, 3H), 5.10-5.29 (m, 2H), 5.86 (s, 1H), 7.60- 7.65 (m, 2H),7.68-7.76 (m, 3H), 7.88-7.91 (m, 1H), 8.01 (s, 1H), 10.88 (s, 1H). 420

HRMS: calculated for (C₂₃H₂₂F₆N₂O₆S + H)⁺ 569.1181; found (ESI [M + H]⁺)569.1187. ¹H NMR (400 MHz, DMSO-d₆, mixture of rotamers, 1.2*:1) δ1.05*, 1.20*, 1.27, 1,28 (2d, 6H), 3.21, 3.22* (s, 3H), 4.75-4.92 (m,3H), 5.64-5.69 (m, 1H), 7.59-7.79 (m, 5H), 7.88-7.93 (m, 1H), 7.98-8.05(m, 1H), 8.65*, 8.66 (s, 1H), 10.76*, 10.79 (s, 1H). 421

HRMS: calculated for (C₂₄H₂₄F₆N₂O₆S + H)⁺ 583.1337; found (ESI [M + H]⁺)583.1346. ¹H NMR (300 MHz, DMSO-d₆, mixture of rotamers, 6.5*:1) δ 1.23,1.27* (s, 6H), 2.55- 2.68 (m, 2H), 3.23, 3.24* (s, 3H), 4.83 (s, 1H),4.77-5.00, 5.09-5.22* (m, 2H), 5.79*, 6.12 (s, 1H), 7.58-7.85 (m, 5H),7.88-7.967 (m, 1H), 7.98-8.07 (m, 1H), 8.67*, 8.68 (s, 1H), 10.68*,10.99 (s, 1H). 422

HRMS: calculated for (C₂₄H₂₄F₆N₂O₆S + H)⁺ 583.1337; found (ESI [M + H]⁺)583.1343. Mixture of diastereomers and rotamers. Ratio diastereomer 1major rotamer: diastereomer 2 major rotamer 1.3^(#):1 Ratio majorrotamer: minor rotamer 5:1 only major rotamer reported: ¹H NMR (600 MHz,DMSO-d₆) δ 0.9-0.96 (m, 6H), 1.95-2.06 (m, 1H), 3.21, 3.22^(#) (s, 3H),3.98, 4.04^(#) (t, 1H), 4.96-5.26 (m, 3H), 5.78, 5.84^(#) (d, 1H),7.6-7.66 (m, 2H), 7.68- 7.75 (m, 3H), 7.88-7.92 (m, 1H), 7.99 (s, 1H),8.66 (br s, 1H), 10.79, 10.82^(#) (s, 1H). 423

HRMS: calculated for (C₂₄H₂₄F₆N₂O₆S + H)⁺ 583.1337; found (ESI [M + H]⁺)583.1346. Mixture of diastereomers and rotamers. Ratio diastereomer 1major rotamer: diastereomer 2 major rotamer 1.2^(#): 1 Ratio majorrotamer: minor rotamer 5:1 only major rotamer reported: ¹H NMR (600 MHz,DMSO-d₆) δ 0.9-0.96 (m, 6H), 1.97-2.05 (m, 1H), 3.21, 3.22^(#) (s, 3H),3.98, 4.04^(#) (d, 1H), 5.06-5.25 (m, 2H), 5.78, 5.84^(#) (d, 1H),7.56-7.65 (m, 2H), 7.66- 7.74 (m, 3H), 7.86-7.93 (m, 1H), 7.99 (s, 1H),8.66 (br s, 1H), 10.78, 10.81^(#) (s, 1H). 424 Isomer 1

HRMS: calculated for (C₂₃H₂₂F₆N₂O₆S + H)⁺ 569.1181; found (ESI [M + H]⁺)569.1174. ¹H NMR (400 MHz, DMSO-d₆, mixture of rotamers, 6.5*:1) δ 0.94(t, 3H), 1.48-1.8 (m, 2H), 3.22 (s, 3H), 3.94-4.03, 4.23-4.31* (m, 1H),4.81-5.26 (m, 3H), 5.84*, 6.13 (s, 1H), 7.60-7.67 (m, 2H), 7.69-7.82 (m,3H), 7.87-7.95 (m, 1H), 7.97-8.05 (m, 1H), 8.51, 8.80* (s, 1H), 10.84*,11.05 (s, 1H). 424 Isomer 2

HRMS: calculated for (C₂₃H₂₂F₆N₂O₆S + H)⁺ 569.1181; found (ESI [M + H]⁺)569.1192. ¹H NMR (400 MHz, DMSO-d₆, mixture of rotamers, 3.2*:1) δ 0.82,0.94* (t, 3H), 1.5- 1.8 (m, 2H), 3.22 (s, 3H), 3.91-4.00, 4.17- 4.26*(m, 1H), 4.78-5.2 (m, 2H), 5.22*, 5.58 (d, 1H), 5.78*, 6.25 (s, 1H),7.58-7.84 (m, 5H), 7.87-7.95 (m, 1H), 7.98-8.07 (m, 1H), 8.53, 8.77* (s,1H), 10.82*, 11.03 (s, 1H). 425

HRMS: calculated for (C₂₃H₂₂F₆N₂O₆S + H)⁺ 569.1181; found (ESI [M + H]⁺)569.1170. Mixture of diastereomers and rotamers; ratio major: minor =6:3:1; only major isomer reported: ¹H NMR (400 MHz, DMSO-d₆) δ 1.06 (d,3H), 2.87-3.03 (m, 1H), 3.23 (s, 3H), 3.43 (s, 1H), 3.51-3.68 (m, 1H),4.76-5.26 (m, 3H), 5.76 (s, 1H), 7.70 (ddt, 5H), 7.88-7.96 (m, 1H),7.98-8.07 (m, 1H), 8.68 (s, 1H), 10.49 (s, 1H). 426

HRMS: calculated for (C₂₄H₂₂F₆N₂O₆S + H)⁺ 581.1181; found (ESI [M + H]⁺)581.1191. ¹H NMR (400 MHz, DMSO-d₆, mixture of rotamers, 5*:1) δ2.86-3.01 (m, 2H), 3.22, 3.24* (s, 3H), 3.26-3.45 (m, 1H), 4.22-4.37 (m,2H), 4.66-4.73 (m, 2H), 4.75-4.94, 5.02-5.10* (m, 2H), 5.72*, 5.99 (s,1H), 7.60- 7.84 (m, 5H), 7.89-7.95 (m, 1H), 8.00- 8.05 (m, 1H), 8.68 (s,1H), 10.70*, 11.03 (s, 1H). 427

HRMS: calculated for (C₂₅H₂₁F₆N₃O₅S + H)⁺ 590.1184; found (ESI [M + H]⁺)590.1200. ¹H NMR (400 MHz, DMSO-d₆, mixture of rotamers, 5:1, data onlyfor major rotamer) δ 0.85-1.16 (m, 4H), 2.99-3.18 (m, 2H), 3.23 (s, 3H),5.10-5.29 (m, 2H), 5.79 (s, 1H), 7.59- 7.77 (m, 5H), 7.88-7.95 (m, 1H),7.99- 8.03 (m, 1H), 8.74 (s, 1H), 10.77 (s, 1H). 428

HRMS: calculated for (C₂₃H₂₀F₆N₂O₆S + H)⁺ 567.1024; found (ESI [M + H]⁺)567.1051. ¹H NMR (300 MHz, DMSO-d₆, mixture of rotamers, 1.4*:1) δ0.74-1.27 (m, 4H), 3.22, 3.23* (s, 3H), 4.82-5.01, 5.27-5.48* (m, 2H),5.84*, 6.48 (s, 1H), 6.51, 6.53* (s, 1H), 7.57-7.96 (m, 6H), 8.00-8.08(m, 1H), 8.73 (s, 1H), 10.82*, 10.83 (s, 1H). 429

HRMS: calculated for (C₂₃H₁₉F₆N₃O₅S + H)⁺ 564.1028; found (ESI [M + H]⁺)564.1042. ¹H NMR (400 MHz, DMSO-d₆, mixture of rotamers, 6*:1) δ 2.70(t, 2H), 2.83-2.99 (m, 2H), 3.23, 3.24* (s, 3H), 4.80-5.00, 5.01- 5.10*(m, 2H), 5.78*, 5.97 (s, 1H), 7.59-7.85 (m, 5H), 7.89-7.95 (m, 1H),8.01-8.07 (m, 1H), 8.67*, 8.69 (s, 1H), 10.76*, 10.98 (s, 1H). 430

HRMS: calculated for (C₂₄H₂₂F₆N₄O₆S + H)⁺ 581.1181; found (ESI [M + H]⁺)581.1183. ¹H NMR (300 MHz, DMSO-d₆, mixture of rotamers, 5*:1) δ2.05-2.22 (m, 2H), 2.41- 2.50 (m, 2H), 3.23 (s, 3H), 3.24-3.33 (m, 1H),4.12-4.26 (m, 1H), 4.78-4.98 (m, 2H), 5.07, 5.16* (d, 1H), 5.77*, 5.85(s, 1H), 7.60- 7.79 (m, 5H), 7.87-7.95 (m, 1H), 7.97-8.06 (m, 1H),8.69*, 8.71 (s, 1H), 10.77*, 10.95 (s, 1H). 431

HRMS: calculated for (C₂₄H₂₂F₆N₂O₆S + H)⁺ 581.1181; found (ESI [M + H]⁺)581.1166. ¹H NMR (300 MHz, mixture of rotamers, 4.5*:1) δ 1.94-2.12 (m,2H), 2.38-2.63 (m, 2H), 2.71-2.96 (m, 1H), 3.23 (s, 3H), 3.88- 4.15 (m,1H), 4.76-5.07 (m, 2H), 5.76*, 5.94 (s, 1H), 7.6-7.81 (m, 5H), 7.88-7.95(m, 1H), 7.97-8.05 (m, 1H), 10.81*, 11.08 (s, 1H). 432

HRMS: calculated for (C₂₃H₂₂F₆N₂O₆S + H)⁺ 569.1181; found (ESI [M + H]⁺)569.1151. Mixture of diastereomers and rotamers; ratio major*: minor =7:6:2:1; only 2 major isomers reported: ¹H NMR (300 MHz, DMSO-d₆) δ1.14-1.21 (m, 3H), 2.41-2.68 (m, 2H), 3.24 (s, 3H), 4.02-4.16 (m, 1H),5.01-5.19 (m, 2H), 5.77 (s, 1H), 7.59-7.82 (m, 5H), 7.89-7.95 (m, 1H),7.99-8.03 (m, 1H), 8.67 (s, 1H), 10.66, 10.73* (s, 1H). 433

HRMS: calculated for (C₂₃H₂₂F₆N₂O₆S + H)⁺ 569.1181; found (ESI [M + H]⁺)569.1190. Mixture of diastereomers/rotamers; ratio major*: minor =6:5:2:1, only 2 major isomers reported: ¹H NMR (400 MHz, DMSO-d₆) δ1.14-1.21 (m, 3H), 2.40-2.55 (m, 1H), 2.58-2.66 (m, 1H), 3.23 (s, 3H),4.04-4.13 (m, 1H), 4.64- 5.15 (m, 3H), 5.76 (s, 1H), 7.58-7.82 (m, 5H),7.88-7.94 (m, 1H), 7.98-8.05 (m, 1H), 8.66 (s, 1H), 10.66, 10.72* (s,1H). 434

HRMS: calculated for (C₂₆H₂₆F₆N₂O₆S + H)⁺ 609.1494; found (ESI [M + H]⁺)609.1520. ¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 12*:1 onlymajor isomer reported) δ 1.52-1.61 (m, 2H), 1.61-1.71 (m, 2H), 1.88-2.05 (m, 3H), 2.1-2.17 (m, 1H), 3.21 (s, 3H), 3.22 (s, 3H), 5.11-5.23(m, 2H), 5.86 (s, 1H), 7.6-7.65 (m, 2H), 7.7-7.76 (m, 3H), 7.86-7.92 (m,1H), 8.01 (s, 1H), 8.67 (br s, 1H), 10.88 (s, 1H).

Example 435:2-Acetyl-N-[3-fluoro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide

Step 1:N-[3-Fluoro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide

tert-Butyl1-((3-fluoro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)-5-(methylsulfonyl)isoindoline-2-carboxylate(402 mg, 0.67 mmol) was suspended in isopropyl acetate (15 mL). hydrogenchloride in IPA (1.473 mL, 7.36 mmol) was added. Stirred at rtovernight. The reaction was concentrated in vacuo. The residue wascoevaporated with EtOAc (2×25 ml), EtOAc/Hept (1:1, 50 ml) to afford thecrude product as its hydrochloride salt. The product was used in thenext step without further purification.

LC/MS: m/z=501 [M+H]⁺.

Step 2:2-Acetyl-N-[3-fluoro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide

N-(3-Fluoro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-5-(methylsulfonyl)isoindoline-1-carboxamide,HCl (100 mg, 0.19 mmol) was dissolved in DCM (1 mL) and to thistriethylamine (0.078 mL, 0.56 mmol) and acetic acid (13.42 mg, 0.22mmol) was added followed by T3P (0.222 mL, 0.37 mmol) 50% in EtOAc wasthen added. The reaction was stirred at rt for 1 hr. LCMS indicatedcomplete conversion to product. The reaction was diluted with DCM andwashed with 0.5M HCl. The layers were separated using a phase separatorand concentrated in vacuo. The residue was dissolved in DMSO andseparated by preparative SFC (chromatographic conditions: MeOH/NH₃ 20mM; column: Waters BEH 5 μm 30×250 mm) to afford2-acetyl-N-(3-fluoro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-5-(methylsulfonyl)isoindoline-1-carboxamide(79 mg, 78%).

HRMS: calculated for (C₂₁H₁₇F₇N₂O₅S+H)⁺543.0825; found (ESI [M+H]⁺)543.0830.

¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 5*:1) δ 1.99, 2.15* (s,3H), 3.21, 3.22* (s, 3H), 4.73-4.94, 4.99-5.1* (m, 2H), 5.71*, 5.94 (s,1H), 7.49*, 7.54 (dd, 1H), 7.62-7.71 (m, 2H), 7.76-7.81 (m, 1H),7.88-7.93 (m, 1H), 8.00*, 8.03 (s, 1H), 8.89 (br s, 1H), 10.92*, 11.15(s, 1H).

Example 436:2-[(1-Cyanocyclopropyl)carbonyl]-N-[2-fluoro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide

Step 1:N-[2-Fluoro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide

tert-Butyl1-((2-fluoro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)-5-(methylsulfonyl)isoindoline-2-carboxylate(402 mg, 0.67 mmol) was suspended in isopropyl acetate (1.5 mL).hydrogen chloride in IPA (1.5 mL, 7.50 mmol) was added. Stirred at rtovernight. The reaction was concentrated in vacuo. The residue wascoevaporated with EtOAc and then, EtOAc/Hept (1:1). The title compoundwas obtained as its hydrochloride salt (353 mg, 99%). The pinkish solidwas used without further purification in the next step.

LC/MS: m/z=501 [M+H]⁺.

Step 2:2-[(1-Cyanocyclopropyl)carbonyl]-N-[2-fluoro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide

N-(2-Fluoro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-5-(methylsulfonyl)isoindoline-1-carboxamide,HCl (50 mg, 0.09 mmol) was dissolved in DCM (1 mL) and to thistriethylamine (0.039 mL, 0.28 mmol) and 1-cyanocyclopropane-1-carboxylicacid (15.52 mg, 0.14 mmol) was added followed by T3P (0.111 mL, 0.19mmol) 50% in EtOAc was then added. The reaction was stirred at rt for 1hr. LCMS indicated complete conversion to product. The reaction wasdiluted with DCM and washed with 0.5M HCl. The layers were separatedusing a phase separator cartridge and concentrated in vacuo. The residuewas dissolved in DMSO and separated by preparative SFC (chromatographicconditions: MeOH/NH₃ 20 mM; column: Waters BEH 5 m 30×250 mm) to afford2-(1-cyanocyclopropane-1-carbonyl)-N-(2-fluoro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-5-(methylsulfonyl)isoindoline-1-carboxamide(31.6 mg, 57.2%).

HRMS: calculated for (C₂₄H₁₈F₇N₃O₅S+H)⁺594.0933; found (ESI [M+H]⁺)594.0894.

¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 6*:1) δ 1.44-1.81 (m,4H), 3.22, 3.23* (s, 3H), 4.86-5.00, 5.32-5.42* (m, 2H), 6.06*, 6.64 (s,1H), 7.43-7.5 (m, 1H), 7.51-7.56 (m, 1H), 7.76 (d, 1H), 7.93-8.02 (m,2H), 8.03, 8.12* (s, 1H), 8.96 (br s, 1H), 10.74*, 11.11 (s, 1H).

Examples 437-449

Examples 437-449 (Table 4B) were prepared using a similar procedures tothose described in the preceding examples.

-   Example 437:    2-Acetyl-N-[2-fluoro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 438:    N-[2-Fluoro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 439:    2-[(1-Cyanocyclopropyl)carbonyl]-N-[3-fluoro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 440:    N-[3-Fluoro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(1-methoxycyclopropyl)carbonyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 441:    N-[2-Fluoro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(1-methoxycyclopropyl)carbonyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 442:    N-[2-Fluoro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 443:    N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(3-methyloxetan-3-yl)carbonyl-5-(methyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 444:    N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2-(oxetan-3-ylcarbonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 445:    N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(2-methyloxetan-2-yl)carbonyl-5-(methyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 446:    2-[(1-Fluorocyclopropyl)carbonyl]-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 447:    N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(2-methoxybutanoyl)-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 448:    N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(1-methoxycyclobutyl)carbonyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 449:    N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(2R)-2-methoxypropanoyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide

TABLE 4B Example No. Structure NMR + MS 437

HRMS: calculated for (C₂₁H₁₇F₇N₂O₅S + H)⁺ 543.0825; found (ESI [M + H]⁺)543.0825. ¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 4*:1) δ 2.01,2.15* (s, 3H), 3.22, 3.23* (s, 3H), 4.75-4.92, 4.99-5.07* (m, 2H),5.95*, 6.12 (s, 1H), 7.43-7.57 (m, 2H), 7.71*, 7.77 (d, 1H), 7.89-7.95(m, 1H), 7.99- 8.04 (m, 2H), 8.93 (br s, 1H), 10.58*, 10.82 (s, 1H). 438

HRMS: calculated for (C₂₄H₂₂F₆N₂O₆S + H)⁺ 581.1181; found (ESI [M + H]⁺)581.1160. 1H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 2*:1) δ 3.21,3.22* (s, 3H), 4.71- 4.92, 5.04-5.16* (m, 2H), 5.76*, 6.00 (s, 1H),7.05*, 7.54 (dd, 1H), 7.62-7.87 (m, 3H), 7.89-7.93 (m, 1H), 8.03, 8.05*(s, 1H), 8.39, 8.49* (s, 1H) 8.88 (br s, 1H), 10.98*, 11.08 (s, 1H). 439

HRMS: calculated for (C₂₄H₁₈F₇N₃O₅S + H)⁺ 594.0933; found (ESI [M + H]⁺)594.0890. ¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 6*:1) δ1.49-1.87 (m, 4H), 3.21, 3.23* (s, 3H), 4.86-5, 5.33-5.43* (m, 2H),5.84*, 6.43 (s, 1H), 7.45-7.55 (m, 1H), 7.6- 7.69 (m, 1H), 7.73-7.84 (m,2H), 7.89- 7.97 (m, 1H), 8.04, 8.13* (s, 1H), 8.89 (s, 1H), 11.09*,11.40 (s, 1H). 440

HRMS: calculated for (C₂₄H₂₁F₇N₂O₆S + H)⁺ 599.1086; found (ESI [M + H]⁺)599.17. ¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 1*:1) δ 0.78-1.20(m, 4H), 3.18, 3.22* (s, 3H), 3.21, 3.35* (s, 3H), 4.83- 5.05,5.16-5.31* (m, 2H), 5.88*, 6.20 (s, 1H), 7.45-7.52 (m, 1H), 7.64 (dd,1H), 7.7- 7.82 (m, 2H), 7.87-7.93 (m, 1H), 8.03, 8.06* (s, 1H), 8.88 (s,1H), 11.02, 11.10* (s, 1H). 441

HRMS: calculated for (C₂₄H₂₁F₇N₂O₆S + H)⁺ 599.1086; found (ESI [M + H]⁺)599.1094. ¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 2:1 only majorreported) δ 0.84- 1.2 (m, 4H), 3.22 (d, 3H), 3.33 (s, 3H), 5.13- 5.31(m, 2H), 6.10 (s, 1H), 7.46 (d, 1H), 7.49- 7.56 (m, 1H), 7.76 (d, 1H),7.89-7.95 (m, 1H), 7.98-8.07 (m, 2H), 8.95 (s, 1H), 10.71 (s, 1H). 442

HRMS: calculated for (C₂₀H₁₅F₇N₂O₅S + H)⁺ 529.0668; found (ESI [M + H]⁺)529.0647. ¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 2:1 only majorreported) δ δ 3.23 (s, 3H), 5.02-5.16 (m, 2H), 5.99 (s, 1H), 7.47 (m,1H), 7.54 (d, 1H), 7.74 (d, 1H), 7.92-8.04 (m, 3H), 8.48 (s, 1H), 8.95(br s, 1H), 10.66 (s, 1H). 443

HRMS: calculated for (C₂₄H₂₂F₆N₂O₆S + H)⁺ 581.1181; found (ESI [M + H]⁺)581.1180. ¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers >10:1 only majorreported) δ 1.68 (s, 3H), 3.20 (s, 3H), 4.27-4.32 (m, 2H), 4.73- 4.9 (m,2H), 4.94 (dd, 2H), 5.81 (d, 1H), 7.63 (d, 2H), 7.71-7.76 (m, 3H), 7.91(d, 1H), 7.95 (s, 1H), 8.68 (s, 1H), 10.82 (s, 1H). 444

HRMS: calculated for (C₂₃H₂₀F₆N₂O₆S + H)⁺ 567.1024; found (ESI [M + H]⁺)567.1061. ¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 4:1 only majorreported) δ 3.20 (s, 3H), 4.2-4.28 (m, 1H), 4.43-4.97 (m, 6H), 5.79 (s,1H), 7.61-7.68 (m, 2H), 7.7-7.8 (m, 3H), 7.90 (d, 1H), 7.96 (s, 1H),8.71 (br s, 1H), 10.80 (s, 1H). 445

HRMS: calculated for (C₂₄H₂₂F₆N₂O₆S + H)⁺ 581.1181; found (ESI [M + H]⁺)581.1178. ¹H NMR (600 MHz, DMSO-d₆, 1:1 mixture of diastereomers, and1:1 ratio of rotamers, for each diastereomer) δ 1.51 (s, 0.75H), 1.61(s, 0.75H), 1.63 (s, 0.75H), 1.64 (s, 0.75H), 2.55- 2.65 (m, 1H), 2.84(m, 0.5H), 2.97 (m, 0.5H), 3.19 (s, 0.5H), 3.20 (s, 2.5H), 4.05- 4.11(m, 0.25H), 4.25-4.3 (m, 0.25H), 4.34- 4.51 (m, 1.5H), 4.82-4.93 (m,0.25H), 4.95- 5.03 (m, 1.25H), 5.24 (d, 0.25H), 5.32 (d, 0.25H), 5.84(d, 0.25H), 5.85 (d, 0.25H), 5.95 (d, 0.25H), 6.49 (d, 0.25H), 7.58-7.65(m, 2H), 7.69-7.77 (m, 2.5H), 7.81 (d, 0.5H), 7.87-7.91 (m, 1H), 7.99(s, 0.5H), 8.01 (s, 0.25H), 8.03 (s, 0.25H), 8.6-8.69 (m, 1H), 10.58 (s,0.25H), 10.81 (s, 0.5H), 10.87 (s, 0.25H). 446

HRMS: calculated for (C₂₃H₁₉F₇N₂O₅S + H)⁺ 569.0981; found (ESI [M + H]⁺)569.1009. ¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 2:1 only majorreported) δ 1.18- 1.48 (m, 4H) 3.22 (s, 3H), 5.22-5.32 (m, 2H), 5.90 (s,1H), 7.6-7.65 (m, 2H), 7.69-7.83 (m, 3H), 7.88-7.94 (m, 1H), 8.02-8.07(m, 1H), 8.65 (s, 1H), 10.85 (s, 1H). 447

HRMS: calculated for (C₂₄H₂₄F₆N₂O₆S + H)⁺ 583.1337; found (ESI [M + H]⁺)583.1317. ¹H NMR (600 MHz, DMSO-d₆, 1:1 mixture of diastereomers andapproximately 6:1 ratio of rotamers for each diastereomer; only majorrotamer for each diastereomer reported) δ 0.91- 0.97 (m, 3H), 1.64-1.75(m, 2H), 3.2- 3.22 (m, 3H), 3.27 (s, 1.5H), 3.31 (s, 1.5H), 3.99-4.06(m, 1H), 5.08 (dd, 1H), 5.19 (t, 1H), 5.81 (d, 0.5H), 5.87 (d, 0.5H),7.59- 7.66 (m, 2H), 7.7-7.76 (m, 3H), 7.87-7.95 (m, 1H), 8.00 (s, 1H),8.67 (s, 1H), 10.82 (s, 0.5H), 10.85 (s, 0.5H). 448

HRMS: calculated for (C₂₅H₂₄F₆N₂O₆S + H)⁺ 595.1337; found (ESI [M + H]⁺)595.1374. ¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 7:1 only majorreported) δ 1.52- 1.61 (m, 1H), 1.76-1.86 (m, 1H), 2.04-2.11 (m, 1H),2.15-2.26 (m, 1H), 2.44-2.49 (m, 1H), 2.57-2.65 (m, 1H), 3.15 (s, 3H),3.20 (s, 3H), 4.92-5.09 (m, 2H), 5.88 (d, 1H), 7.59- 7.66 (m, 2H),7.69-7.78 (m, 3H), 7.89 (d, 1H), 8.01 (s, 1H), 8.67 (s, 1H), 10.90 (s,1H). 449

HRMS: calculated for (C₂₃H₂₂F₆N₂O₆S + H)⁺ 569.1181; found (ESI [M + H]⁺)569.1174. ¹H NMR (600 MHz, DMSO d₆, 1:1 mixture of diastereomers andapproximately 6:1 ratio of rotamers for each diastereomer; only majorrotamer for each diastereomer reported) δ 1.29 (d, 1.5H), 1.32 (d,1.5H), 3.21 (s, 3H), 3.27 (s, 1.5H), 3.31 (s, 1.5H), 4.20 (q, 0.5H),4.27 (q, 0.5H), 5.03-5.1 (m, 1H), 5.12-5.24 (m, 1H), 5.80 (s, 1H), 5.84(d, 1H), 7.56-7.66 (m, 2H), 7.69-7.76 (m, 3H), 7.91 (d, 1H), 8.00 (s,1H), 10.82 (s, 0.5H), 10.83 (s, 0.5H).

Example 450:2-Acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)(1-²H)-2,3-dihydro-1H-isoindole-1-carboxamide

2-Acetyl-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-5-(methylsulfonyl)isoindoline-1-carboxamide(0.156 g, 0.30 mmol) was mixed with CD₃OD (2 mL) and triethylamine(0.082 mL, 0.59 mmol) was added. The resulting mixture was stirred atambient temperature for 18 h. A precipitate had formed and the mixturewas diluted with more CD₃OD (3 mL) and heated at 50° C. for 3 h. Themixture was then stirred at ambient temperature for 20 h. Acetic acid(2.1 equiv.) was added and the mixture was partitioned between water (5mL) and dichloromethane (50 mL). The layers were separated in a phaseseparator and the organic layer was concentrated under reduced pressureto give a white solid (0.160 g, 102%).

HRMS: calculated for (C₂₁H₁₇DF₆N₂O₅S+H)⁺ 526.0982; found: (ESI [M+H]+)526.0964.

¹H NMR (500 MHz, MeOD) δ 2.27 (s, 3H), 3.12-3.15 (m, 3H), 5.06-5.2 (m,2H), 7.66-7.76 (m, 5H), 7.94-7.98 (m, 1H), 8.02-8.06 (m, 1H).

Separation of the (1R) and the (1S) Enantiomers:

The racemate (0.14 g) was separated into the enatiomers by a preparativeSFC system equipped with a YMC SA (IA) column, 250×20, 35% isopropylalcohol 100 in CO₂ (120 bar), flow: 70 mL/min; injection volume was 5.0mL of a 14 mg/mL ethanol/dichloromethane 1/1 solution.

Isomer 1 (peak 1): 0.065 g, 99.4% ee by analytical chiral SFC(analytical conditions: YMC SA (IA) column, 150×3 mm, 3 m, 3.5 ml/min,40% IPA in CO2, 120 bar, 40° C.). HRMS: calculated for(C₂₁H₁₇DF₆N₂O₅S+H)⁺526.0982; found: (ESI [M+H]⁺) 526.0989.

¹H NMR (500 MHz, MeOD, mixture of rotamers, 6:1, only data for majorrotamer reported) δ 2.26 (s, 3H), 3.12 (s, 3H), 5.06 (d, 1H), 5.16 (d,1H), 7.66-7.69 (m, 4H), 7.70 (d, 1H), 7.93 (d, 1H), 8.02 (s, 1H).

Isomer 2 (peak 2): 0.073 g, 96.6% ee by analytical chiral SFC(analytical conditions: YMC SA (IA) column, 150×3 mm, 3 m, 3.5 ml/min,40% IPA in CO₂, 120 bar, 40° C.). HRMS: calculated for(C₂₁H₁₇DF₆N₂O₅S+H)⁺526.0982; found: (ESI [M+H]⁺) 526.0978.

¹H NMR (500 MHz, MeOD, mixture of rotamers, 6:1, only data for majorrotamer reported) δ 2.26 (s, 3H), 3.13 (s, 3H), 5.07 (d, 1H), 5.16 (d,1H), 7.66-7.69 (m, 4H), 7.70 (d, 1H), 7.94 (d, 1H), 8.02 (s, 1H).

Example 451:(1R)-2-Acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide

Step 1:(1R)—N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide

(R)-tert-Butyl1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)-5-(methylsulfonyl)isoindoline-2-carboxylate(132 g, 226.6 mmol) was suspended in isopropyl acetate (500 mL).Hydrogen chloride in isopropyl alcohol (500 ml, 2500.00 mmol) was added.The resulting mixture was stirred at 20° C. for 16½ h and thentransfered to an evaporation flask. The solvents were removed underreduced pressure at a bath temperature of 30° C. and the residue wascoevaporated with EtOAc (2×500 ml), EtOAc/Hept (1:1 800 ml) and heptane(2×400 ml), and subsequently dried under vacuum for 20 h. Thehydrochloride salt of(R)—N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-5-(methylsulfonyl)isoindoline-1-carboxamide(125 g, 106%) was obtained as a solid and used without furtherpurification in the next step.

LC/MS: m/z=483 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 3.23 (s, 3H), 4.72(d, 1H), 4.80 (d, 1H), 5.96 (s, 1H), 7.68 (d, 2H), 7.81 (d, 2H), 7.97(d, 1H), 8.02 (d, 1H), 8.06 b (s, 1H), 8.71 (s, 1H), 9.75 (bs, 1H),10.96 (bs, 1H) 11.93 (s, 1H).

Step 2:(1R)-2-Acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide

(1R)—N-(4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl)-5(methylsulfonyl)isoindoline-1-carboxamide hydrochloride (125 g, 216.82mmol) was dissolved in ethyl acetate (1250 mL). Acetic acid (24.82 mL,433.64 mmol) and pyridine (73.8 mL, 867.29 mmol) was added. T3P in ethylacetate (50% in EtOAc, 258 mL, 433.64 mmol) was added slowly over 10 minand the resultant mixture was stirred for 30 min. The reaction mixturewas diluted with EtOAc (500 mL) and washed with an aqueous solution ofcitric acid (1M, 2×750 ml), aqueous NaHCO₃ (4%, 2×750 ml) and water (500ml). The organic layer was evaporated and the resulting greyish foamcrushed and dried under vacuum overnight. The crude solid (123 g) wasdissolved in EtOAc (300 mL) and the material was filtered through a plugof silica gel (450 g) and eluted with EtOAc (1000 mL). The filtrate wasevaporated, and the crude was dissolved in EtOAc (600 mL) and cooled to10° C. n-Heptane (275 mL) was added slowly. Seed crystals were addedafter addition of half of the heptane. After addition, the temperatureof the mixture was raised to 55° C. for 50 min. The cycling between 10and 55° C. was then repeated two more times. The precipitate wasfiltered off using a P3 glas filter and the solid was washed withEtOAc/heptane (1:1 400 ml) and heptane (200 ml), and then dried in thefunnel for 30 min, before being dried in the vacuum oven at 30° C. for 2h.(1R)-2-Acetyl-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-5-(methylsulfonyl)isoindoline-1-carboxamide(62.6 g, 51.5%) was obtained as a solid (mp=228° C.).

Analytical chiral SFC 99.9% ee (analytical conditions: 1 mg ofcompound/ml in ACN; CelluCoat column, 150×4.6 mm, 3 m, 3.5 ml/min, 25%IPA in CO₂, 120 bar, 40° C., 240 nm). [α]D₅₈₉+108° (c=1.0, CH₃CN, 20°C.).

HRMS: calculated for (C₂₁H₁₈F₆N₂O₅S+H)⁺525.0919; found: (ESI [M+H]⁺)525.0917.

¹H NMR (400 MHz, DMSO-d₆, mixture of rotamers, 4*:1) δ 1.99, 2.15* (s,3H), 3.22, 3.23* (s, 3H), 4.79 (d, 1H), 4.89 (d, 1H), 4.98-5.11* (m,2H), 5.73*, 5.93 (s, 1H), 7.6-7.81 (m, 5H), 7.88-7.92 (m, 1H), 8.00*,8.03 (s, 1H), 8.64*, 8.67 (s, 1H), 10.70*, 10.92 (s, 1H).

The mother liqour was evaporated and the solid was dissolved in ethylacetate (200 mL) and heptane (90 mL) was slowly added. After about halfof the heptane was added, seed crystal were added, and the mixture washeated to 55° C. for 64 h. The solid was filtered off and washed withEtOAc/Hept (1:1, 120 ml) and Heptane (2×120 ml), dried in the funnel for15 min and then under vacuum at 40° C. for 72 h. A second batch of(1R)-2-acetyl-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-5-(methylsulfonyl)isoindoline-1-carboxamide(30.0 g, 24.7%) was thus obtained as a solid. 98.3% ee by analyticalchiral SFC (analytical conditions: 1 mg of compound/ml in ACN; CelluCoatcolumn, 150×4.6 mm, 3 m, 3.5 ml/min, 25% IPA 100 in CO₂, 120 bar, 40°C., 240 nm). [α]_(D) ⁵⁸⁹+1030 (c=1.0, ACN).

The seed crystals were obtained from 440 mg crude(1R)-2-Acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide,prepared as described above, by crystallization from EtOAc and heptane,and leaving the mixture stirring overnight. The solid was filtered offto give a colorless solid (377 mg, 85%) and washed with EtOAc/heptane(1:4, 1.3 ml) and heptane (1 ml).

Example 452:(1R)—N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(2-methyloxetan-2-yl)carbonyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide

(R)—N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-5-(methylsulfonyl)isoindoline-1-carboxamide,HCl (620 mg, 1.19 mmol) was suspended in DCM (10 mL) and to this2-methyloxetane-2-carboxylic acid (278 mg, 2.39 mmol) and pyridine(0.242 mL, 2.99 mmol) was added followed by T3P (1.423 mL, 2.39 mmol,50% in EtOAc). The reaction was stirred at RT for 1 hr. LCMS indicatedcomplete conversion to product. The reaction was diluted with DCM andwashed with 0.5M HCl. The layers were separated using a phase sep andconcentrated in vacuo. The crude product (690 mg) was purified on apreparative SFC system equipped with a YMC SA (IA) column, 250×20, 5 μM,18% IPA in CO₂ (160 bar), flow: 70 mL/min; injection volume was 0.30 mLof a 138 mg/mL ethanol solution.

Isomer 1 (peak 1): 160 mg, 23% yield; 99.9% ee by analytical chiral SFC(analytical conditions: YMC SA (IA) column, 150×4.6 mm, 3 μm, 3.5ml/min, 25% IPA in CO₂, 120 bar, 40° C.). [α]_(D) ⁵⁸⁹+92° (c=0.6,CH₃CN).

HRMS: calculated for (C₂₄H₂₂F₆N₂O₆S+H)⁺581.1181; found (ESI [M+H]⁺)581.1182.

¹H NMR (500 MHz, DMSO-d₆, 1:1 ratio of rotamers) δ 1.51 (s, 1.5H), 1.63(s, 1.5H), 2.51-2.7 (m, 1H), 2.77-2.88 (m, 0.5H), 2.87-2.97 (m, 0.5H),3.17 (s, 1.5H), 3.20 (s, 1.5H), 4.34-4.56 (m, 2H), 4.89 (d, 0.5H), 4.99(d, 1H), 5.24 (d, 0.5H), 5.85 (s, 0.5H), 6.49 (s, 0.5H), 7.63 (dd, 2H),7.69-7.78 (m, 2.5H), 7.81 (d, 0.5H), 7.90 (d, 1H), 7.99 (s, 0.5H), 8.03(s, 0.5H), 8.66 (s, 1H), 10.80 (s, 0.5H), 10.86 (s, 0.5H).

Isomer 2 (peak 2): 172 mg, 25% yield; 98.5% ee by analytical chiral SFC(analytical conditions: YMC SA (IA) column, 150×4.6 mm, 3 m, 3.5 ml/min,25% IPA in CO₂, 120 bar, 40° C.). [α]_(D) ⁵⁸⁹+94° (c=0.6, CH₃CN).

HRMS: calculated for (C₂₄H₂₂F₆N₂O₆S+H)⁺581.1181; found (ESI [M+H]+)581.1159.

¹H NMR (500 MHz, DMSO-d₆, 1:1 ratio of rotamers) δ 1.61 (s, 1.5H), 1.64(s, 1.5H), 2.51-2.64 (m, 1H), 2.81-2.88 (m, 0.5H), 2.97-3.03 (m, 0.5H),3.19 (s, 1.5H), 3.2 (s, 1.5H), 4.04-4.12 (m, 0.5H), 4.25-4.31 (m, 0.5H),4.33-4.4 (m, 0.5H), 4.46-4.52 (m, 0.5H), 4.87 (d, 0.5H), 4.96 (s, 0.5H),5.02 (d, 0.5H), 5.33 (d, 0.5H), 5.84 (s, 0.5H), 5.95 (s, 0.5H), 7.61(dd, 2H), 7.73 (dd, 2.5H),

Example 453:N¹-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-N²-methyl-5-(methylsulfonyl)-1,3-dihydro-2H-isoindole-1,2-dicarboxamide

Methyl isocyanate (21.99 mg, 0.39 mmol) was added to a mixture ofN-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-5-(methylsulfonyl)isoindoline-1-carboxamide,HCl (100 mg, 0.19 mmol) and triethylamine (0.081 mL, 0.58 mmol) in DCM(1 mL)/THF (1 mL). The reaction was stirred at room temperature for 15min. The reaction mixture was diluted with EtOAc and washed withsaturated brine. The layers were separated and the organic layer wasdried using a phase separator cartridge. The solvent was removed invacuo and the residue triturated with DCM. The solid obtained wascollected by filtration and washed with DCM before being dried undervacuum. The title compound (84 mg, 81%) was obtained as a colorlesssolid.

HRMS: calculated for (C₂₁H₁₉F₆N₃O₅S+H)⁺540.1028; found: (ESI [M+H]⁺)540.1050.

¹H NMR (500 MHz, DMSO d₆) δ 2.64 (d, 3H), 3.22 (s, 3H), 4.75 (d, 1H),4.82 (dd, 1H), 5.66 (d, 1H), 6.59 (q, 1H), 7.61 (d, 2H), 7.68 (d, 1H),7.73 (d, 2H), 7.88 (dd, 1H), 7.96 (s, 1H), 8.62 (s, 1H), 10.60 (s, 1H).

Examples 454-456

Examples 454-456 (Table 4C) were prepared using a similar procedures tothose described in the preceding examples.

-   Example 454:    N²-Ethyl-N¹-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-1,3-dihydro-2H-isoindole-1,2-dicarboxamide-   Example 455:    N¹-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-1,3-dihydro-2H-isoindole-1,2-dicarboxamide-   Example 456:    N²—Cyclopropyl-N¹-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-1,3-dihydro-2H-isoindole-1,2-dicarboxamide

TABLE 4C Example No. Structure NMR + MS 454

HRMS: calculated for (C₂₂H₂₁F₆N₃O₅S + H)⁺ 554.1184; found (ESI [M + H]⁺)554.1165. ¹H NMR (600 MHz, DMSO d₆) δ 1.06 (t, 3H), 3.05-3.17 (m, 2H),3.22 (s, 3H), 4.75 (d, 1H), 4.82 (dd, 1H), 5.66 (d, 1H), 6.63 (t, 1H),7.61 (d, 2H), 7.68 (d, 1H), 7.72 (d, 2H), 7.88 (d, 1H), 7.95 (s, 1H),8.66 (s, 1H), 10.62 (s, 1H). 455

HRMS: calculated for (C₂₀H₁₇F₆N₃O₅S + H)⁺ 526.0871; found (ESI [M + H]⁺)526.0860. ¹H NMR (500 MHz, DMSO-d₆) δ 3.22 (s, 3H), 4.77 (d, 1H), 4.84(dd, 1H), 5.64 (d, 1H), 6.23 (s, 2H), 7.61 (d, 2H), 7.68 (d, 1H), 7.73(d, 2H), 7.87 (d, 1H), 7.94 (s, 1H), 8.62 (s, 1H), 10.59 (s, 1H). 456

HRMS: calculated for (C₂₃H₂₁F₆N₃O₅S + H)⁺ 566.1184; found (ESI [M + H]⁺)566.1182. ¹H NMR (600 MHz, DMSO d6) δ 0.39-0.52 (m, 2H), 0.54-0.63 (m,2H), 2.55-2.58 (m, 1H), 3.21 (s, 3H), 4.71 (d, 1H), 4.79 (dd, 1H), 5.66(d, 1H), 6.77 (d, 1H), 7.62 (d, 2H), 7.67 (d, 1H), 7.72 (d, 2H), 7.87(d, 1H), 7.92 (s, 1H), 8.67 (s, 1H), 10.62 (s, 1H).

Example 500:2-Acetyl-5-(cyclopropylsulfamoyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide

DIPEA (0.162 mL, 0.92 mmol) was added to2-acetyl-5-(cyclopropylsulfamoyl)-2,3-dihydro-1H-isoindole-1-carboxylicacid (100 mg, 0.31 mmol),2-(4-aminophenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol (88 mg, 0.34 mmol)and HATU (129 mg, 0.34 mmol) in DCM (5 mL) under nitrogen. The resultingsolution was stirred at room temperature for 1 hour. The reactionmixture was quenched with saturated NH₄Cl (20 mL), extracted with DCM(3×20 mL), the organic layer was dried over Na₂SO₄, filtered andevaporated to afford dark solid. The crude product was purified by flashsilica chromatography, elution gradient 0 to 100% EtOAc in petroleumether. Pure fractions were evaporated to dryness to afford2-acetyl-5-(cyclopropylsulfamoyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide(40.0 mg, 22.94%) as a colorless solid. LC/MS: m/z=566 [M+H]⁺.

HRMS: calculated for (C₂₃H₂₁F₆N₃O₅S+H)⁺566.1184; found (ESI [M+H]⁺)566.1185.

¹H NMR (400 MHz, DMSO-d₆, mixture of rotamers, 4.5*:1) δ 0.36-0.54 (m,4H), 1.99, 2.15* (s, 3H), 2.08-2.10 (m, 1H), 4.76-4.93, 5.00-5.09* (m,2H), 5.71*, 5.91 (s, 1H), 7.61-7.70 (m, 3H), 7.71-7.82 (m, 3H),7.84-7.92 (m, 1H), 8.00, 8.02* (d, 1H), 8.67*, 8.69 (s, 1H), 10.71*,10.94 (s, 1H).

Example 600:5-(Cyclopropylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide

HCl (gas) was bubbled into a solution of tert-butyl5-(cyclopropylsulfonyl)-1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)isoindoline-2-carboxylate(1.3 g, 2.14 mmol) in DCM (20 mL) at room temperature and the resultingmixture was stirred at room temperature for 3 hours. The reactionmixture was basified with saturated Na₂CO₃. The reaction mixture wasextracted with DCM (3×25 mL), the organic layer was dried over Na₂SO₄,filtered and evaporated to afford yellow oil. The crude product waspurified by flash C18-flash chromatography, elution gradient 0 to 30%MeCN in water. Pure fractions were evaporated to dryness to afford5-(cyclopropylsulfonyl)-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)isoindoline-1-carboxamide(0.750 g, 69.1%) as a pale yellow solid.

HRMS: calculated for (C₂₁H₁₈F₆N₂O₄S+H)⁺509.0970; found (ESI [M+H]⁺)509.0957.

¹H NMR (300 MHz, DMSO-d₆) δ 0.98-1.2 (m, 4H), 2.76-2.95 (m, 1H),3.87-4.11 (m, 1H), 4.24-4.53 (m, 2H), 5.10 (s, 1H), 7.59-7.66 (m, 2H),7.7-7.76 (m, 1H), 7.77-7.88 (m, 4H), 8.65 (s, 1H), 10.35 (s, 1H).

Example 601:2-Acetyl-5-(cyclopropylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide

5-(Cyclopropylsulfonyl)-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)isoindoline-1-carboxamide(50 mg, 0.10 mmol) was added to AcOH (6.2 μl, 0.11 mmol), HATU (41.1 mg,0.11 mmol) and DIPEA (0.052 mL, 0.30 mmol) in DCM (2 mL) under nitrogen.The resulting solution was stirred at room temperature for 1 hour. Thereaction mixture was quenched with saturated NH₄Cl (10 mL), extractedwith DCM (3×10 mL), the organic layer was dried over Na₂SO₄, filteredand evaporated to afford yellow oil. The crude product was purified byflash silica chromatography, elution gradient 0 to 70% EtOAc inpetroleum ether. Pure fractions were evaporated to dryness to afford thetitle compound (50 mg, 78%) as a white solid. LC/MS: m/z=551 [M+H]⁺.HRMS: calculated for (C₂₃H₂₀F₆N₂O₅S+H)⁺551.1075; found (ESI [M+H]⁺)551.1071.

¹H NMR (300 MHz, DMSO-d₆, mixture of rotamers, 4.5*:1) 0.97-1.27 (m,4H), 1.98, 2.14* (s, 3H), 2.68-2.91 (m, 1H), 4.73-5.11 (m, 2H), 5.72*,5.92 (s, 1H), 7.58-7.84 (m, 5H), 7.84-7.92 (m, 1H), 7.94-8.03 (m, 1H),8.66, 8.68 (s, 1H), 10.71*, 10.94 (s, 1H).

Example 602: Methyl5-(cyclopropylsulfonyl)-1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-1,3-dihydro-2H-isoindole-2-carboxylate

Methyl carbonochloridate (22.30 mg, 0.24 mmol) was added dropwise to5-(cyclopropylsulfonyl)-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)isoindoline-1-carboxamide(60 mg, 0.12 mmol) in DCM (5 mL) cooled to 0° C. under nitrogen. Theresulting mixture was stirred at room temperature for 2 hours. Thereaction mixture was quenched with water (20 mL), extracted with DCM(3×25 mL), the organic layer was dried over Na₂SO₄, filtered andevaporated to afford yellow solid. The crude product was purified byflash C18-flash chromatography, elution gradient 10 to 80% MeCN inwater. Pure fractions were evaporated to dryness to afford the titlecompound (40 mg, 59.8%) as a solid. LC/MS: m/z=567 [M+H]⁺.

HRMS: calculated for (C₂₃H₂₀F₆N₂O₆S+H)⁺567.1024; found (ESI [M+H]⁺)567.1041.

¹H NMR (400 MHz, DMSO-d₆, mixture of rotamers, 1.3*:1) 8 0.98-1.21 (m,4H), 2.81-2.91 (m, 1H), 3.64, 3.71* (s, 3H), 4.79-4.91 (m, 2H), 5.68*,5.70 (s, 1H), 7.61-7.68 (m, 2H), 7.69-7.78 (m, 3H), 7.84-7.9 (m, 1H),7.96-8.02 (m, 1H), 8.68 (s, 1H), 10.79*, 10.81 (s, 1H).

Examples 603-609

Examples 603-609 (Table 6) were prepared using similar procedures tothose described in the preceding examples. Example 610 was preparedusing a similar procedure to those described for Examples 314 or 453.

-   Example 603:    5-(Cyclopropylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(1-methoxycyclopropyl)carbonyl]-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 604:    5-(Cyclopropylsulfonyl)-2-formyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 605:    5-(Cyclopropylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(hydroxyacetyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 606:    5-(Cyclopropylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(methoxyacetyl)-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 607:    2-[(1-Cyanocyclopropyl)carbonyl]-5-(cyclopropylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 608:    5-(Cyclopropylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(2S)-tetrahydrofuran-2-ylcarbonyl]-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 609:    5-(Cyclopropylsulfonyl)-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(2R)-tetrahydrofuran-2-ylcarbonyl]-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 610:    5-(Cyclopropylsulfonyl)-N′-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-N²-methyl-1,3-dihydro-2H-isoindole-1,2-dicarboxamide

TABLE 6 Example No. Structure NMR + MS 603

HRMS: calculated for (C₂₆H₂₄F₆N₂O₆S + H)⁺ 607.1337; found (ESI [M + H]⁺)607.1351. ¹H NMR (400 MHz, DMSO-d₆, mixture of rotamers, 2.3*:1) δ0.84-1.21 (m, 8H), 2.80- 2.90 (m, 1H), 3.19, 3.36* (s, 3H), 4.85- 5.04,5.19-5.31* (m, 2H), 5.90*, 6.22 (s, 1H), 7.60-7.69 (m, 2H), 7.70-7.84(m, 3H), 7.86-7.91 (m, 1H), 8.00-8.06 (m, 1H), 8.66, 8.68* (s, 1H),10.83, 10.90* (s, 1H). 604

HRMS: calculated for (C₂₂H₁₈F₆N₂O₅S + H)⁺ 537.0919; found (ESI [M + H]⁺)537.0928. ¹H NMR (400 MHz, DMSO-d₆, mixture of rotamers, 1.8*:1) δ0.98-1.32 (m, 4H), 2.86 (s, 1H), 4.74-4.94, 5.04-5.19* (m, 2H), 5.78*,5.99 (s, 1H), 7.61-7.69 (m, 2H), 7.71- 7.93 (m, 4H), 7.98-8.06 (m, 1H),8.40, 8.49* (s, 1H), 8.66*, 8.67 (s, 1H), 10.77*, 10.87 (s, 1H). 605

HRMS: calculated for (C₂₃H₂₀F₆N₂O₆S + H)⁺ 567.1024; found (ESI [M + H]⁺)567.1004. ¹H NMR (300 MHz, DMSO-d₆, mixture of rotamers, 5*:1) δ0.98-1.21 (m, 4H), 2.81- 2.93 (m, 1H), 3.87-4.34 (m, 2H), 4.81-5.25 (m,3H), 5.80*, 6.01 (s, 1H), 7.58-7.84 (m, 5H), 7.89 (d, J = 9.0 Hz, 1H),8.00 (d, J = 12.1 Hz, 1H), 8.67*, 8.69 (s, 1H), 10.77*, 10.95 (s, 1H).606

HRMS: calculated for (C₂₄H₂₂F₆N₂O₆S + H)⁺ 581.1181; found (ESI [M + H]⁺)581.1175. ¹H NMR (300 MHz, DMSO-d₆, mixture of rotamers, 5*:1) δ0.97-1.29 (m, 5H), 2.80- 2.92 (m, 1H), 3.27, 3.36* (s, 3H), 3.93-4.13,4.16-4.34* (m, 2H), 4.81-5.07 (m, 2H), 5.80*, 5.99 (s, 1H), 7.64 (d, J =8.3 Hz, 2H), 7.7-7.81 (m, 3H), 7.88 (d, J = 8.0 Hz, 1H), 7.97-8.03 (m,1H), 8.67 (s, 1H), 10.78*, 10.88 (s, 1H). 607

HRMS: calculated for (C₂₆H₂₁F₆N₃O₅S + H)⁺ 602.1184; found (ESI [M + H]⁺)602.1210. ¹H NMR (300 MHz, DMSO-d₆, mixture of rotamers, 6*:1) δ0.98-1.17 (m, 4H), 1.52- 1.65 (m, 2H), 1.65-1.78 (m, 2H), 2.80-2.92 (m,1H), 4.86-5.00, 5.32-5.43* (m, 2H), 5.85*, 6.44 (s, 1H), 7.60-7.69 (m,2H), 7.69- 7.81 (m, 3H), 7.86-7.99 (m, 1H), 8.00- 8.14 (m, 1H), 8.67 (s,1H), 10.89*, 11.22 (s, 1H). 608

HRMS: calculated for (C₂₆H₂₄F₆N₂O₆S + H)⁺ 607.1337; found (ESI [M + H]⁺)607.1342. 1H NMR (300 MHz, DMSO-d₆, mixture of 4 isomers, only 2 mainisomers reported) δ 0.97- 1.27 (m, 4H), 1.72-2.00 (m, 2H), 2.00- 2.27(m, 2H), 2.80-2.91 (m, 1H), 3.75-3.91 (m, 2H), 4.69-4.78 (m, 1H),5.00-5.24 (m, 2H), 5.77*, 5.79 (s, 1H), 7.63 (d, J = 8.7 Hz, 2H),7.68-7.77 (m, 3H), 7.84-7.91 (m, 1H), 7.95-8.01 (m, 1H), 8.67 (s, 1H),10.78*, 10.80 (s, 1H). 609

HRMS: calculated for (C₂₆H₂₄F₆N₂O₆S + H)⁺ 607.1337; found (ESI [M + H]⁺)607.1320. 1H NMR (300 MHz, DMSO-d₆, mixture of 4 isomers, only 2 mainisomers reported) δ 1.00- 1.16 (m, 4H), 1.81-1.93 (m, 2H), 2.00- 2.27(m, 2H), 2.79-2.9 (m, 1H), 3.73-3.92 (m, 2H), 4.68-4.79 (m, 1H),5.00-5.13 (m, 1H), 5.13-5.24 (m, 1H), 5.77*, 5.78 (s, 1H), 7.63 (d, J =8.6 Hz, 2H), 7.68-7.77 (m, 3H), 7.84-7.90 (m, 1H), 7.95-8.01 (m, 1H),8.63- 8.72 (m, 1H), 10.78*, 10.80 (s, 1H). 610

HRMS: calculated for (C₂₃H₂₁F₆N₃O₅S + H)⁺ 566.1184; found (ESI [M + H]⁺)566.1199. ¹H NMR (300 MHz, DMSO-d₆) δ 0.98-1.08 (m, 2H), 2.65 (d, 3H),2.81-2.94 (m, 1H), 4.75 (d, 1H), 4.83 (dd, 1H), 5.67 (d, 1H), 6.60 (q,1H), 7.62 (d, 2H), 7.68 (d, 1H), 7.75 (d, 2H), 7.85 (dd, 1H), 7.94 (s,1H), 8.65 (s, 1H), 10.63 (s, 1H).

Example 700:N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-[(2-methoxyethyl)sulfonyl]-2,3-dihydro-1H-isoindole-1-carboxamide

HCl (gas) (0.171 mL, 5.63 mmol) was passsed through a solution oftert-butyl1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)-5-((2-methoxyethyl)sulfonyl)isoindoline-2-carboxylate(3.53 g, 5.63 mmol) in DCM (35 mL). The resulting mixture was stirred atroom temperature for 3 hours. The reaction mixture was basified withsaturated NaHCO₃. The reaction mixture was extracted with DCM (3×50 mL),the organic layer was dried over Na₂SO₄, filtered and evaporated toafford brown oil. The crude product was purified by flash C18-flashchromatography, elution gradient 0 to 50% MeCN in water. Pure fractionswere evaporated to dryness to afford the title compound (2.110 g, 71.1%)as a solid. LC/MS: m/z=527 [M+H]⁺.

HRMS: calculated for (C₂₁H₂₀F₆N₂O₅S+H)⁺527.1075; found (ESI [M+H]⁺)527.1071.

¹H NMR (300 MHz, DMSO-d₆) δ 3.10 (s, 3H), 3.51-3.65 (m, 4H), 4.38 (s,2H), 5.08 (s, 1H), 7.60 (d, 2H), 7.70 (d, 1H), 7.74-7.89 (m, 4H), 8.63(s, 1H), 10.33 (s, 1H).

Example 701:2-Formyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-[(2-methoxyethyl)sulfonyl]-2,3-dihydro-1H-isoindole-1-carboxamide

DIPEA (0.080 mL, 0.46 mmol) was added toN-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-5-((2-methoxyethyl)sulfonyl)isoindoline-1-carboxamide(80 mg, 0.15 mmol), formic acid (13.99 mg, 0.30 mmol) and HATU (63.6 mg,0.17 mmol) in DCM (10 mL) under nitrogen. The resulting solution wasstirred at room temperature for 5 hours. The reaction mixture wasquenched with saturated NH₄Cl (15 mL), extracted with DCM (3×20 mL), theorganic layer was dried over Na₂SO₄, filtered and evaporated to affordyellow solid. The crude product was purified by flash C18-flashchromatography, elution gradient 0 to 50% MeCN in water. Pure fractionswere evaporated to dryness to afford the title compound (67.0 mg, 80%)as a white solid. LC/MS: m/z=555 [M+H]⁺. HRMS: calculated for(C₂₂H₂₀F₆N₂O₆S+H)⁺555.1024; found (ESI [M+H]⁺) 555.117.

¹H NMR (300 MHz, DMSO-d₆, mixture of rotamers, 1.7*:1) δ 3.11 (s, 3H),3.63 (s, 4H), 4.72-4.94, 5.03-5.21* (m, 2H), 5.78*, 6.00 (s, 1H),7.59-7.94 (m, 6H), 8.02 (s, 1H), 8.40, 8.50* (s, 1H), 8.68 (s, 1H),10.79*, 10.89 (s, 1H).

Example 702:2-Acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-[(2-methoxyethyl)sulfonyl]-2,3-dihydro-1H-isoindole-1-carboxamide

Following the procedure in example 701 but using acetic acid instead offormic acid, a brown oil was obtained after work-up. The crude productwas purified by flash C18-flash chromatography, elution gradient 0 to30% MeCN in water. Pure fractions were evaporated to dryness to affordthe title compound (20 mg, 6.67%) as a white solid. LC/MS: m/z=569[M+H]⁺.

HRMS: calculated for (C₂₃H₂₂F₆N₂O₆S+H)⁺569.1181; found (ESI [M+H]⁺)569.1197.

¹H NMR (300 MHz, DMSO-d₆, mixture of rotamers, 4.2*:1) δ 1.98, 2.14* (s,3H), 3.06-3.11 (m, 3H), 3.60 (s, 4H), 4.72-5.08 (m, 2H), 5.72*, 5.95 (s,1H), 7.57-7.80 (m, 5H), 7.82-7.88 (m, 1H), 7.93-8.00 (m, 1H), 8.66 (s,1H), 10.73*, 11.01 (s, 1H).

Example 703:N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-[(1-methoxycyclopropyl)carbonyl]-5-[(2-methoxyethyl)sulfonyl]-2,3-dihydro-1H-isoindole-1-carboxamide

Following the procedure in example 701 but using1-methoxycyclopropanecarboxylic acid instead of formic acid afforded acolorless solid as the crude product, which was purified by flashC18-flash chromatography, elution gradient 0 to 70% MeCN in water. Purefractions were evaporated to dryness to affordN-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-2-(1-methoxycyclopropanecarbonyl)-5-((2-methoxyethyl)sulfonyl)isoindoline-1-carboxamide(50.8 mg, 86%) as a colorless solid.

HRMS: calculated for (C₂₆H₂₆F₆N₂O₇S+H)⁺625.1443; found (ESI [M+H]⁺)625.1461.

¹H NMR (400 MHz, DMSO-d₆, mixture of rotamers, 2.2*:1) δ 0.83-1.27 (m,4H), 3.11, 3.12* (s, 3H), 3.19, 3.36* (s, 3H), 3.55-3.66 (m, 4H),4.86-5.04, 5.18-5.31* (m, 2H), 5.90*, 6.22 (s, 1H), 7.60-7.68 (m, 2H),7.7-7.82 (m, 3H), 7.84-7.91 (m, 1H), 7.98-8.05 (m, 1H), 8.66, 8.68* (s,1H), 10.82, 10.90* (s, 1H).

Examples 704-706 (Table 7) were prepared using similar procedures tothose described in the preceding examples. Example 707 was preparedusing a similar procedure to those described for Examples 314 or 453.

-   Example 704: Methyl    1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-5-[(2-methoxyethyl)sulfonyl]-1,3-dihydro-2H-isoindole-2-carboxylate-   Example 705:    N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(hydroxyacetyl)-5-[(2-methoxyethyl)sulfonyl]-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 706:    N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(methoxyacetyl)-5-[(2-methoxyethyl)sulfonyl]-2,3-dihydro-1H-isoindole-1-carboxamide-   Example 707:    N′-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-[(2-methoxyethyl)    sulfonyl]-N²-methyl-1,3-dihydro-2H-isoindole-1,2-dicarboxamide

TABLE 7 Example No. Structure NMR + MS 704

HRMS: calculated for (C₂₃H₂₂F₆N₂O₇S + H)⁺ 585.1130; found (ESI [M + H]⁺)585.1130. ¹H NMR (300 MHz, DMSO-d₆, mixture of rotamers, 1.4*:1) δ 3.09(s, 3H), 3.56-3.73 (m, 7H), 4.80-4.91 (m, 2H), 5.68 (m, 1H), 7.56-7.77(m, 5H), 7.86 (d, J = 8.1 Hz, 1H), 7.97 (d, J = 6.1 Hz, 1H), 8.67 (s,1H), 10.77, 10.79* (s, 1H). 705

HRMS: calculated for (C₂₃H₂₂F₆N₂O₇S + H)⁺ 585.1130; found (ESI [M + H]⁺)585.1145. ¹H NMR (300 MHz, DMSO-d₆, mixture of rotamers, 5*:1) δ 3.09(s, 3H), 3.57-3.64 (m, 4H), 3.86-4.33 (m, 2H), 4.80-5.10 (m, 3H), 5.79*,6.00 (s, 1H), 7.59-7.66 (m, 2H), 7.68-7.80 (m, 3H), 7.83-7.91 (m, 1H),7.93-8.02 (s, 1H), 8.66*, 8.68 (s, 1H), 10.75*, 10.92 (s, 1H). 706

HRMS: calculated for (C₂₄H₂₄F₆N₂O₇S + H)⁺ 599.1287; found (ESI [M + H]⁺)599.1309. ¹H NMR (300 MHz, DMSO-d₆, mixture of rotamers, 4*:1) δ 3.09(s, 3H), 3.26, 3.36* (s, 3H), 3.61 (s, 4H), 3.93-4.12, 4.17-4.32* (m,2H), 4.78-5.16 (m, 2H), 5.79*, 5.99 (s, 1H), 7.64 (d, J = 8.7 Hz, 2H),7.68-7.81 (m, 3H), 7.87 (d, J = 8.1 Hz, 1H), 7.95- 8.01 (m, 1H), 8.68(s, 1H), 10.79* 10.89 (s, 1H). 707

HRMS: calculated for (C₂₃H₂₃F₆N₃O₆S + H)⁺ 584.1290; found (ESI [M + H]⁺)584.1282. 1H NMR (300 MHz, DMSO-d₆) δ 2.65 (d, 3H), 3.11 (s, 3H), 3.63(s, 4H), 4.75 (d, 1H), 4.84 (d, 1H), 5.67 (d, 1H), 6.62 (d, 1H), 7.63(d, 2H), 7.68 (d, 1H), 7.75 (d, 2H), 7.85 (dd, 1H), 7.94 (s, 1H), 8.66(s, 1H), 10.64 (s, 1H).

Example 800:N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-[(2-hydroxyethyl)sulfonyl]-2,3-dihydro-1H-isoindole-1-carboxamide

Diethylamine (59.7 mg, 0.82 mmol) was added to (9H-fluoren-9-yl)methyl1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)-5-((2-hydroxyethyl)sulfonyl)isoindoline-2-carboxylate(60 mg, 0.08 mmol) in DCM (3 mL) at 25° C. over a period of 10 minutesunder nitrogen. The resulting solution was stirred at 25° C. for 4hours. The solvent was removed under reduced pressure. The crude productwas purified by flash silica chromatography, elution gradient 50 to 70%EtOAc in petroleum ether. Pure fractions were evaporated to dryness toaffordN-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-5-((2-hydroxyethyl)sulfonyl)isoindoline-1-carboxamide(25.0 mg, 59.7%) as a white solid. LC/MS: m/z=513 [M+H]⁺.

HRMS: calculated for (C₂₀H₁₈F₆N₂O₅S+H)⁺513.0919; found (ESI [M+H]⁺)513.0927.

¹H NMR (400 MHz, DMSO-d₆, mixture of rotamers, 4.5*:1, only major isomerreported) δ 3.43 (t, 2H), 3.67 (q, 2H), 3.94 (br.s, 1H), 4.33-4.46 (m,2H), 4.86 (t, 1H), 5.09 (s, 1H), 7.57-7.65 (m, 2H), 7.68-7.74 (m, 1H),7.76-7.87 (m, 4H), 8.64 (s, 1H), 10.34 (s, 1H).

Example 801:2-Acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-[(2-hydroxyethyl)sulfonyl]-2,3-dihydro-1H-isoindole-1-carboxamide

Tribromoborane (485 mg, 1.93 mmol) was added dropwise to2-acetyl-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-5-((2-methoxyethyl)sulfonyl)isoindoline-1-carboxamide(220 mg, 0.39 mmol) in DCM (20 mL) cooled to −40° C. over a period of 30minutes under nitrogen. The resulting solution was stirred at 0° C. for1 hour. The reaction mixture was quenched with saturated NaHCO₃ (25 mL),extracted with DCM (3×25 mL). The precipitate was collected byfiltration, washed with DCM (20 mL) and dried under vacuum to afford2-acetyl-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-5-((2-hydroxyethyl)sulfonyl)isoindoline-1-carboxamide(42.0 mg, 17.95%) as a white solid. LC/MS: m/z=555 [M+H]⁺.

HRMS: calculated for (C₂₂H₂₀F₆N₂O₆S+H)⁺555.1024; found (ESI [M+H]⁺)555.1019.

¹H NMR (300 MHz, DMSO-d₆, mixture of rotamers, 4.4*:1) δ 1.98, 2.14* (s,3H), 3.45 (t, 2H), 3.67 (q, 2H), 4.78-4.91, 5.00-5.07* (m, 3H), 5.74*,5.92 (s, 1H), 7.58-7.78 (m, 5H) 7.83-7.89 (m, 1H), 7.93-8.00 (m, 1H),8.64*, 8.67 (s, 1H), 10.70*, 10.94 (s, 1H).

Example 802:N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-[(2-hydroxyethyl)sulfonyl]-2-[(1-methoxycyclopropyl)carbonyl]-2,3-dihydro-1H-isoindole-1-carboxamide

Step 1:5-((2-((tert-Butyldimethylsilyl)oxy)ethyl)sulfonyl)-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-2-(1-methoxycyclopropanecarbonyl)isoindoline-1-carboxamide

DIPEA (0.084 ml, 0.48 mmol) was added to5-((2-((tert-butyldimethylsilyl)oxy)ethyl)sulfonyl)-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)isoindoline-1-carboxamide(100 mg, 0.16 mmol), 1-methoxycyclopropanecarboxylic acid (37.1 mg, 0.32mmol) and HATU (66.7 mg, 0.18 mmol) in under nitrogen. The resultingsolution was stirred at room temperature for 2 hours. The crude productwas purified by flash silica chromatography, elution gradient 0 to 70%EtOAc in petroleum ether. Pure fractions were evaporated to dryness toafford the title compound (120 mg, 104%) as a colourless dry film.

LC/MS: m/z=725 [M+H]⁺.

Step 2:N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-[(2-hydroxyethyl)sulfonyl]-2-[(1-methoxycyclopropyl)carbonyl]-2,3-dihydro-1H-isoindole-1-carboxamide

Triethylamine trihydrofluoride (0.270 mL, 1.66 mmol) was added to5-((2-((tert-butyldimethylsilyl)oxy)ethyl)sulfonyl)-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-2-(1-methoxycyclopropanecarbonyl)isoindoline-1-carboxamide(120 mg, 0.17 mmol) in THF (6 mL) under nitrogen. The resulting solutionwas stirred at room temperature for 2 hours. The crude product waspurified by preparative HPLC (XBridge Prep C18 OBD column usingdecreasingly polar mixtures of water (containing 0.1% TFA) and MeCN aseluents. Fractions containing the desired compound were evaporated todryness to afford the title compound (32.0 mg, 31.7%) as a colorlesssolid.

HRMS: calculated for (C₂₅H₂₄F₆N₂07S+H)⁺611.1287; found (ESI [M+H]⁺)611.1304.

¹H NMR (400 MHz, DMSO-d₆, mixture of rotamers, 2.2*:1) δ 0.87-1.22 (m,4H), 3.20, 3.36* (s, 3H), 3.46 (t, 2H), 3.69 (q, 2H), 4.85-5.31 (m, 3H),5.90*, 6.22 (s, 1H), 7.61-7.68 (m, 2H), 7.71-7.82 (m, 3H), 7.86-7.91 (m,1H), 7.98-8.04 (m, 1H), 8.66, 8.68* (s, 1H), 10.82, 10.89* (s, 1H).

Example 900:5-{[(1-Cyanocyclopropyl)methyl]sulfonyl}-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide

Diethylamine (1.5 mL, 0.19 mmol) was added to (9H-fluoren-9-yl)methyl5-(((1-cyanocyclopropyl)methyl)sulfonyl)-1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)isoindoline-2-carboxylate(150 mg, 0.19 mmol) in DCM (15 mL) under nitrogen. The resultingsolution was stirred at rt for 14 hours.5-(((1-cyanocyclopropyl)methyl)sulfonyl)-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)isoindoline-1-carboxamide(100 mg, 94%) was detected by LCMS. The solvent was removed underreduced pressure. The crude product was purified by flash C18-flashchromatography, elution gradient 0 to 40% MeCN in water. Pure fractionswere evaporated to dryness to afford5-(((1-cyanocyclopropyl)methyl)sulfonyl)-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)isoindoline-1-carboxamide(100 mg, 94%). LC/MS: m/z=548 [M+H]⁺. HRMS: calculated for(C₂₃H₁₉F₆N₃O₄S+H)⁺548.1087; found (ESI [M+H]⁺) 548.1098. ¹H NMR (300MHz, DMSO-d₆) δ 0.99-1.13 (m, 2H), 1.27-1.31 (m, 2H), 3.69 (s, 2H), 4.42(s, 2H), 5.12 (s, 1H), 7.60-7.89 (m, 7H), 8.64 (s, 1H), 10.34 (s, 1H).

Example 901:2-Acetyl-5-{[(1-cyanocyclopropyl)methyl]sulfonyl}-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide

Ac₂O (0.138 mL, 1.46 mmol) was added to5-(((1-cyanocyclopropyl)methyl)sulfonyl)-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)isoindoline-1-carboxamide(80 mg, 0.15 mmol) in DCM (5 mL) at 0° C. under nitrogen. The resultingsolution was stirred at room temperature for 3 hours. The reactionmixture was treated with water (5 mL), extracted with DCM (3×10 mL), theorganic layer was dried over Na₂SO₄, filtered and evaporated to affordwhite solid. The crude product was purified by preparative HPLC Column:XBridge Prep C18 OBD Column, 5 um, 19*150 mm; Mobile Phase A: Waters(0.05% TFA), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 10% Bto 54% B in 7 min; 254/220 nm. Fractions containing the desired compoundwere evaporated to dryness to afford2-acetyl-5-(((1-cyanocyclopropyl)methyl)sulfonyl)-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)isoindoline-1-carboxamide(60.0 mg, 69.7%). LC/MS: m/z=590 [M+H]⁺. HRMS: calculated for(C₂₅H₂₁F₆N₃O₅S+H)⁺590.1184; found (ESI [M+H]⁺) 590.1185. ¹H NMR (300MHz, DMSO-d₆, mixture of rotamers, 4*:1) δ 1.00-1.04 (m, 2H), 1.29-1.33(m, 2H), 2.00, 2.16* (s, 3H), 3.73 (s, 2H), 4.85-5.07 (m, 2H), 5.75*,5.96 (s, 1H), 7.62-8.04 (m, 7H), 8.66*, 8.68 (s, 1H), 10.71*, 10.93 (s,1H).

Example 902: Methyl5-{[(1-cyanocyclopropyl)methyl]sulfonyl}-1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-1,3-dihydro-2H-isoindole-2-carboxylate

Methyl carbonochloridate (69.0 mg, 0.73 mmol) was added dropwise to5-(((1-cyanocyclopropyl)methyl)sulfonyl)-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)isoindoline-1-carboxamide(80 mg, 0.15 mmol) in DCM (10 mL) at 0° C. over a period of 10 minutesunder nitrogen. The resulting solution was stirred at room temperaturefor 12 hours. The reaction mixture was treated with water (10 mL),extracted with DCM (3×10 mL), the organic layer was dried over Na₂SO₄,filtered and evaporated to afford brown oil. The crude product waspurified by preparative HPLC, Column: XSelect CSH Prep C18 OBD Column,19*250 mm, 5 um; Mobile Phase A:Water (0.1% FA), Mobile Phase B: ACN;Flow rate: 25 mL/min; Gradient: 52% B to 52% B in 6 min; 254/220 nm; Rt:5.50 min. Fractions containing the desired compound were evaporated todryness to afford methyl5-(((1-cyanocyclopropyl)methyl)sulfonyl)-1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)isoindoline-2-carboxylate(60.0 mg, 67.8%).

LC/MS: m/z=606 [M+H]⁺. HRMS: calculated for (C₂₅H₂₁F₆N₃O₆S+H)⁺606.1133;found (ESI [M+H]⁺) 606.1160. ¹H NMR (300 MHz, DMSO-d₆, mixture ofrotamers, 1.5*:1) δ 1.00-1.01 (m, 2H), 1.26-1.30 (m, 2H), 3.61-3.76 (m,5H), 4.87 (s, 2H), 5.67-5.74 (m, 1H), 7.63 (d, J=8.7 Hz, 2H), 7.72-7.76(m, 3H), 7.90 (d, J=8.1 Hz, 1H), 8.01 (d, J=5.7 Hz, 1H), 8.67 (s, 1H),10.78*, 10.80 (s, 1H).

Example 1000:N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-[(2-methylpropyl)sulfonyl]-2,3-dihydro-1H-isoindole-1-carboxamide

tert-Butyl1-{[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]carbamoyl}-5-[(2-methylpropyl)sulfonyl]-1,3-dihydro-2H-isoindole-2-carboxylate(130 mg, 0.21 mmol) was dissolved in isopropyl acetate (1 mL). 5Mhydrogen chloride in IPA (1 ml, 5.00 mmol) was added and the reactionstirred at room temperature overnight. The reaction was concentrated invacuo and the residue was co-evaporated with EtOAc/Hept (1:1 20 ml).N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-[(2-methylpropyl)sulfonyl]-2,3-dihydro-1H-isoindole-1-carboxamideHCl salt (100 mg, 92%) was obtained as an off-white solid. The materialwas used without further purification.

LC/MS: m/z=525 [M+H]⁺.

Example 1001:2-Acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-[(2-methylpropyl)sulfonyl]-2,3-dihydro-1H-isoindole-1-carboxamide

N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-[(2-methylpropyl)sulfonyl]-2,3-dihydro-1H-isoindole-1-carboxamideHCl salt (60 mg, 0.11 mmol) was dissolved in DCM (5 mL) and to thistriethylamine (0.045 mL, 0.32 mmol) and acetic acid (7.35 μl, 0.13 mmol)were added followed by T3P (50% solution in EtOAc) (0.127 mL, 0.21mmol). The reaction was stirred at room temperature for 30 min. Thereaction was diluted with DCM and washed with saturated aqueous NaHCO₃.The layers were separated using a phase separator cartridge and the DCMremoved in vacuo. A sample for biological screening was purified:Instrument: SFC-MS. Chromatographic conditions: MeOH/NH₃ 20 mM. Column:Waters Acquity UPC2 BEH 2-EP 3.5 μm 3×100 mm.2-Acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-[(2-methylpropyl)sulfonyl]-2,3-dihydro-1H-isoindole-1-carboxamide(42.5 mg, 70.1%) HRMS: calculated for (C₂₄H₂₄F₆N₂O₅S+H)⁺567.1388; found:(ESI [M+H]⁺) 567.1381.

¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 4*:1) δ 0.96 (d, 3H),0.98 (d, 3H), 1.99-2.05 (m, 1H), 1.99, 2.14* (s, 3H), 3.20, 3.22* (d,2H), 4.75-4.91, 5-5.09* (m, 2H), 5.72*, 5.92 (s, 1H), 7.6-7.79 (m, 5H),7.87 (d, 1H), 7.97*, 8.00 (s, 1H), 8.68 (br s, 1H), 10.71*, 10.94 (s,1H).

Example 1100:N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-{[(1-hydroxycyclopropyl)methyl]sulfonyl}-2,3-dihydro-1H-isoindole-1-carboxamide

TFA (3 mL, 40 mmol) was added to tert-butyl5-(((1-((tert-butyldimethylsilyl)oxy)cyclopropyl)methyl)sulfonyl)-1-((4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)isoindoline-2-carboxylate(60 mg, 0.08 mmol) in DCM (3 mL) at 0° C. under nitrogen. The resultingsolution was stirred at room temperature for 1 hour. The solvent wasremoved under reduced pressure. The crude product was purified bypreparative HPLC Column: XBridge Prep C18 OBD Column, 5 um, 19*150 mm;Mobile Phase A:Waters (0.05% TFA), Mobile Phase B: ACN; Flow rate: 20mL/min; Gradient: 10% B to 54% B in 7 min; 254/220 nm. Fractionscontaining the desired compound were evaporated to dryness to affordN-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-5-(((1-hydroxycyclopropyl)methyl)sulfonyl)isoindoline-1-carboxamide(TFA salt) (40.0 mg, 61.5%).

LC/MS: m/z=539[M+H]⁺. HRMS: calculated for (C₂₂H₂₀F₆N₂O₅S+H)⁺539.1075;found: (ESI [M+H]⁺) 539.1069. ¹H NMR (300 MHz, DMSO-d₆) δ 0.51-0.61 (m,4H), 3.56 (s, 2H), 4.76 (dd, J=25.2, 15.0 Hz, 2H), 5.35 (brs, 1H), 5.74(s, 1H), 7.69-7.79 (m, 4H), 7.82-7.88 (m, 1H), 7.92-7.98 (m, 1H), 8.03(s, 1H), 8.73 (s, 1H), 11.28 (s, 1H).

Example 1101:2-Acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-{[(1-hydroxycyclopropyl)methyl]sulfonyl}-2,3-dihydro-1H-isoindole-1-carboxamide

Ac₂O (15.17 mg, 0.15 mmol) was added toN-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-5-(((1-hydroxycyclopropyl)methyl)sulfonyl)isoindoline-1-carboxamide(80 mg, 0.15 mmol) in DCM (1 mL) at 0° C. under nitrogen. The resultingsolution was stirred at room temperature for 1 hour. The solvent wasremoved under reduced pressure. The crude product was purified bypreparative HPLC Column: XBridge Prep C18 OBD Column, 5 um, 19*150 mm;Mobile Phase A: Waters (0.05% TFA), Mobile Phase B: ACN; Flow rate: 20mL/min; Gradient: 10% B to 54% B in 7 min; 254/220 nm. Fractionscontaining the desired compound were evaporated to dryness to afford2-acetyl-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-5-(((1-hydroxycyclopropyl)methyl)sulfonyl)isoindoline-1-carboxamide(40.0 mg, 46.4%).

LC/MS: m/z=581[M+H]⁺. HRMS: calculated for (C₂₄H₂₂F₆N₂O₆S+H)⁺581.1181;found: (ESI [M+H]⁺) 581.1208. ¹H NMR (300 MHz, DMSO-d₆, mixture ofrotamers, 4*:1) δ 0.48-0.60 (m, 4H), 2.00, 2.16* (s, 3H), 3.53 (s, 2H),4.76-5.10 (m, 2H), 5.34, 5.35* (s, 1H), 5.73*, 5.93 (s, 1H), 7.62-7.77(m, 5H), 7.85-7.91 (m, 1H), 7.95-8.00 (m, 1H), 8.65*, 8.67 (s, 1H),10.70*, 10.93 (s, 1H).

Example 1102:2-Formyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-{[(1-hydroxycyclopropyl)methyl]sulfonyl}-2,3-dihydro-1H-isoindole-1-carboxamide

DIPEA (0.052 mL, 0.30 mmol) was added toN-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-5-(((1-hydroxycyclopropyl)methyl)sulfonyl)isoindoline-1-carboxamide(80 mg, 0.15 mmol), formic acid (68.4 mg, 1.49 mmol) and HATU (169 mg,0.45 mmol) in DCM (1 mL) under nitrogen. The resulting solution wasstirred at room temperature for 1 hour. The solvent was removed underreduced pressure. The crude product was purified by preparative HPLCColumn: XBridge Prep C18 OBD Column, 5 um, 19*150 mm; Mobile Phase A:Waters (0.05% TFA), Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient:10% B to 54% B in 7 min; 254/220 nm. Fractions containing the desiredcompound were evaporated to dryness to afford2-formyl-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-5-(((1-hydroxycyclopropyl)methyl)sulfonyl)isoindoline-1-carboxamide(62.0 mg, 59.0%).

LC/MS: m/z=567 [M+H]⁺. HRMS: calculated for (C₂₃H₂₀F₆N₂O₆S+H)⁺567.1024;found: (ESI [M+H]⁺) 567.1004. ¹H NMR (300 MHz, DMSO-d₆, mixture ofrotamers, 1.7*:1) δ 0.48-0.61 (m, 4H), 3.53 (s, 2H), 4.74-4.92,5.02-5.18* (m, 2H), 5.34, 5.35* (s, 1H), 5.77*, 5.99 (s, 1H), 7.63-7.84(m, 5H), 7.87-7.93 (m, 1H), 8.00 (s, 1H), 8.40, 8.49* (s, 1H), 8.65*,8.67 (s, 1H), 10.76*, 10.86 (s, 1H).

Example 1103:N-[4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl]-2-(hydroxyacetyl)-5-{[(1-hydroxycyclopropyl)methyl]sulfonyl}-2,3-dihydro-1H-isoindole-1-carboxamide

DIPEA (0.058 mL, 0.33 mmol) was added toN-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-5-(((1-hydroxycyclopropyl)methyl)sulfonyl)isoindoline-1-carboxamide(60 mg, 0.11 mmol), 2-hydroxyacetic acid (42.4 mg, 0.56 mmol) and HATU(169 mg, 0.45 mmol) in DCM (2 mL) under nitrogen. The resulting solutionwas stirred at room temperature for 2 hours. The reaction mixture wastreated with NH₄Cl (5 mL), extracted with DCM (3×10 mL), the organiclayer was dried over Na₂SO₄, filtered and evaporated to affordcolourless dry film. The crude product was purified by preparative HPLCColumn: CHIRALPAK IF, 2*25 cm, 5 m; Mobile Phase A: Hex—HPLC, MobilePhase B: EtOH—HPLC; Flow rate: 20 mL/min; Gradient: 30 B to 30 B in 16min; 220/254 nm; Fractions containing the desired compound wereevaporated to dryness to affordN-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-2-(2-hydroxyacetyl)-5-(((1-hydroxycyclopropyl)methyl)sulfonyl)isoindoline-1-carboxamide(18.00 mg, 27.1%).

LC/MS: m/z=597 [M+H]⁺. HRMS: calculated for (C₂₄H₂₂F₆N₂07S+H)⁺597.1130;found: (ESI [M+H]⁺) 597.1130. ¹H NMR (400 MHz, DMSO-d₆, mixture ofrotamers, 5*:1) δ 0.49-0.59 (m, 4H), 3.53 (s, 2H), 3.85-4.31 (m, 2H),4.83-5.21 (m, 3H), 5.35, 5.36* (s, 1H), 5.79*, 6.00 (s, 1H), 7.63-7.78(m, 5H), 7.88 (d, J=8.1 Hz, 1H), 7.94-8.01 (m, 1H), 8.67*, 8.68 (s, 1H),10.76*, 10.93 (s, 1H).

Example 1200:2-Acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-[(2-hydroxypropyl)sulfonyl]-2,3-dihydro-1H-isoindole-1-carboxamide

Step 1:2-Acetyl-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-5-((2-hydroxypropyl)thio)isoindoline-1-carboxamide

A solution of2-acetyl-5-bromo-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)isoindoline-1-carboxamide(83 mg, 0.16 mmol) in dioxane (1.5 mL) was degassed before, Xantphos(9.14 mg, 0.02 mmol), DIPEA (0.033 mL, 0.19 mmol), Pd₂(dba)₃ (7.24 mg,7.90 μmol) and 1-mercaptopropan-2-ol (102 mg, 1.11 mmol) was added. Thereaction was heated to 80° C. for 40 min. The reaction was concentratedin vacuo and the residue was purified by flash chromatography elutingwith 0-40% EtOAc in heptane.2-Acetyl-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-5-((2-hydroxypropyl)thio)isoindoline-1-carboxamide(60.0 mg, 70.8%) was obtained as a foam.

LC/MS: m/z=535 [M−H]⁻. ¹H NMR (500 MHz, DMSO d₆, mixture of rotamers,4*:1) δ 1.15 (d, 3H), 1.96, 2.12* (s, 3H), 2.87-2.96 (m, 1H), 2.98-3.04(m, 1H), 3.72-3.8 (m, 1H), 4.63-4.97 (m, 3H), 5.56*, 5.74 (s, 1H),7.24-7.44 (m, 3H), 7.59-7.66 (m, 2H), 7.69-7.76 (m, 2H), 8.62*, 8.65 (s,1H), 10.55*, 10.78 (s, 1H).

Step 2:2-Acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-[(2-hydroxypropyl)sulfonyl]-2,3-dihydro-1H-isoindole-1-carboxamide

2-Acetyl-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-5-((2-hydroxypropyl)thio)isoindoline-1-carboxamide(60 mg, 0.11 mmol) was dissolved in DCM (2 mL) and to this mCPBA (≥77%)(60.2 mg, 0.27 mmol) was added and the reaction stirred at roomtemperature for 30 min. Sulphoxide could still be seen in the LCMS.mCPBA (≥77%)

(25.06 mg, 0.11 mmol) was added and the reaction stirred at roomtemperature for another 30 min. The reaction was diluted with EtOAc andwashed with 1M aq NaOH. The layers were separated and the aqueous wasextracted twice with EtOAc. The combined organic extracts were driedusing a phase separator cartridge and the solvent was removed in vacuo.Sample for biological screening was purified: Instrument: SFC2-MS.Chromatographic conditions: MeOH/NH₃ 20 mM. Column: Phenomenex LunaHilic 5 30×250 mm.2-Acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-[(2-hydroxypropyl)sulfonyl]-2,3-dihydro-1H-isoindole-1-carboxamide(28.4 mg, 44.7%). HRMS: calculated for (C₂₃H₂₂F₆N₂O₆S+H)⁺569.1181;found: (ESI [M+H]⁺) 569.1178.

¹H NMR (600 MHz, DMSO-d₆, mixture of rotamers, 4*:1) δ 1.09-1.15 (m,3H), 1.99, 2.15* (s, 3H), 3.96-4.07 (m, 1H), 4.76-4.88, 4.99-5.08* (m,2H), 4.90 (d, 1H), 5.72*, 5.92 (s, 1H), 7.59-7.78 (m, 5H), 7.86 (d, 1H),7.95*, 7.98 (s, 1H), 8.67*, 8.70 (s, 1H), 10.70*, 10.94 (d, 1H).

Example 1300:5-{[(1-Fluorocyclopropyl)methyl]sulfonyl}-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide

TFA (1 mL, 12.98 mmol) was added to tert-butyl5-(((1-fluorocyclopropyl)methyl)sulfonyl)-1-((4-(1,3,3,3-h1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)carbamoyl)isoindoline-2-carboxylate(200 mg, 0.31 mmol) in DCM (5 mL) cooled to 0° C. under nitrogen. Theresulting solution was stirred at room temperature for 3 hours. Thereaction mixture was quenched with saturated NaHCO₃ (10 mL), extractedwith DCM (3×20 mL), the organic layer was dried over Na₂SO₄, filteredand evaporated to afford5-(((1-fluorocyclopropyl)methyl)sulfonyl)-N-(4-(1,1,1,3,33-hexafluoro-2-hydroxypropan-2-yl)phenyl)isoindoline-1-carboxamide(100 mg, 59.3%) as an oil.

HRMS: calculated for (C₂₂H₁₉F₇N₂O₄S+H)⁺541.1032; found: (ESI [M+H]⁺)541.1049.

¹H NMR (300 MHz, DMSO d₆) δ 0.69-0.77 (m, 2H), 0.92-1.05 (m, 2H), 3.96(d, 2H), 4.34-4.44 (m, 2H), 5.09 (s, 1H), 7.60 (d, 2H), 7.60 (d, 1H),7.77-7.90 (m, 4H), 8.63 (s, 1H), 10.33 (s, 1H).

Example 1301:2-Acetyl-5-{[(1-fluorocyclopropyl)methyl]sulfonyl}-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-2,3-dihydro-1H-isoindole-1-carboxamide

Acetic anhydride (151 mg, 1.48 mmol) was added dropwise to5-(((1-fluorocyclopropyl)methyl)sulfonyl)-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)isoindoline-1-carboxamide(80 mg, 0.15 mmol) in DCM (5 mL) at 0° C. over a period of 10 minutesunder nitrogen. The resulting solution was stirred at room temperaturefor 4 hours. The reaction mixture was quenched with ice/water (5 mL),extracted with DCM (3×10 mL), the organic layer was dried over Na₂SO₄,filtered and evaporated to afford brown oil. The crude product waspurified by preparative HPLC, Column: XBridge Prep C18 OBD Column 19×150mm 5 um; Mobile Phase A: Water (0.05% TFA), Mobile Phase B: ACN; Flowrate: 20 mL/min; Gradient: 39% B to 47% B in 7 min; 254/220 nm; Rt: 6.33min. Fractions containing the desired compound were evaporated todryness to afford2-acetyl-5-(((1-fluorocyclopropyl)methyl)sulfonyl)-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)isoindoline-1-carboxamide(54 mg, 62%) as a solid.

HRMS: calculated for (C₂₄H₂₁F₇N₂O₅S+H)⁺583.1138; found: (ESI [M+H]⁺)583.1135.

¹H NMR (300 MHz, DMSO-d₆, mixture of rotamers, 3.5*:1) δ 0.66-0.79 (m,2H), 0.92-1.06 (m, 2H), 1.99, 2.14* (s, 3H), 4.00 (d, 2H), 4.78-4.90,5.01-5.07* (m, 2H), 5.73*, 5.93 (s, 1H), 7.58-7.81 (m, 5H), 7.88-7.91(m, 1H), 7.98-8.01 (m, 1H), 8.64*, 8.66 (s, 1H), 10.69*, 10.94 (s, 1H).

Biological Data

Compounds according to Formula I are RORγ modulators and theiractivities were determined in one of the following assays.

RORγ Radioligand Competition Binding Assay (SPA)

The aim of this assay is to identify compounds which bind to the RORγligand binding domain, by competing with tritiated2-(4-(ethylsulfonyl)phenyl)-N-(4-(2-(methoxymethyl)phenyl)thiophen-2-yl)acetamide.

Preparation of tritiated2-(4-(Ethylsulfonyl)phenyl)-N-(4-(2-(methoxymethyl)phenyl)thiophen-2-yl)acetamide

Step 1: N-(4-Bromothiophen-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide

The trifluoroacetate salt of 4-bromothiophen-2-amine (2.45 g, 8.42 mmol,obtained by deprotection of tert-butyl N-(4-bromo-2-thienyl)carbamatewith TFA in DCM) was added to 2-(4-(ethylsulfonyl)phenyl)acetic acid (2g, 8.76 mmol), EDC (2.016 g, 10.51 mmol) and DMAP (3.21 g, 26.29 mmol)in DCM (30 mL) under nitrogen. The resulting mixture was stirred at rtfor 12 hours. The reaction mixture was diluted with EtOAc (100 mL), andwashed sequentially with water (150 mL) and saturated brine (125 mL).The organic layer was dried over Na₂SO₄, filtered and evaporated toafford the crude product. The crude product was purified by flash silicachromatography, elution gradient 10% to 60% EtOAc in petroleum ether.Pure fractions were evaporated to dryness to affordN-(4-bromothiophen-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide (2.0 g,61%) as a solid. LC/MS: m/z=535 [M−H]⁻. ¹H NMR (400 MHz, DMSO-d₆) δ1.09, (t, 3H), 3.26 (q, 2H), 3.85 (s, 2H), 6.63 (d, 1H), 7.06, (d, 1H),7.58 (d, 2H), 7.84 (d, 2H), 11.64 (s, 1H).

Step 2:2-(4-(Ethylsulfonyl)phenyl)-N-(4-(2-(methoxymethyl)phenyl)thiophen-2-yl)acetamide

PdCl₂(dppf) (9.42 mg, 0.01 mmol) was added toN-(4-bromothiophen-2-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide (100 mg,0.26 mmol), (2-(methoxymethyl)phenyl)boronic acid (85 mg, 0.52 mmol) andK₂CO₃ (107 mg, 0.77 mmol) in 1,4-dioxane (4 mL) and water (0.5 mL) at25° C. under nitrogen. The resulting mixture was stirred at 100° C. for5 hours. The reaction mixture was quenched with water (10 mL) andextracted with EtOAc (30×2 mL). The organic layer was dried over Na₂SO₄,filtered and evaporated to afford yellow solid. The crude product waspurified by flash C18-flash chromatography, elution gradient 5 to 50%MeCN in water. Pure fractions were evaporated to dryness to afford2-(4-(ethylsulfonyl)phenyl)-N-(4-(2-(methoxymethyl)phenyl)thiophen-2-yl)acetamide(81 mg, 73.2%) as a solid.

HRMS: calculated for (C₂₂H₂₃NO₄S+H)⁺430.1133; found: (ESI [M+H]⁺)430.1147.

¹H NMR (300 MHz, CDCl₃) δ 1.29 (t, 3H), 3.11 (q, 2H), 3.38 (s, 3H), 3.82(s, 2H), 4.38 (s, 2H), 6.80 (s, 1H), 6.92 (s, 1H), 7.28-7.39 (m, 3H),7.43-7.47 (m, 1H), 7.51 (d, 2H), 7.85 (d, 2H), 8.35 (s, 1H).

Step 3: Tritiationof2-(4-(ethylsulfonyl)phenyl)-N-(4-(2-(methoxymethyl)phenyl)thiophen-2-yl)acetamide

2-(4-(Ethylsulfonyl)phenyl)-N-(4-(2-(methoxymethyl)phenyl)thiophen-2-yl)acetamide(2.3 mg, 5.35 μmol) and 1-iodopyrrolidine-2,5-dione (1.3 mg, 5.78 μmol)were dissolved in DCM (0.2 mL) and TFA (0.02 mL) was added. The reactionmixture was stirred for 5 minutes, then concentrated by a stream ofnitrogen. The residue was dissolved in EtOH (0.4 mL), triethylamine (20μl, 144.28 μmol) was added and the solution was transferred to atritiation vial containing Pd/C (3 mg, 2.82 μmol, 10% Pd). The vial wasdegassed by 3 freeze-pump-thaw-cycles. The flask was filled with T₂ gas(290 GBq). The reaction mixture was stirred at rt for 2.5 h. T₂ gas wasrecovered via the washing bed and the reaction mixture was concentratedby a stream of nitrogen. MeOH (0.7 mL) were added and the reactionmixture was concentrated by a stream of nitrogen. This procedure wasrepeated 3 times. The reaction mixture was filtered and dissolved inMeOH (15 mL total). After evaporation, the crude product was dissolvedin DMSO and purified by preparative HPLC on a XBridge C18 column (10 m,250×19 mm) using a gradient of 5-95% acetonitrile in H₂O/ACN/HOAc95/5/0.5 buffer over 40 minutes with a flow of 15 mL/min. The productwas detected by UV at 244 nm. Yield: 1717 MBq.

Protein Production

Human RORγ (Ligand Binding Domain (RORγ LBD) was expressed in E. coli(BL21DE3 Star) as a fusion protein: N-6×HN-Avi-GST-TCS-hRORγ LBD(S258-K518) subcloned into pET24a(+). The LBD (258-518) is underlined inthe protein sequence:

(SEQ ID NO: 1) HNHNHNHNHNHNGGLNDIFEAQKIEWHEGSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDYDIPTTGSGSGSLVPRGSTPEAPYASLTEIEHLVQSVCKSYRETCQLRLEDLLRQRSNIFSREEVTGYQRKSMWEMWERCAHHLTEAIQYVVEFAKRLSGFMELCQNDQIVLLKAGAMEVVLVRMCRAYNADNRTVPPEGKYGGMELFRALGCSELISSIFDFSHSLSALHFSEDEIALYTALVLINAHRPGLQEKRKVEQLQYNLELAFHHHLCKTHRQSILAKLPPKGKLRSLCSQHVERLQIFQHLHPIVVQAAFPPLYKELFSTETESPVGLSK.The bacteria was grown in TB with Autoinduction media (Stock50×ZYM-5052: 25% Glycerol, 2.5% Glucose, 10% Lactose), 3 mM MgOAc and100 ug/ml Kan A. The culture was incubated at 180 rpm, at 37° C. AtOD600 1.9, the temperature was decreased to 20° C. and at OD600 7.9 thecells were harvested. After centrifugation the bacterial pellet wasresuspended in ice cold Lysis Buffer (20 mM Tris pH8.0, 250 mM NaCl, 10%(v/v) Glycerol, 0.5% CHAPS (w/v), 20 mM Imidazole, 1 mM TCEP, lxProtease inhibitor (Complete, Roche), lul Benzonase/100 ml buffer(E1014, Sigma)). Lysis was performed on ice at 30 kpsi using a Celldisruptor. To remove cell debris the sample was centrifuged at 48 000 xg(20 000 rpm) for 20 minutes, at 4° C.

The protein was purified in two steps at room temperature. The 6×HN tagwas utilized in the first affinity purification step where lysate wasrun over a HisTrap 5 ml Crude column (Amersham Pharmacia) using AKTAFPLC system (Amersham Pharmacia). After washing with Affinitypurification buffer A (20 mM Tris pH8.0, 250 mM NaCl, 10% (v/v)Glycerol, 0.5% CHAPS (w/v), 20 mM Imidazole, 1 mM TCEP), proteins wereeluted with a step gradient (50-100-150-200-250-300-500 mM Imidazole).Fractions of 0.5 ml volume were collected and analysed with SDS-PAGE(Novex system) and Coomassie staining. Fractions containing protein withexpected molecular weight (from 50 mM Imidazole elution step) werepooled. The pool also contained protein with molecular weightcorresponding to free GST. To separate GST from GST-RORγ a second sizeexclusion purification step was performed using a SEC Sephadex200 16/60column (Amersham Pharmacia) at 0.8 ml/min in Size Exclusion/StorageBuffer (20 mM Tris pH8.0, 150 mM KCl, 0.5 mM EDTA, 20% (v/v) Glycerol,0.5% (w/v) CHAPS, ImM TCEP). Fractions of 0.5 ml volume were collectedand were analysed on a gel as described above. Fractions with no or lowlevels of the band corresponding to free GST, were pooled, frozen inliquid nitrogen and stored at −80° C. for use in the SPA binding assay.

Assay Protocol

The scintillation proximity assay (SPA) was run in white polystyreneflat-bottom 384-well plates (Greiner, cat. No. 781075). Assays werecarried out in 40 i1 reaction volumes. Various concentrations of testligands in 0.4 microlitres of DMSO were added to assay plates using anacoustic liquid dispenser. 4 nM purified N—(HN)6-GST-TCS-hRORγ (258-518)was mixed with 40 micrograms Yttrium oxide (YOx) glutathione SPA imagingbeads in assay buffer (20 mM Tris, 150 mM NaCl, 10% Glycerol, 0.25%CHAPS, 1 mM TCEP) prior to adding 30 microlitres to test ligands. Assayplates were incubated for one hour at room temperature before adding 10microlitres tritiated2-(4-(ethylsulfonyl)phenyl)-N-(4-(2-(methoxymethyl)phenyl)thiophen-2-yl)acetamideto test plates in assay buffer (final concentration, 25 nM). Test plateswere incubated for 16 hours and read using a LEADseeker Multimodalityimaging instrument.

The raw data was analysed and IC50 and Ki values for the compounds werecalculated using Genedata Screener software. Raw data was transformed to% effect using equation 1:Compound % effect=100*[(X−min)/(max−min)],where X represents the normalized value for the compound based on theMin (vehicle) and Max (reference compound) inhibition controls.

The concentration of test ligand that inhibited radioligand binding by50% (i.e., the IC₅₀) was calculated by plotting the % effect versus testligand concentration and fitting the data using the Genedata ScreenerSmart fit algorithm. K_(i) is calculated from the IC₅₀ value using theequation Ki=IC50/1+[L]/Kd) where [L]=25 nmol/L and K_(d)=17 nmol/L

RORγ Co-Factor Recruitment Assay (FRET)

A high throughput coactivator binding assay for the identification ofinverse agonists of the recruitment of peptide SRC-1 (NCOA1_677-_700) tothe RORγ ligand binding domain was established.

Protein Production

The ligand binding domain (LBD) of human RORγ was expressed in E. coli(BL21DE3 Star) as a fusion protein:N-6×HN-MBP-Avi-TCS-hRORγLBD(P260-K518) subcloned into pET24a(+). The LBD(P260-K518) is underlined in the protein sequence:

(SEQ ID NO: 2) MHNHNHNHNHNHNGGLNDIFEAQKIEWHEGMKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTGSDYDIPTTGSGSGSLVPRGSTPEAPYASLTEIEHLVQSVCKSYRETCQLRLEDLLRQRSNIFSREEVTGYQRKSMWEMWERCAHHLTEAIQYVVEFAKRLSGFMELCQNDQIVLLKAGAMEVVLVRMCRAYNADNRTVFFEGKYGGMELFRALGCSELISSIFDFSHSLSALHFSEDEIALYTALVLINAHRPGLQEKRKVEQLQYNLELAFHHHLCKTHRQSILAKLPPKGKLRSLCSQHVERLQIFQHLHPIVVQAAFPPLYKELFSTETESPVGLSK.Bacterial colonies were picked and inoculated in 16×500 mL TB mediumsupplemented with 25 mM (NH₄)₂SO₄, 50 mM KH₂PO₄, 50 mM Na₂HPO₄, 0.8% v/vGlycerol, 0.05% w/v Glucose, 0.2% w/v α-Lactose, 1 mM MgSO₄ and 200μg/ml Kanamycin to promote autoinduction. After incubation at 37° C. at200 rpm for two hours the temperature was decreased to 20° C. When theOD600 was 12.4, the temperature was further decreased to 16° C. Cellswere harvested at OD600 24 by centrifugation at 4000 rpm for 10 minutesat 4° C. The pellet, approximately ˜320 g was stored at −80° C.

The pellet was resuspended in 1600 mL Lysis Buffer (50 mM Tris-HCl, 10%v/v Glycerol, 1 mM TCEP, 2 tablets Protease Inhibitor/100 mL LysisBuffer (Complete, Roche), 4 l Benzonase/100 mL Lysis Buffer (E1014,Sigma), pH 8.0). Lysis was performed at 25 kpsi using Cell disruptor(Constant Cell Disruptor Systems). The sample was kept on ice during thewhole lysis procedure For removal of cell debris, the lysed cells wereultracentrifuged at 143719×g (43000 rpm) for 45 minutes at 4° C. Thesupernatant was stored at −80° C.

The thawed supernatant was captured utilizing the N-6×HN tag with washed100 mL NiNTA Superflow resin (Qiagen) in Wash Buffer (50 mM Tris-HCl, 50mM NaCl, 30 mM Imidazole, 10% v/v Glycerol, 1 mM TCEP, pH 8.0) andslowly stirred with a magnetic bar at room temperature. After 1.5 hoursthe supernatant was removed by vacuum suction through a porcelain funnel(sieve size 2). The resin, with the captured protein was washed with 700mL Wash Buffer and transferred to three PD columns with filter (GE).Each column was eluted with 10 mL+90 mL Elution Buffer (50 mM Tris-HCl,50 mM NaCl, 300 mM Imidazole, 10% v/v Glycerol, 1 mM TCEP, pH 8.0) andcollected. All fractions from the columns were pooled and analyzed withSDS-PAGE (Novex System) and stained in commassie. The pooled sample wasconcentrated to −30 mL using concentrators with 30K cutoff (Amicon,Millipore) at 4000 rpm and at 4° C. The concentrated sample wasclarified at 30000×g for 15 minutes at 4° C. After centrifugation asmall pellet of aggregated protein was visible which was discarded. In asize exclusion column (XK50/60, GE) 1000 mL Superdex 200 resin (GE) wasequilibrated with GF Buffer (20 mM Tris-HCl, 150 mM NaCl, 10% v/vGlycerol, 1 mM TCEP, pH 8.0). The concentrated sample was loaded ontothe column at the flow rate 6 mL/min and 14 mL fractions were collected.The fractions were analyzed on a gel as described above. Fractionscontaining the major band which corresponded to the expected molecularweight for N-6×HN-MBP-Avi-TCS-hRORγLBD(P260-K518) (75.9 kDa) werecollected and pooled. To further verify the mass, the pooled sample wasanalysed using mass spectrometry (Waters) and the mass corresponded tothe expected mass. From 8 litres culture (˜320 g bacteria cells) 348 mgof N-6×HN-MBP-Avi-TCS-hRORγLBD(P260-K518) was purified. Purified proteinwas flash frozen in liquid nitrogen and stored at −80° C.

Protein N-6×HN-MBP-Avi-TCS-hRORγLBD(P260-K518), 42 μM (223 mg) purifiedas described above was incubated with 15000 units BirA/L (Avidity LLC)in 70 mL Biotinylation Buffer (200 μM Biotin, 10 mM ATP, 10 mM Mg₂OAc)at room temperature whilst slowly stirring with a magnetic bar for 9hours. The reaction was analyzed using mass spectrometry and the massdetermined to be 76.2 kDa corresponding to biotinylatedN-6×HN-MBP-Avi-TCS-hRORγLBD(P260-K518). After centrifugation at 19000rpm for 15 minutes at 4° C. precipitation was visible which wasdiscarded. The sample was concentrated as described above to −25 mL. Thereaction was polished in size exclusion columns (HiLoad Superdex 20026/60, GE) equilibrated with GF Buffer using aflow rate of 2.5 mL/minand 2 mL/fractions were collected. The fractions were analyzed on a gelas described above. Fractions containing the major band whichcorresponded to the expected molecular weight for biotinylatedN-6×HN-MBP-Avi-TCS-hRORγ LBD(P260-K518) (76.2 kDa) were collected andpooled. The estimated yield was −185 mg. Biotinylated protein was flashfrozen in liquid nitrogen and stored at −80° C.

Assay Protocol

The assay was run in black 384 well plates (Greiner cat no: 784900).Various concentrations of test ligands in 0.1 microlitres DMSO weredispensed to assay plates using an Echo acoustic dispenser. Twopre-mixes were prepared and incubated for 1 h at room temp in the dark.Pre-mix 1 comprised 100 nM Protein (Biotinylated HN-Avi-MBP-TCS-hRORγ(258-518)) and 60 nM Streptavidin APC in assay buffer, 50 mM MOPS pH7.4,50 mM KF, 0.003% (w/v) CHAPS, 10 mM DTT and 0.01% (w/v) BSA and pre-mix2 comprised 160 nM biotinylated SRC-1 peptide (NCOA1-677-700) and 20 nMEuropium-W8044 labelled Streptavidin in assay buffer. Five microlitresof pre-mix 2 was dispensed to assay plates containing 0.1 microlitres oftest compound and was incubated for 15 minutes prior to adding fivemicrolitres of pre-mix 1. Plates were incubated at room temperature for1 hour in the dark, prior to reading in a Pherastar multi-mode platereader using HTRF filter set (ex 320, em 612 and 665). The FRET signalat 665 nm was divided by the signal at 612 nm and multiplied by 10,000to generate a signal ratio value for each well. The raw data wastransformed to % effect using the equation:Compound % effect=100*[(X−min)/(max−min)],where X represents the normalized value for the compound based on theMin (vehicle) and Max (reference compound) inhibition control.

The concentration of test ligand that inhibited the activity by 50%(i.e., the IC₅₀) was calculated by plotting the % effect versus testligand concentration and fitting the data using the Genedata ScreenerSmart fit algorithm.

Inhibition of IL-17 Release from Human T_(H)17 Cells (IL-17 Release)

This test is designed to screen compounds for their inhibitory effect onthe release of IL-17 from isolated and cultured human T_(H)17 cells.

Peripheral blood mononuclear cells (PBMC) were isolated from heparintreated human whole blood fromhealthy donors by density gradientcentrifugation. T_(H)17 cells (CD4+CXCR3-CCR6+) were enriched using ahuman T_(H)17 Cell Enrichment Kit (Stemcell Technologies) according tothe manufacturer's protocol. The isolated T_(H)17 cells were activatedwith aCD3aCD28 beads (MACS Miltenyi) and cultured in X-Vivol5 medium(Lonza) supplemented with L-glutamine, β-mercaptoethanol and a cytokinecocktail consisting of; IL-2, IL-23, IL-1β, IL-6, TGF-β. Cells wereseeded at 8000 cells/well in a 384-plate (Corning, #3707) in thepresence of compounds or DMSO and cultured for 4 days (37° C., 5% CO₂).On day 4 supernatants were collected and IL-17A was measured using aHuman IL-17 HTRF Assay kit (Cisbio Bioassays) according to themanufacturer's protocol. The IC₅₀ values for the tested compounds wascalculated using Genedata Screener® software (Genedata) using thefollowing calculation method;Compound % effect=100*[(X−min)/(max−min)],where X represents the normalized value for the compound based on theMin (DMSO) and Max (compound3-(1,3-benzodioxol-5-yl)-1-(3,5-dimethylpiperidin-1-yl)-3-(2-hydroxy-4,6-dimethoxyphenyl)propan-1-oneat 10 jM, described in J. R. Hu et al. ACS Med. Chem. Lett. 2013, 4,79-84) inhibition controls.Results

All exemplified compounds were tested in the FRET assay described above.All of the exemplified compounds were also tested in the SPA assay.Selected compounds were further characterized for the inhibition of11-17 release in the cell assay. Results are summarized in the tablebelow.

TABLE Screening results of exemplified compounds pIC₅₀ pIC₅₀ pIC₅₀Example No. (FRET) (SPA) IL-17 release 100 7.2 6.4 7.4 101 7.3 7.5 7.9102 6.7 7.1 7.1 103 racemate 7.2 7.5 7.9 103 isomer 1 7.2 7.5 7.9 103isomer 2 6.5 6.8 7.6 104 6.7 7.1 7.7 105 6.4 6.9 7.7 106 6.5 6.9 7.2 1076.8 7.2 7.3 108 7.0 7.4 7.4 109 7.0 7.2 7.7 110 7.1 7.1 7.7 111 6.9 7.47.2 112 7.0 7.1 7.5 113 6.4 6.9 7.1 114 6.7 7.0 7.5 115 6.3 6.5 7.2 1166.7 7.2 6.7 117 7.3 7.4 7.1 200 7.2 7.8 7.5 201, racemate 7.2 7.9 8.1201, isomer 1 6.3 7.0 7.4 201, isomer 2 7.4 8.2 8.2 202 7.5 8.1 8.2 2037.2 7.9 8.0 204 7.0 7.6 8.1 205 6.9 7.7 7.8 206 7.1 7.8 7.4 207 7.1 7.67.4 208 7.0 7.5 7.7 209 7.0 7.8 7.6 210 6.7 7.4 7.6 211 6.7 7.3 6.7 2126.6 7.3 7.8 213 7.5 7.8 8.1 214 6.8 7.7 8.0 300 7.3 6.5 7.6 301 7.3 7.37.7 302 7.2 7.6 8.2 303, isomer 1 6.3 6.9 6.7 303, isomer 2 6.9 7.4 7.5304 6.8 7.0 7.9 305 7.0 6.1 8.0 306 6.6 7.2 7.7 307, isomer 1 7.1 7.47.5 307, isomer 2 6.3 6.7 6.5 308 7.3 7.3 7.5 309 6.9 7.3 7.3 310 6.67.4 7.5 311 6.8 7.1 7.5 312 6.4 6.0 7.4 313 7.1 7.5 7.0 314 7.0 7.5 7.2400 6.7 5.7 6.5 401, racemate 7.0 6.8 7.6 401, isomer 1 7.4 7.1 7.8 401,isomer 2 5.7 <5.4 6.9 402 7.0 7.6 7.9 403 7.2 6.6 7.6 404, racemate 6.76.7 7.5 404, isomer 1 6.8 6.9 7.6 404, isomer 2 4.8 5.2 6.5 405,racemate 6.6 6.7 7.4 405, isomer 1 6.9 7.1 7.8 405, isomer 2 4.7 <5.2<6.8  406 7.3 6.8 7.6 407 7.1 6.6 7.2 408 6.5 6.8 7.9 409, isomer 1 6.46.3 7.2 409, isomer 2 7.1 6.8 7.1 410 6.9 6.9 7.7 411 7.0 6.8 7.6 4126.8 6.5 7.6 413 6.7 7.1 7.5 414 7.2 6.7 7.5 415 7.0 7.1 7.5 416 6.4 6.67.5 417 6.9 6.4 7.5 418 6.5 6.9 7.4 419 6.2 6.5 7.3 420 6.1 6.2 7.1 4216.8 6.4 7.0 422 6.8 6.6 7.4 423 7.0 6.6 7.1 424, isomer 1 6.8 6.5 6.8424, isomer 2 6.4 6.3 6.5 425 6.7 6.7 7.1 426 6.5 6.0 6.5 427 6.6 6.87.0 428 6.9 7.0 6.9 429 7.1 7.0 6.9 430 6.6 6.7 6.9 431 6.8 6.7 6.6 4326.8 6.4 6.8 433 6.9 6.8 7.1 434 6.3 6.7 7.6 435 7.0 7.1 7.7 436 6.6 6.77.8 437 6.8 6.6 7.7 438 7.2 7.0 7.7 439 6.5 7.2 7.6 440 6.4 6.9 7.5 4416.3 6.6 7.6 442 7.2 6.6 7.3 443 6.0 6.3 7.0 444 6.5 6.7 7.2 445 6.7 6.77.6 446 6.7 6.5 7.5 447 6.1 6.3 7.3 448 6.1 6.5 7.1 449 6.3 6.6 7.1 450,racemate 6.9 6.8 7.6 450, isomer 1 7.3 7.0 7.9 450, isomer 2 6.1 6.2 7.0452, isomer 1 6.8 7.0 7.7 452, isomer 2 6.7 6.8 7.3 453 6.8 6.9 7.4 4546.9 6.9 7.4 455 7.0 7.0 7.0 456 6.8 6.6 7.9 500 7.3 7.7 8.0 600 6.4 5.4— 601 7.4 6.6 7.5 602 7.1 6.6 7.6 603 6.6 <5.8 7.5 604 7.2 6.6 7.3 6057.2 6.9 6.9 606 7.0 6.6 7.5 607 6.8 6.6 7.4 608 6.7 6.4 7.4 609 6.6 6.67.3 610 7.1 6.8 7.2 700 6.4 5.7 7.0 701 7.1 7.0 7.8 702 7.2 6.8 7.5 7036.4 6.7 7.6 704 7.0 6.9 7.6 705 7.0 7.1 7.0 706 6.8 7.0 7.3 707 7.0 7.17.3 800 6.2 5.4 — 801 6.7 6.7 7.1 802 6.2 6.5 7.1 900 6.3 5.5 — 901 7.16.8 7.1 902 7.1 6.4 7.3 1001  6.9 6.2 7.0 1100  7.2 6.0 6.7 1101  7.07.1 7.2 1102  7.2 7.2 7.5 1103  6.8 7.1 6.3 1200  6.7 6.7 6.8 1300  7.47.5 6.6 1301  7.2 7.9 6.8

The above description of illustrative embodiments is intended only toacquaint others skilled in the art with the Applicant's specification,its principles, and its practical application so that others skilled inthe art may readily adapt and apply the specification in its numerousforms, as they may be best suited to the requirements of a particularuse. This description and its specific examples, while indicatingembodiments of this specification, are intended for purposes ofillustration only. This specification, therefore, is not limited to theillustrative embodiments described in this specification, and may bevariously modified. In addition, it is to be appreciated that variousfeatures of the specification that are, for clarity reasons, describedin the context of separate embodiments, also may be combined to form asingle embodiment. Conversely, various features of the specificationthat are, for brevity reasons, described in the context of a singleembodiment, also may be combined to form sub-combinations thereof.

The invention claimed is:
 1. A method of treating a disease state in ahuman suffering from said disease state, which comprises administeringto the human in need of such treatment a therapeutically effectiveamount of(1R)-2-acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide,or a pharmaceutically acceptable salt thereof, and wherein the diseasestate is selected from ulcerative cholitis, Crohn's disease, multiplesclerosis, inflammatory bowel disease, rheumatoid arthritis, graftversus host disease, systemic lupus erythematosis, and lupus nephritis.2. The method of treating according to claim 1, wherein the diseasestate is ulcerative cholitis.
 3. The method of treating according toclaim 1, wherein the disease state is Crohn's disease.
 4. The method oftreating according to claim 1, wherein the disease state is multiplesclerosis.
 5. The method of treating according to claim 1, wherein thedisease state is inflammatory bowel disease.
 6. The method of treatingaccording to claim 1, wherein the disease state is rheumatoid arthritis.7. The method of treating according to claim 1, wherein the diseasestate is graft versus host disease.
 8. The method of treating accordingto claim 1, wherein the disease state is systemic lupus erythematosis.9. The method of treating according to claim 1, wherein the diseasestate is lupus nephritis.